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ABSTRACT OF DISSERTATION
Novel Mammalian Models for Understanding and Treating Spinal Cord Injury
Spinal cord injury (SCI) is devastating and often leaves the injured individual with
persistent dysfunction. The injury persists because humans have poor wound repair and
there are no pharmacologic treatments to induce wound repair after SCI. The continued
efforts to discover therapeutic targets and develop treatments heavily relies on animal
models. The purpose of this project is to develop and study novel mammalian models of
SCI to provide insights for the development and effective implementation of SCI therapies.
Lab mice (Mus musculus) are a powerful tool for recapitulating the progression and
persistent damage evident in human SCI, but our insight to naturally occurring wound
repair because Mus recover poorly from SCI without intervention. Some non-mammalian
species and neonates, on the other hand, can be used to identify therapeutic targets because
they naturally regenerate spinal tissues. Unfortunately, translating therapeutic targets from
non-mammalian or neonatal models to humans is onerous due to their phylogenetic and
developmental disparity from adult mammals. One aspect of this project investigates SCI
in the African spiny mouse (Acomys cahirinus), a rodent species with robust wound repair.
In this investigation, I have identified enhanced functional recovery and tissue integrity in
Acomys compared to Mus. Further investigations show that Acomys respond to injury with
a dampened inflammatory and fibrotic scarring response, including a decrease in cells with
fibroblast markers. The association of dampened inflammatory and fibrotic scarring
responses with enhanced tissue integrity and functional recovery in the subacute window
after SCI suggests that inhibiting subacute inflammatory and fibroblast proliferation and
activation may be an effective strategy for inducing endogenous functional repair in the
mammalian spinal cord. Further studies of SCI in Acomys can continue to illuminate the
mechanism of endogenous repair in the mammalian spinal cord.
Effectively implementing therapies depends on accurately understanding the nature
of the injury, which is doubly important in SCI because it is inherently heterogeneous.
Several studies have suggested that the specific biomechanics of the initial SCI can
influence overall outcomes of injury and perhaps even the secondary cellular responses to
injury. While we have a broad understanding of these influences in SCI, the particular
aspects of injury biomechanics and secondary injury responses have not been thoroughly
investigated. In another aspect of my project, I investigation how subsequent compression
affects the overall outcomes and inflammatory responses in Mus contusion SCI. This study
identifies a unique injury progression specific to compression injuries, manifesting as a
proportional increase in pathological macrophages, exacerbated tissue pathology, and a
premature cessation of functional recovery in the subacute recovery window. Insights from
this study provide strong rationale for the effectiveness of immunomodulatory therapies,
particularly in SCI that involves sustained compression.
The novel mammalian models of SCI developed in this project point toward a
strong influence of cellular dynamics in the subacute window after compression SCI.
Insights across these studies can be applied to advance therapeutic development and to
inform the effective application of these therapies.
KEYWORDS: Spinal cord injury, Acomys, wound repair, injury biomechanics,
inflammation, fibrotic scarring
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CHAPTER 1. AN INTRODUCTION TO UNDERSTANDING AND TREATING SPINAL CORD
INJURY
Developing biomedical therapies requires researchers to discover physiologicallyrelevant targets and identify the proper contexts to enable efficacy of intervention. A
critical first step toward developing therapies is building an understanding of the key
differences between pathological and functional systems. This process is no less arduous
or important than the creation of the intervention itself. Animal models are perhaps the
most fundamental and powerful tools available to biomedical researchers because they
provide the opportunity to create and test hypotheses in the complex contexts of a living
creature. Throughout my doctoral training, I have developed and studied novel animal
models of spinal cord injury (SCI) to identify potential therapeutic targets and the contexts
in which these therapies would be efficacious.

1.1

Clinical Presentation and Approaches for Spinal Cord Injury
Each year in the United States, roughly 18,000 individuals survive a SCI and seek

medical attention. Unfortunately, less than 1% experience complete neurological recovery
by the time of discharge1. This lack of recovery is due to an inability to naturally regenerate
damaged spinal pathways and an absence of clinical treatments to induce robust reparative
processes. The purpose of my research is to discover translatable therapeutic targets that
will enable induction of endogenous repair processes after SCI, thereby improving the
standard of care and standard of living for people with SCIs.
The inherently unexpected and heterogeneous nature of SCI makes the
development of safe and effective therapies an onerous task for biomedical researchers.
The most common stereotype is a young male suffering a SCI during an inherently
1

dangerous activity, but the reality of SCI is much more diverse. The most common causes
of SCI are: vehicular crashes (39.2%), falls (31.8%), acts of violence (13.5%),
sports/recreation activity (8.0%), and medical/surgery-related (3.1%)1. These causes
preclude preventative therapies due to their unexpected onset. Furthermore, the clinical
presentation of injury is highly heterogeneous. Injuries vary in spinal location, injury
severity, and injury type. Additionally, the patient population is not limited to any
particular socioeconomic group, race, gender, or age. The sum of these factors means that
biomedical researchers are striving to develop a therapy that can be administered after the
SCI takes a place, and a therapy that will be efficacious across a spectrum of injury types
and patients.
After the initial trauma inflicted by a SCI, resident neuronal and glial cells change
physiological functions and peripheral cells cross the disrupted blood-spinal cord-barrier.
The amalgamation of infiltrating and activated resident cells creates a complex SCI
microenvironment. Some of these injury responses are critical for restoring and
maintaining normal function of the spinal cord, but many aspects of these injury responses
exacerbate the initial damage in a process known as secondary injury. The duality of this
system allows researchers an opportunity to manipulate injury responses to better facilitate
endogenous repair of spinal pathways. However, understanding each aspect of the injury
response—both individually and within its greater microenvironmental context—is a
challenging necessity to effective employ therapies. The goal of this particular project is to
understand how secondary injury responses contribute to reparative and pathological
aspects of SCI, with the hope of identifying targets for therapies that will induce
endogenous repair of damaged spinal pathways.

2

1.2

Normal Function of the Spinal Cord
The spinal cord is rich in neurons and glial cells. While glia are fairly ubiquitous

throughout the cord, researchers have come to understand a fairly rigid organization of
spinal neurons. Broadly speaking, the grey matter in the center of the spinal cord houses
neuron cell bodies, called soma, and is surrounded by white matter that is rich in the axonal
tracts that propagate information via action potentials. These action potentials carry
information that governs sensory, motor, and autonomic function throughout the body.
Sensory information is carried through afferent pathways, which travel from
peripheral tissues to the brain, while motor and autonomic control is carried through
efferent pathways, which travel from the brain to peripheral targets. These pathways are
strictly separated within the spinal cord and have distinct spinal exit points to preserve
signal fidelity, but there is also controlled crosstalk between these pathways via
interneurons that exist entirely within the spinal cord. Collectively, the afferent, efferent,
and interneuron pathways facilitate transmission of sensory information, control autonomic
function of involuntary actions, and perform controlled, voluntary motor functions.
In addition to neurons, a suite of glial cells are required for normal central nervous
system (CNS) function. Oligodendrocytes wrap axons with myelin sheaths, insulating the
axon to increase action potential conduction velocity and decrease signal decrement.
Astrocytes interface with neurons and vasculature, where they sequester and transport
neurotransmitters, ions, and nutrients to enable and optimize neuronal signaling. Pericytes
ensheath endothelial cells of the CNS capillaries, where they optimize neurovascular
function. Microglia patrol the CNS as resident immune cells, sampling the environment,
destroying unwelcome constituents, phagocytosing pathogens and debris, and secreting

3

growth and supportive factors. Each of these glial cell types are necessary complements to
their neuronal collaborators to maintain efficient signaling in the spinal cord2.

1.3

Endogenous Repair of the Damaged Spinal Cord
While damage to the spinal cord causes neuron death and robust loss of axonal

pathways, the injured spinal cord is capable of modest repair. In fact, there are several ways
in which the spinal cord can re-establish functional pathways after injury. Damaged
neurons can reform synaptic connections with the same or new targets or form similar or
novel pathways. Additionally, axons can get to their destinations by regrowing directly
through damaged areas or sprouting around the injury core3. Strict regeneration would form
the same neuron-target connections through the same axonal pathways, but spinal repair
through other means can elicit similar functional recovery.
One critical step in re-establishing spinal function is creating a permissive
microenvironment for axon growth. For a long time, dogma dictated that CNS neurons
were incapable of axon regrowth, unlike peripheral nervous system (PNS) neurons that
readily regrow damaged axons. More recently, this dogma has been thoroughly overturned.
Both CNS and PNS neurons are capable of robust axon regrowth in vitro and in vivo, but
we have come to understand that the microenvironmental context is critical in determining
the axon growth potential. When peripheral nerves are grafted onto the injured spinal cord,
axons readily grow through the permissive PNS microenvironment4. Furthermore, specific
manipulation of ECM proteoglycans allows enhanced axon regrowth into the SCI lesion5.
While these studies indicate that adding a permissive environment or removing inhibitory
factors allows regrowth, the unaltered SCI microenvironment is not completely inhibitory.
Genetic manipulation of spinal neurons can induce axon regeneration through the unaltered
4

lesion core6. Collectively, we now understand that CNS are capable of axon regrowth, but
the SCI microenvironment is a potent—though not insurmountable—barrier to axon
regrowth.
It is critical to consider non-neuronal cells to create a spinal microenvironment that
enables spinal repair. Upon injury, microglia transition from their quiescent, ramified
morphology into activated states that are nearly indistinguishable from peripheral
macrophages in their protein expression and morphology. These activated microglia, along
with infiltrating neutrophils and macrophages, release proteolytic enzymes and reactive
oxygen species (ROS) to break down debris and protect from potential invaders. In
addition, fibroblasts proliferate and invade into the lesion core, where they deposit a variety
of ECM molecules. Some posit that the provisional ECM scar serves a similar role in the
CNS as in peripheral tissues, acting as a temporary scaffolding for cellular infiltration and
facilitating eventual wound closure7-10. Astrocytes also play a critical role in the CNS injury
response. Astrocytes proliferate, grow, and form a dense barrier at the edge of the lesion
core to corral toxic species and limit the spread of damage into penumbral tissues11. The
functions of these resident glia and infiltrating cells, including other cell types not
discussed above, are critical to clear the SCI site while preserving the structural integrity
and protecting penumbral spared tissues.

1.4

Pathological Responses to Spinal Cord Injury
At the time of injury, synaptic connections are lost, axonal damage disrupts signal

propagation, and neurons undergo mechanically-induced cell death. While some of this
damage is immediately evident from blunt force mechanical trauma, much of the damage
becomes evident over time through secondary cellular responses. One aspect of this
5

secondary damage is Wallerian Degeneration, where damaged axons and their associated
myelin sheaths degrade away from the site of injury12. This primary and secondary damage
to axonal tracts is the most direct contributor to functional deficits from SCI.
Simply increasing spinal connectivity through inducing axon growth and synapse
formation does not necessarily lead to improved outcomes, though. It is important to
consider the dangerous dichotomy of novel synapse formation in the CNS, where the dense
collection of potential neuronal targets can have myriad downstream effects. Synapses on
random targets can give rise to maladaptive spasticity, which leads to complications
including hypersensitivity, persistent pain, and autonomic dysreflexia13,14. Therefore, truly
beneficial spinal therapies must not only stabilize damaged neurons and re-establish
functional pathways, but also ensure that only the right kind of spinal circuits are supported.
Non-neuronal cells also mount pathological responses to SCI. The primary injury
triggers secondary injury responses, which are meant to clear debris, corral toxic species,
and enable endogenous repair of damaged spinal pathways, but can also cause damage
through a process known as secondary injury. In the injured spinal cord, resident glia
secrete toxins and cytokines, which can damage tissue initially spared from mechanical
trauma15. The diverse assemblage of glial cells, which is necessary to maintain healthy
CNS function, becomes a complicated array of activated cells with pathological and
reparative properties. Mechanical trauma and downstream signaling cascades further drive
injury progression by facilitating infiltration of nonresident cells. Immune cells extravasate
into the injury site and persist chronically within the injured spinal cord16-18. Fibroblasts
infiltrate, proliferate, and deposit inhibitory ECM molecules within the injured spinal
cord19,20. Together, these resident and infiltrating cells facilitate the secondary injury.

6

1.5

Effects of Spinal Cord Injury Biomechanics
The accidental nature of SCI results in a wide variety of clinical presentations.

Beyond the fact that any person—regardless of genetic background or lifestyle—can suffer
a SCI, each injury can have distinct characteristics. Hereafter, I will refer to the specific
aspects of the SCI as biomechanics. One of the most basic ways in which SCI biomechanics
can differ is by severity. Many studies have shown that increasing the severity of the same
type of SCI leads to worse damage to the spinal anatomy and worse subsequent motor
function21-25. While this is somewhat intuitive, it is important to understand that SCI is not
an all-or-nothing system. Not only can deficits from injury manifest across a spectrum, but
also benefits from treatment can provide meaningful improvements without achieving full
anatomical or functional recovery. Indeed, people with lived experience specifically called
for treatments that restore some, if not all, functionality at the National Institutes of Healthled conference “SCI 202026.”
Beyond severity, more specific SCI biomechanics can also affect the progression
of injury. The initial SCI insult can result from fast or slow addition of force at a focal site
or diffuse across the cord, which can be applied translationally (perpendicular or parallel
with the cord) and/or rotationally. Each of these factors affect the deformation pattern of
the soft spinal tissues, and can cause unique cellular dysfunction27. These distinct
biomechanics are at play in the heterogeneous clinical presentation of SCI. For example,
consider two common types of SCI: gunshot wounds and fracture burst injury (vertebra
breaks and presses into the cord). The gunshot wound would disrupt the blood-spinal cordbarrier (BSCB) in a penetrating injury with severe and transient application of force. The
fracture burst injury, on the other hand, features rapid force generation across a greater
surface area and sustained compressive force for a long period. Understanding the
7

similarities and differences in each of these injuries is key for effectively implementing
therapies across this clinically heterogeneous condition.
Biomedical researchers are building an understanding of the effects of SCI
biomechanics through animal models. A study of contusion (impacting), distraction
(stretching), or dislocation (displacing) SCI reveals that these disparate biomechanics lead
to unique lesion shapes and unique functional deficits28. In another study, adding graded
increases of compression to a contusion injury causes greater tissue damage and worsens
functional recovery from injury23. Counterintuitively, though, another study finds
increased duration of compression does not affect anatomical or functional outcomes29.
Collectively, these studies show that specific SCI biomechanics are highly influential on
the overall outcomes of SCI.
Decades of research have shown that the progression of SCI is largely determined
by secondary injury responders. Unfortunately, little is known about how initial insult
biomechanics affect secondary injury responses. Some studies have shown more severe
injuries lead to more inflammation and fibrotic scarring21,30. However, the little that we do
understand is commonly investigated across various severities of the same injury type, not
vice versa. It is reasonable to conceive that a particular injury biomechanic may play a
specific role across a variety of injury severities. The very limited studies of this nature
have shown that cellular function can be affected by injury biomechanics such as a
direction of force application27,31. The same may be true of another clinically-relevant
injury biomechanic: compression. One aspect of my project investigates the role of
compression, regardless of injury severity, in shaping the inflammatory response to SCI
and the overall progression of injury.

8

1.6

Understanding Spinal Cord Injury through Comparative Models
The complexity and dynamic nature of SCI creates a challenge for deductive

investigation by biomedical researchers. In one approach, researchers can take out specific
cells to test their activity in a highly controlled environment (in vitro). Alternatively,
researchers can test specific questions in live animals (in vivo) to gain insight in a more
appropriately complex context. Rodents, including lab mice (Mus musculus) and lab rats
(Rattus norvegicus), are perhaps the most common in vivo models for SCI. Using these
rodent models allows researchers to test particular questions with the knowledge that
general aspects of rodent SCI—including long-term deficits, the inflammatory response,
and the scarring response—approximate the responses seen in human SCI.
While recapitulating the human condition is important, the fact that common rodent
models do not naturally regenerate damage pathways limits the insight they can provide.
Plainly, these rodents indicate intervention effectiveness, but do not naturally point the way
toward effective therapeutic targets. Instead, researchers will often try to change the
naturally-occurring systems in Mus musculus, commonly through genetic manipulation, in
an attempt to induce regeneration. This approach can provide answers to very precise
questions, but the genetic changes can also cause widespread, off-target effects by altering
fundamental processes established over millions of years of evolution.
An alternative approach for identifying therapeutic interventions is to use naturallyoccurring models of regeneration. Comparative biologists have studied SCI in regenerating
animals such as salamanders, fish, newts, frogs, and neonatal opossums32. Unfortunately,
we have only identified robust regeneration and spinal repair in these non-mammalian
species and neonates. Translating therapeutic targets identified in non-mammalian species
or neonates is incredibly difficult due to their phylogenetic or developmental differences
9

from adult humans. For instance, non-mammalian species have fundamentally different
populations of glial cells and neuroarchitecture within the spinal cord32.
My project investigates SCI in a novel mammalian model, Acomys cahirinus,
which shows enhanced repair after a wide variety of injuries. Thus far, Acomys have been
shown to regenerate kidney, skeletal muscle, skin, glands, adipose tissue, cartilage, and
axons33-37. Importantly, Acomys ear regeneration involves a unique, pro-regenerative
deposition of ECM molecules34, and requires a unique, pro-regenerative inflammatory
response38. The robust and wide-spread regeneration in Acomys, along with the importance
of ECM and inflammation in SCI, provides strong rationale that Acomys may be a valuable
comparative model to uncover therapeutic targets for inducing mammalian spinal repair.

10

CHAPTER 2. A NOVEL MAMMALIAN MODEL OF ENHANCED RECOVERY FROM SPINAL
CORD INJURY, THE AFRICAN SPINY MOUSE (ACOMYS CAHIRINUS)
Neural information and control of the body’s motor, sensory, and autonomic
systems flow between peripheral systems and the brain through the spinal cord.
Accordingly, SCI results in motor, sensory, and autonomic functional deficits. While the
human body is capable of wound repair of many peripheral tissues, we exhibit poor spinal
cord repair39,40. Indeed, the initial SCI spreads to damage nearby spinal tissues and results
in chronic anatomical damage and functional deficits41,42. Limiting the spread of injury and
inducing spinal repair has remained an elusive goal for biomedical researchers. One
approach to uncovering novel therapeutic targets is to study animals with enhanced
anatomical and/or functional recovery from SCI. Unfortunately we have only identified
non-mammalian and neonatal model systems in which to study enhanced spinal repair32.
In this chapter, I will discuss my investigations into the anatomy and functional recovery
of Acomys, a novel mammalian model of enhanced repair43, after SCI. By comparing
Acomys to Mus musculus, a common rodent model of SCI, I will show that Acomys can
serve as an informative model to better understand enhanced recovery from SCI in
mammals.

2.1

Functional Deficits from Spinal Cord Injury in the Clinic
At least 99% of patients have functional deficits at the time of hospital discharge

following SCI1. For decades, the nominal and functional goal of SCI therapies has been to
restore walking. Many consider wheelchairs as the hallmark of SCI, but motor functional
deficits are much more widespread than the ability to walk. Injuries above the fourth
cervical vertebrae can lead to dysfunctions of all 4 limbs (tetraplegia), while injuries at
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thoracic spinal levels lead to dysfunctions in the mid-torso and lower limbs (paraplegia).
Furthermore, high cervical injuries can prevent proper respiratory muscle function, leading
to the necessity of consistent mechanical ventilation and a heightened propensity for
respiratory infections. Therefore, therapeutic strategies improving motor function could
have life-saving functional benefits beyond restoring the ability to walk.
Non-motor functional deficits are equally, if not more important after SCI.
Dysregulation of autonomic control of circulation, known as autonomic dysreflexia, is a
constant consideration and can prove fatal44. Chronic pain from SCI often necessitates
prescription pain medication and is associated with mortality45. Non-fatal deficits are also
widespread and critically important. Both paraplegics and quadraplegics prioritize sexual
dysfunction, bladder/bowel control, and trunk stability above walking, while quadraplegics
prioritize arm/hand function above all others46. This is not meant to minimize any particular
functional deficit from SCI, but it is important to remember that the functional detriments
of SCI are widespread and devastating.
Personal accounts at national meetings from individuals living with SCI and
research surveys gathering data on the true desires of the population have identified that
autonomic and sensory functions are oftentimes a higher priority than motor function26,46.
Studying these pathways is difficult, due to their complicated nature, but is nonetheless
critical. Voluntary bladder voiding is a key example. Proper function involves coordinated
efforts from the sacral micturition center, pontine micturition center, and cerebral cortex,
where parasympathetics provide excitatory input for muscle contraction, somatic nerves
inhibit sphincters to allow fluid flow, and sympathetic nerves provide inhibition for
relaxation47. Immediately after injury, spinal shock can render these nerves inactive,
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leaving no micturition reflex to void and no awareness of the bladder’s fullness48. Later
after injury, the neurogenic bladder can recover some function, become overactive, or stay
unresponsive48. The complexity of these pathways make them both difficult to study, and
vulnerable via multiple mechanisms to multiple types of dysfunction. Metanalysis
estimates that urinary incontinence is present in 33.1% of individuals with SCI49 and other
studies estimate some sort of bladder dysfunction in up to 80% of individuals living with
SCI48. Unfortunately, those individuals without independent bladder and bowel control
have lower physical independence, mobility, occupation function, and overall life
satisfaction50.
Collecting data on these motor, sensory, and autonomic functions is critical to
diagnose the injury and to evaluate any therapeutic benefits of interventions. The most
common clinical evaluation tool today is the American Spinal Injury Association (ASIA)
Impairment Scale, which measures motor and sensory function at various dermatomes and
classifies injury severity across 5 classes (A, B, C, D, or E)51,52. The graded measurement
across various dermatomes/myotomes is necessary because, as discussed above, functional
deficits depend on many factors, including the location and severity of SCI. Collectively,
these nuances are incredibly important for the individual living with SCI because deficits
can persist for their entire life, and the nature of these deficits can have extreme impacts
on their quality of life46.

2.2

Open Field Testing of Motor Functional Recovery from Spinal Cord Injury
Preclinical research uses a wide battery of functional recovery outcomes, but

perhaps the most common are open field tests. The Basso Battie Bresnahan (BBB) scale
was developed for rats53, followed by the Basso Mouse Scale (BMS) for mice54. In these
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tests, animals are allowed to roam freely in an open field and trained observers rate their
hindlimb function based on a pre-determined set of movements. As these are among the
most common outcomes for rodent SCI experiments, they have been well-described.
Furthermore, centralized training courses have been established to ensure consistency
amongst various labs in the field.
While the BMS is a powerful tool to describe the wide range of hindlimb motor
function after SCI, the scale is not a perfect fit for all situations. Some animals may respond
with an abnormal progression through the scale parameters, in which case BMS subscores
are used to describe individual aspects of hindlimb function53. BMS subscores provide the
additional benefit of presenting data in a readily-interpretable state. Rather than showing a
functional improvement from 2 to 3 on the BMS scale, a subscore can effectively relate
that animals are able to plant their paw beneath their body. In this study, I use the total
BMS scores and subscores derived from the BMS, thereby assessing the full spectrum of
hindlimb motor function while also analyzing accessible and relevant functional outcomes
individually.
One of the most difficult motor feats for a tetrapedal animal with a thoracic spinal
cord injury is supporting its weight on solely on its hindlimbs, also known as “rearing”55.
Rodents readily perform the rearing action as part of normal exploration55 (as shown in
Figure 2.3.1). However, rearing is a complex motor challenge. Rearing requires the animals
to have the proprioceptive ability to maintain balance while simultaneously supporting its
own weight to move upward. Both of these complex motor tasks are important in SCI
functional recovery. Proprioception is critical to initiate and maintain locomotor recovery56
and body weight support has been heavily adopted as a means to induce functional recovery
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in humans57,58. Therefore, analyzing rearing in rodents gives insight into complex and
critical aspects of motor functional recovery.

2.3

Acomys Show Enhanced Recovery from Spinal Cord Injury
Functional recovery is the clinical focus of SCI therapies and therefore is a critically

important outcome for preclinical biomedical research. Spinal damage disrupts motor,
sensory, and autonomic pathways, but motor functional deficits have historically received
the most focus. Considering that Acomys exhibit regeneration of various tissues including
functional recovery in the skin and kidney37,43, I sought to test the functional recovery of
Acomys after SCI. Here, I will describe the functional outcomes in Acomys compared to a
standard mammalian model, Mus, after SCI.As discussed earlier, Mus are a useful control
because they largely recapitulate human SCI responses and recovery and because they are
among the most commonly employed in vivo SCI model systems. We matched animals
based on developmental stage, using young sexually mature animals. Animals were 3-6
months old, which reaches well-established timelines for sexual maturity in Mus; Acomys
were determined to be sexually mature based on changes in fur patterns that occurs upon
sexual maturity59. All male animals were used to preserve breeders for the Acomys colony.
Our lab typically uses the Mus strain C57BL/6J, but for these experiments we used the
Swiss Webster strain. Swiss Webster are a multipurpose model commonly used for safety
and efficacy testing. I chose Swiss Webster because they are generally larger than C57BL/6
and were therefore closer to Acomys weight when developmentally matching animals.
Animals were tested for baseline function and acclimated to home cages before
administering a spinal crush injury and allowing intervention-free recovery for specified
days or weeks post injury (dpi or wpi, respectively). 10 animals of each species were deeply
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anesthetized, the spinal cord was exposed, and modified forceps were used to administer a
spinal crush for 1 second at thoracic level 9 (T9). The animals were allowed to recover
from anesthesia and were returned to home cages, where they were checked twice daily
and provided access to food and water ad libitum. Animals were given analgesic
immediately after injury and antibiotic for the first 5 days after surgery, but were given no
other treatments. 1 Acomys and 2 Mus died through the course of the study, leading to final
sample sizes of 9 Acomys and 8 Mus.
Functional recovery data were collected longitudinally from animals until a chronic
time point 12wpi. This time point was determined based on the a-priori criteria that both
species had ceased recovering function, with a minimum time post-injury of 8wpi. To
determine when both species had reached a functional recovery plateau, a blinded
statistician reviewed longitudinally-collected functional recovery data and indicated to the
researchers when hindlimb function did not change in both species over time. Therefore,
animals were euthanized 12wpi, several weeks after statistically reaching a recovery
plateau. Further details of the animal husbandry, SCI surgery, and functional testing are
included in Appendix 2 (sections A2.1, A2.2, and A2.3, respectively).
I set out to evaluate both motor and sensory functional recovery in Acomys. Our
approach to test mechanical and thermal sensitivity (Von Frey and Hargreave’s,
respectively) requires animals to be reliably capable of withdrawing their hindpaws from
mechanical and thermal stimuli. Unfortunately, we were unable to perform these tests after
injury because the animals did not recover sufficient motor control to reliably withdraw
their paws. However, unexpected phenomena in Acomys routine care gave potential
insights into autonomic functional recovery. As a part of routine animal care, I manually
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palpated the lower abdomen to void the animal’s bladder twice daily (described in more
detail in Appendix 2). As described above, voluntary bladder voiding is controlled by both
somatic and autonomic spinal pathways. Humans and other rodents have been shown to
lose the ability to voluntarily void bladders either transiently or permanently after SCI48,60.
While Mus showed expected bladder dysfunction—recorded as small, medium, or large
bladders at the time of routine voiding—Acomys unexpectedly returned to having empty
bladders soon after injury. I quantified this phenomenon in retrospective analysis of these
routine animal care sheets, recording bladder voiding as the first of 3 consecutive days with
an empty bladder. These retrospective data show a significant improvement of bladder
voiding in Acomys compared to Mus (Figure 2.4.1A, p<0.0001).
Similarly, routine animal care involves weighing animals weekly as a gross
indicator of health. Body weight was similar between Acomys and Mus both 1 week preinjury and at the time of surgery (Supplementary Figure A1.1). As expected from historical
rodent SCI experiments, animals lost ~10% of body weight immediately after SCI, and
there was a significant change in body weight over time (p<0.0001). However, Acomys
recovered significantly more body weight (species effect p<0.05) significantly quicker
(interaction effect p<0.001) than Mus (Figure 2.4.1B).
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Figure 2.3.1: Acomys recover empty bladders and body weight more
quickly than Mus.
A) Routine bladder care was unnecessary in all Acomys by 11dpi while 89%
of Mus required manual bladder voiding for the full 12 week course of the
study. Data analyzed as a log-rank using the Mantel-Cox test, ****p<0.0001.
B) Animals were weighed weekly throughout the study, and Acomys
recovered closer to pre-injury body weight more quickly than Mus. n=8 Mus,
n=9 Acomys. Bladder voiding analyzed by log-rank Mantel-Cox test. Body
weight analyzed by two-way ANOVA with Sidak’s multiple comparison
correction. *p<0.05, ***p<0.001, ****p<0.0001.
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While these unexpected data are reflective of important and robust effects, it is
important to note the caveats of these retrospective analyses. Interpretation of these results
is difficult considering the number of factors that may affect bladder voiding and body
weight. The bladder size of Acomys preinjury was not established, nor are the urodynamics
well understood. Unlike Mus, Acomys are native to semi-arid climates and may therefore
store water differently. Furthermore, while I administered saline injections for the first 5
days after injury as part of routine animal care, I did not control for water intake. While
these are hefty considerations when interpreting the robust increase in bladder voiding in
Acomys, the trend is consistent with an independent study of Acomys SCI61. Further study
is warranted to understand if Acomys have improved bladder voiding, and these
investigations could identify if Acomys could serve as a model of enhanced somatic and/or
autonomic signaling to regain control of the bladder after SCI.
To evaluate hindlimb functional recovery, we employed open field tests including
the BMS, BMS subscores, and rearing. Methods are detailed in Appendix 2. For BMS and
BMS subscores, animals are allowed to roam freely in a large plastic environment for 4
minutes while at least 2 trained observers score the animal’s hindlimb function according
to the ability to perform each movement prescribed by Basso et al. in their original paper
developing the scale62. These hindlimb scores are used to grade hindlimb motor function
on a scale from complete paralysis (score = 0) to normal (score = 9). Alternatively,
individual hindlimb functions can be analyzed independent of the full scale as a subscore.
These subscores are particularly important in this study because they do not presume the
ordered progression of functions originally created specifically for Mus. In this study, I
analyze hindlimb plantar placement, plantar stepping, and coordination in outcomes
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derived from the original BMS development publication. Additionally, I evaluated
hindlimb function by measuring rearing, a difficult task that involves sophisticated motor
and proprioceptive control. Briefly, I allowed animals to roam freely for 10 minutes in an
activity box with an array of infrared beams. Movement across the ground—or horizontal
movement—was measured by “beam breaks” on a lower row of infrared beams, while
rearing—or vertical movement—was measured by “beam breaks” on a higher row of
infrared beams. By analyzing the vertical/horizontal movement, I normalized the amount
of rearing to the total amount of movement for each animal to avoid misinterpreting
inactivity as less rearing.
Establishing baseline functional readouts was critical for this comparative study to
ensure that proper hindlimb function was being analyzed for each species. Accordingly,
trained observers watched Acomys and Mus hindlimb locomotion pre-injury. One
important note is that some Acomys did not have tails before injury, so our subsequent
analyses disregarded the final grading criteria, tail positioning, on the BMS scale.
Otherwise, both animals were capable of performing all aspects of the BMS grading scale
and exhibited normal scores, achieving a maximum score of 8 (normally 9 is achieved
based on tail positioning)62. Allowing animals 10 minutes in the activity box showed that
both species are both capable of measurable hindlimb rearing. Furthermore, both species
were shown to rear a similar amount pre-injury, as shown by similar vertical/horizontal
movement (Mus = 0.85±0.35 vertical/horizontal episodes vs. Acomys = 0.74±0.26
vertical/horizontal episodes; p = 0.47; Figure 2.3.2A). Collectively, these baseline
measurements show that Acomys and Mus have similar scores on hindlimb functional
assessments before injury.
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Immediately after injury, animals typically show a rapid and robust loss of motor
function. After spinal crush injury, both Acomys and Mus show similar hindlimb functional
dysfunctions. Specifically, both species reach an average BMS score of about 1 at 3dpi,
which is reflective of slight ankle movement (Figure 2.3.2B). Collectively, the data shown
in Figure 2.3.2 show that Acomys and Mus have similar baseline functional ability
(according to these measures), and that both species experience similar initial functional
deficits from SCI.
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Figure 2.3.2: Acomys and Mus have similar baseline hindlimb function
and similar functional deficits from spinal crush.
Open field tests were used to evaluate pre-injury (baseline) and post-injury
hindlimb function. A) Acomys and Mus have fully functional hindlimbs
1week before injury, including the ability and inclination to perform the
“rearing” motion supporting themselves on their hindlimbs. B) However, at
3dpi both Acomys and Mus show diminished hindlimb function with an
average score that reflects an average hindlimb functionality of “slight ankle
movement.” n=8 Mus, n=9 Acomys. Analyzed by student’s T test, ns=no
significant difference. Video of baseline (uninjured) and 3dpi hindlimb
function is included as an additional file.
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From previous experience in mammalian spinal cord injury, we expect to see some
functional recovery during the first few weeks after injury. As expected, both Mus and
Acomys recovered some hindlimb function over the first 2wpi. However, Acomys recovered
significantly better hindlimb function, beginning around 2wpi, which resulted in
significantly better hindlimb function at chronic time points after injury (Figure 2.3.3). At
11wpi, Mus reach a BMS score of ~3, which reflects plantar placing of the paw or dorsal
(but not plantar) stepping, while Acomys reach a BMS score ~5, which reflects frequent or
consistent stepping without coordination or with some coordination and improper paw
rotation (Figure 2.3.3A). When analyzing specific individual hindlimb functions by BMS
subscores at 11wpi, we see improvement in Acomys hindlimb plantar paw placement with
weight support (p<0.001, Figure 2.3.3C) and hindlimb plantar stepping (p<0.05, Figure
2.3.3D), which is significantly different from Mus. It is important to note, though, that
Acomys had improved but not completely recovered hindlimb function after injury. For
example, Acomys do not have statistically significant improvements in coordination at
chronic time points after injury (Figure 2.4.3E).
Although Acomys functional recovery is not perfect after SCI, the hindlimb
function improvements are both robust and meaningful. This is perhaps most poignantly
shown in rearing, which was measured longitudinally after animals first recovered the
ability to step frequently. Acomys recover significantly better rearing than Mus, which is
consistent from 4-10wpi (Figure 2.3.3B). Video collected 10wpi further illustrates the
robust differences between species (videos included as additional files).
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Figure 2.3.3: Acomys exhibit enhanced functional recovery from SCI.
A) Acomys recover significantly better hindlimb function according to the
Basso Mouse Scale, which covers a wide variety of movements that span
paralysis (score of 0.0) to normal hindlimb function (score of 8.0, excluding
tail function). B) Acomys also recover significantly better rearing ability,
beginning at 4wpi, after animals first recovered the ability to step on their
hindlimbs. Subscores explicitly analyzing specific aspects of the Basso
Mouse Scale at 11wpi show significantly better plantar placement (C) and
plantar stepping (D) in Acomys, but both species fail to reach consistent
coordination (E). n=8 Mus, n=9 Acomys. BMS (A) and Rearing (B) analyzed
by two-way ANOVA with Sidak’s multiple comparison test; subscores (C-E)
analyzed by student’s T-test. Species effect and interaction (species x time)
effect displayed below graphs, ns=no significant difference, *p<0.05,
**p<0.01, ***p<0.001, ****p<0.0001. Video of hindlimb function is
included as additional files.
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The robust and consistent improvements in Acomys hindlimb motor function are
unique amongst known mammals and provide incredible insight and promise for inducing
endogenous mammalian functional recovery. Functional recovery is not only evident using
the bins from BMS, but also specifically evident for specific hindlimb functions using the
subscores. While these two findings are complementary, it is important to note the caveat
that the BMS is somewhat subjective and based on the prior experience of the observers.
Each trained observer used in this study was extensively trained for BMS using Mus. While
the same movements are readily evident in Acomys, there may be subtle differences that
affect the grading, especially concerning the stepping and coordination scores. For
instance, differences in Acomys gait may lead an observer to judge that a normally-walking
Acomys is not “coordinated”. However, the bias of observers to the natural Mus movements
is more likely to lead to low Acomys scores. If this bias is influencing the functional
recovery data, then Acomys would have an even greater improvement in functional
recovery based on BMS.
Additionally, it is important to consider the potential for bias in data collectors,
particularly considering that trained observers can readily tell the group difference based
on phenotypic differences between species. The BMS outcome is limited by the repeated
measures of individuals that are not blinded to the group code. To counteract this
shortcoming, chronic BMS and subscores were graded by 6 trained observers that had not
participated in longitudinal analysis. This approach aimed to circumnavigate any potential
bias developed by longitudinal observation of animals obviously belonging to a particular
group. Importantly, 2 of the 6 observers were blinded to the overall hypothesis in the study,
and the scores from these individuals clustered well on an animal-by-animal basis with the
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full cohort of 6 observers. Chronic BMS and subscore values displayed in Figure 3.3 are
average values amongst the 6 novel observers. Therefore, while bias may be present based
on obvious group code, steps were taken to validate the effects as best as possible.
The activity box rearing test was implemented at least in part because it is an
unbiased test relying simply on “beam breaks” rather than any human grading. It is
important to consider, though, that rearing involves both the ability and the inclination for
each animal. It is possible that Mus were simply unmotivated to rear after injury.
Furthermore, it is possible that Mus were simply unable to reach the higher row of beams
to trigger a rearing episode. I ran several additional tests to ensure that these factors did not
account for species differences in rearing. First, I suspended food above the apparatus to
motivate animals to explore the vertical space. In a subsequent iteration, I moved the upper
row of infrared beams to a lower position. In both tests, Acomys exhibited even more
rearing, while Mus remained similarly disabled. Furthermore, considering the context of
the BMS subscores, most Mus did not regain the ability to support their weight on plantarplaced paws; this logically precludes supporting the body on the hindlimbs alone. Finally,
the baseline test shows a trend for slightly more rearing in the Mus than Acomys, which
suggests that Mus do not have a decreased inclination to perform rearing. However, some
studies have noted that rodents decrease rearing with familiarity of a location 55. While my
additional investigations into rearing suggest that the above-mentioned factors are not
likely to have affected my outcomes, it may be worthwhile to test baseline rearing in Mus
and Acomys over time with repeated weekly measures.
As discussed above, SCI affects autonomic, motor, and sensory functions. While I
have presented strong evidence for robust motor functional recovery in Acomys (Figure
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2.3.3), the evidence for autonomic functional recovery (Figure 2.3.1) has many caveats,
and I do not have evidence for improved sensory functional recovery. At the outset of these
experiments, I intended to collect sensory functional recovery data. Indeed, I collected
baseline measurements of mechanical and thermal sensitivity in the hindpaws of both Mus
and Acomys. These baseline readings show that Acomys have significantly higher threshold
to withdrawal from mechanical stimulus of the hindpaw (p<0.001), but similar threshold
to withdrawal from heat stimulus of the hindpaw (Supplementary Figure A1.2). As shown
above, several Mus were unable to achieve plantar placement on the floor of the testing
area, and it did not seem that most of the animals were capable of reliable withdrawal
motions in response to stimuli. Therefore, we did not collect sensory functional recovery
data in Mus and Acomys after injury. Future studies implementing a less severe SCI may
allow animals to recover the ability to withdraw paws from mechanical and/or thermal
stimuli, and these studies could identify if Acomys also show enhanced sensory functional
recovery after SCI.

2.4

Anatomical Damage from Spinal Cord Injury
The functional deficits that follow SCI are oftentimes considered the symptoms of

underlying anatomical pathology. The initial mechanical damage can sever axons and kill
resident neurons and glia at the injury site. Subsequent cellular responses can further
exacerbate tissue pathology by damaging surrounding cells and replacing functional tissue
with non-functional fibrotic material. Indeed, spinal pathology is readily evident in rodents
and humans at chronic times post injury42, and many note that anatomical pathology and
functional deficits are oftentimes correlated21,22. While some evidence identifies that
anatomical and functional recovery can operate independently63, it is difficult to imagine
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normal motor, sensory, and/or autonomic function in the absence of functional spinal
circuitry. Therefore, many biomedical scientists still focus on anatomical recovery as a
complement to the critical goal of functional recovery.
Neurons are arguably the most commonly studied cell type within the spinal cord.
The grey matter is rich with neural soma, including motor neurons of the ventral horn,
sensory neurons of the dorsal horn, and interneurons interspersed throughout the grey
matter. These neurons are long-lived and do not seem to be readily replenished by
intraspinal stem cell pools, so neurotoxicity after SCI is a serious concern.
Unfortunately, there are many potential sources of neural damage during the spinal
cord injury. Initial mechanical damage can destroy cells outright or cause more subtle shifts
in cell membrane permeability that can lead to dysregulation and eventual neural death27.
Subsequently, environmental changes such as increasing pressure, hypoxia, or iron from
hemorrhage can also lead to neuron death64. Neurons can damage one another by releasing
excessive neurotransmitter and over-activating targets in a deadly process known as
excitotoxicity65. To further complicate matters, there are a wide array of cellular effectors
that can damage neurons after injury. Resident and infiltrating cells release toxic cytokines
and factors that can lead to neuron death. For instance, while astrocytes of the glial scar
form a barrier to isolate the lesion core and protect penumbral tissues, these astrocytes also
exhibit concurrent neurotoxicity66. This neurotoxicity is readily evident through a variety
of histological stains, including immunolabeling of the neuronal nuclear antigen NeuN.
Even if neurons survive, the white matter on the edges of the spinal cord contains
long axonal tracts that are subject to damage that could inhibit function. A process known
as Wallerian degeneration occurs in neurons with damaged axons, where the axons retract,
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losing their myelinated sections, and sometimes leading to total neuron death12. Axons are
capable of regrowth, as discussed earlier, but re-establishing full function requires
concerted effort from both neurons and glial cells. For instance, myelination of axons in
the spinal cord is critical to enabling and optimizing signal propagation67,68. For this reason,
stains of myelin have been employed to understand frank tissue pathology, or total tissue
pathology that is likely to contribute to functional deficits69,70. Other studies also use
astrocytic scar formation as a measure of frank tissue pathology because GFAP+ astrocytes
will form a stark delineation at the border of the lesion71,72.
When investigating axons specifically, a useful approach is to target cytoskeletal
components that provide structural support and facilitate intracellular transport. Neurons
have some specific cytoskeletal components, including specialized intermediate filaments
known as neurofilaments. Neurofilaments are composed of subunits, including high
molecular weight NF (NF-H), which is a key cytoskeletal component commonly used to
stain axons CNS71. High molecular weight NF is present in most axons, but is most highly
expressed in mature, myelinated axons73. Targeting NF-H for immunolabeling allows
visualization of the full length of most axons. Because of this, I target NF-H to
immunolabel mature axons in the injured spinal cord.
Alternatively, targeting neurotransmitters can provide more nuanced control by
labeling

specific neuron subpopulations.

Serotonin

(5-HT) is

a monoamine

neurotransmitter synthesized by a subset of CNS neurons primarily in the brainstem74.
Supraspinal serotonergic neurons project axons into the spinal cord, where they have axon
terminals in the grey matter at all spinal levels75,76. Serotonergic fibers are known to affect
sensory and motor systems, and are involved in autonomic control77. Specifically,
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serotonin is known to regulate rhythm and coordinated movements through regulation of
central pattern generators (CPGs)78. In fact, administering serotonin to CPGs can improve
hindlimb function and increase functional training-induced recovery74. As a histological
tool, serotonin has been previously used to evaluate axonal growth across spinal lesions
because the supraspinal source of 5-HT means that caudal serotonergic fibers must traverse
the lesion plane5,79,80. Similarly, in this study I use 5-HT as a tool to immunolabel
descending supraspinal pathways that can affect motor function to evaluate rostral-tocaudal regrowth of axons after injury.

2.5

Spinal Tissue Pathology in Acomys after Injury
Functional recovery is often attributed to increased axons or neurons available to

propagate signal through the injured spinal cord. It is reasonable that sparing or recovering
more neural tissues should improve functional outcomes from SCI. I investigated if robust
functional improvements seen in Acomys could be attributed to improvements in decreased
anatomical damage.
To better understand the spinal structure after injury, I stained and analyzed sagittal
spinal sections harvested from animals euthanized 3 days, 1 week, 2 weeks, or 12 weeks
after SCI (as described in Section 2.2 and Appendix 2.2). These spinal sections were
stained with a variety of antibody- or chemical-based stains to visualize various aspects of
the spinal cord, and images were collected using brightfield or fluorescent microscopy.
These images were evaluated for qualitative differences in pathology and were analyzed
on HALO histology analysis software to determine quantitative differences between
species. Methods are described in more detail in Appendix 2, section 2.4.1.

30

Chronic spinal sections from 12wpi were evaluated to identify any long-term
improvements in axon growth between species. The SCI lesion is easily identified using
antibodies targeting glial fibrillary acidic protein (GFAP) to visualize astrocytes and the
astrocytic scar that forms at the lesion border in mammals. Axons were visualized by
targeting NF-H, which stains all mature axons in the spinal cord, and by targeting 5-HT,
which stains serotonergic axons descending from the brain. Both Mus (Figure 2.5.1) and
Acomys (Figure 2.5.2) have NF-H-positive axons traversing the injury. Few 5-HT-positive
axons are evident in both species, but surprisingly it seems that Mus may have more 5-HTpositive axons than Acomys caudal to the injury site. In both cases, it seems that any axons
have either been spared at the edges of the injury or have regrown around the edges of the
spinal lesion.
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Figure 2.5.1: Chronic axon pathology in Mus.
Mus spinal cords isolated 12wpi were fluorescently immunostained for
astrocytes (GFAP, Green), axons (NF-H, blue), and serotonergic axons (5HT,
red). Three sagittal sections from a representative animal are shown in each
column, which approximately correspond to spinal locations displayed in the
top schematic (A). Each row shows images of merged channels (B) GFAP
(C), NF-H (D), and 5HT (E). Scale bar for all images is 500µm.
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Figure 2.5.2: Chronic axon pathology in Acomys.
Acomys spinal cords isolated 12wpi were fluorescently immunostained for
astrocytes (GFAP, Green), axons (NF-H, blue), and serotonergic axons (5HT,
red). Three sagittal sections from a representative animal are shown in each
column, which approximately correspond to spinal locations displayed in the
top schematic (A). Each row shows images of merged channels (B) GFAP
(C), NF-H (D), and 5HT (E). Scale bar for all images is 500µm.
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Axon sparing is profoundly affected by acute injury responses after SCI. The
expansion of spinal damage can be facilitated by secondary injury responses, as outlined
in chapter 1. To evaluate axon sparing after injury, I immunostained for astrocytes (GFAP)
to visualize the injury area, axons (NF-H), and cell nuclei (DAPI) in spinal sections isolated
3dpi, 1wpi, and 2wpi. At 3dpi the dynamic injury site has dystrophic axons with swollen
endbulbs, likely in the beginning phases of Wallerian degeneration, and the GFAP+ glial
scar border has not yet been established around the injury site (Figure 2.5.3A-F). By 1wpi
the glial scar border has been established, and while some axons are growing past the glia
limitans, they do not appear to reach the injury core (Figure 2.5.3G-L). Interestingly, Mus
seems to send more axons past the glia limitans than Acomys (Figure 2.5.3I,L). This trend
seems to hold at 2wpi, where both species have a strongly-established glial scar border.
Mus axons abut and exceed this border while Acomys axons largely stay distant (Figure
2.5.3M-R).
Axon histology does not identify a robust decrease in axon pathology to
complement the robust functional recovery in Acomys. Chronic histology shows axons do
traverse the injury site around the edges of the lesion core, and these strips of astrocytes
and axons are recognizable by 2wpi (illustrated in Figure 2.5.3P-R). While the strip is only
readily evident in the representative image from Acomys at 2wpi (Figure 2.5.3P-R), it is
important to note that this was evident in both species. Lateral spinal sections—analogous
to regions 1 and 3 in the schematic from Figure 2.5.1A—show very similar strips of intact
tissue. Despite this similarity in strips of axon growth, Mus surprisingly have a slightly less
axon pathology, as shown qualitatively by more axon growth into/near the lesion core at
subacute time points and more serotonergic fibers in the caudal cord at the chronic time
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point. Furthermore, by 2wpi it appears that there is a non-cellular cavity formed in the
Acomys spinal cord whereas Mus have continuous cellular tissue throughout the lesion
core. These are unexpected results given the context of robust Acomys functional recovery
versus Mus.
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Figure 2.5.3: Mus and Acomys axon pathology after SCI.
Both species show significant pathology as visualized by immunostaining for
axons (NF, red), astrocytes (GFAP, green), and nuclei (DAPI, blue). Axon
pathology begins to become evident at 3dpi, but astrocytic borders show the
lesion core established by 1wpi. Both species show significant axon
pathology at 1 and 2wpi, but Mus show more axons unassociated with
astrocytes in the lesion core at 1wpi and 2wpi. Scale bar listed at the bottom
of each column. Species and timepoint listed to the left of each row.
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Spinal cord injury incurs both axonal damage and neural cell death. Grey matter
contains the soma of spinal neurons, and the death of these spinal neurons can be readily
identified by staining the soma with NeuN81. I stained sagittal spinal sections from animals
euthanized 3dpi, 1wpi, and 2wpi with antibodies targeted to NeuN and NF-H to gain a
better understanding of neuron cell death after injury in each species (Figure 2.5.4).
Subsequent analysis measuring the rostral-caudal distance between areas of NeuN+ soma
quantifies the rostral-caudal spread of neuron pathology in each species. This
quantification reveals a mild recovery of soma from 3dpi to 2wpi, but no statistical
difference in the rostral-caudal spread of neuron pathology between species (Figure 2.5.5).
Again, this finding is surprising considering the robust functional improvement in Acomys
versus Mus.
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Figure 2.5.4: Mus and Acomys soma pathology after SCI.
Images are sagittal spinal sections isolated from injured animals and stained
for neuron soma (NeuN, black) and axons (NF, brown). Each spinal section
is representative of the average value for each species at 3dpi (A-F), 1wpi (GL), and 2wpi (M-R). Scale bars provided at the bottom of each image pane.
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Figure 2.5.5: Mus and Acomys have similar soma pathology after SCI.
Sagittal spinal sections were collected from injured animals 3dpi, 1wpi, or
2wpi, and were stained for neural soma by immunolabeling NeuN. The
distance between areas of normal soma anatomy was measured, and analysis
shows no statistical difference between species. Mus 3dpi (n=4), 1wpi (n=7),
2wpi (n=5); Acomys 3dpi (n=8), 1wpi (n=8), 2wpi (n=4). Data analyzed by
two-way ANOVA with Sidak’s multiple comparison correction, species
effect and interaction (species x time) effect displayed below graphs, ns=no
significant difference.
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Non-axonal tissue pathology is equally important to understand after SCI,
especially considering that non-axonal aspects are critical for proper spinal function. As
such, I use Eriochrome Cyanine (EC) to stain myelin, along with a brightfield stain of NFH-targeted antibodies. This combination of myelin and axon staining is common in the SCI
field to assess frank tissue pathology69,70. From this stain, I evaluated the frank spinal lesion
as EC-negative area because the area of myelin loss are indicative of pathology, even if
demyelinated axons are present. Analysis shows that Acomys had significantly smaller
spinal lesions. as measured by lesion area (Figure 2.5.6A, species effect p < 0.001) and
rostral-caudal lesion length (Figure 2.5.6B, species effect p < 0.01).
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Figure 2.5.6: Acomys have significantly more myelin sparing after SCI.
Spinal cord sections from various times post injury were stained with EC and
NF-H to label myelin (blue) and axons (brown), respectively. A) Acomys had
significantly smaller spinal lesions, as determined by area of myelin
pathology normalized to the total cord width at the epicenter of injury, at 2wpi
and as a species effect across all time points. B) Acomys also had less rostralcaudal spread of myelin pathology as a species effect across all time points.
C-J) Representative images from Mus and Acomys are representative of the
mean tissue pathology at each time point. Lesion size (A) sample sizes: Mus
3dpi (n=4), 1wpi (n=10), 2wpi (n=4), 12wpi (n=8); for Acomys 3dpi (n=8),
1wpi (n=8), 2wpi (n=4), 12wpi (n=9). Lesion Length (B) sample sizes: Mus
3dpi (n=3), 1wpi (n=10), 2wpi (n=5), 12wpi (n=8); Acomys 3dpi (n=8), 1wpi
(n=8), 2wpi (n=4), 12wpi (n=9). Data analyzed by two-way ANOVA with
Sidak’s multiple comparison correction, species effect and interaction
(species x time) effect displayed below graphs, ns=no significant difference,
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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The rostral-caudal spread of pathology is used as a fundamental outcome in the
quantification anatomical damage. This is an informative measure of lesion growth,
sparing, or repair because both species were injured with the same modified forceps.
Therefore, the initial spinal insult was delivered to the same rostral-caudal extent of the
spinal cord and secondary physiological differences between the two species can therefore
be assumed to account for differences in rostral-caudal neuron and/or frank tissue
pathology. Due to the novel nature of Acomys SCI research, little is known about these
subsequent injury responses. In fact, a paper from Streeter et al. is the only other study of
SCI in Acomys to supplement findings of this document, and they show significant
differences in post-injury responses of Mus vs. Acomys61. Therefore, while we may assume
that secondary injury responses account for differences in Acomys spinal function and frank
tissue pathology, it is unclear exactly what those responses are and how they work. More
information to inform the interpretation of this chapter is included in chapters 3 and 4,
where I investigate Acomys inflammatory and fibrotic response to SCI, respectively.
The histological approaches listed above give valuable insight into the frank tissue
integrity, myelination, and axonal profile in the injured cord, but these stains are not
perfect. High molecular weight NF is more highly expressed in mature axons, so NF-H
stains may underestimate the total number of axons or neurites in the injury site. However,
these immature axons are less likely to be facilitating proper function within the spinal
cord, and a histological snapshot of these immature axons may misrepresent these highly
transient neurites. Targeting 5-HT allows visualization of spinal pathways descending from
the brain that facilitate motor function. However, it is important to note that 5-HT is a
neurotransmitter rather than a structural protein (like NF-H), and may therefore reflect axon
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terminals more robustly that axon tracts themselves. While this is true, 5-HT terminals are
readily found throughout the grey matter of the spinal cord in non-human primates and
rodents74, so we would expect to see expression of either axons or their terminals
throughout the intact cord. Finally, labeling with EC is a common practice for visualizing
frank tissue pathology in SCI69,70, but it is important to remember that this stain is specific
to myelin. The pathology seen in EC-stained images can be influenced by the dynamic
degradation and recovery of myelin independent of other cell types, as illustrated by nude
axons in the injury site in the phenomenon of “myelin ghosts” that form in the absence of
axonal counterparts82. That being said, oligodendrocytes in the spinal cord are critical for
optimized neuron signaling, and are one of the better outcomes we have to assess “intact”
spinal tissues.
When considering these histological outcomes, it is important to remember that
tissue sections taken from different time points are simply snapshots from an individual
animal at an individual time. While these investigations are helpful to understand
generalized species effects at various times before/after injury, they do not allow for an
understanding of the progression of injury/recovery within an individual animal. Further
investigations that use longitudinal imaging methods would be highly informative to
accurately establish immediate injury effects and subsequent lesion expansion and/or
resolution at various times after injury. One relatively simple method to perform this
analysis would be by ultrasound, where edema in the soft spinal tissues could be used as a
generalized measure of tissue damage. Alternatively, magnetic resonance imaging (MRI)
provides more powerful quantitative imaging methods to assess fluid dynamics within the
cord. An optimal test for assessing spinal pathway integrity could be diffusor tensor
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imaging (DTI), to visualize fiber tracts in the spinal cord before and after SCI83. Both of
these imaging techniques are complicated by the small size of the rodents and even smaller
size of their spinal cords; imaging would require extremely high resolution to provide
adequate voxel-to-voxel discrimination of lesion size with sufficient sensitivity to assess
any subtle differences between groups. Additionally, the location of the SCI needs to be
accessible to both imaging methods. The spinal cord is normally housed beneath layers of
skin, fat, muscle, and bone. While the dorsal aspect of the vertebra is removed during the
SCI surgery procedure, the spinal level varies in the amount of overlying muscle and bone.
A low-thoracic injury may be optimal for minimizing the depth of the imaging plane, but
many factors and outcomes must be considered in concert to ensure that a SCI experiment
provides the most and best possible data for each animal used in the study. While
longitudinal imaging methods would be onerous, these experiments would provide
incredibly useful insight into the progression of anatomical pathology in Acomys.
While longitudinal imaging would be advantageous in future studies, the presented
histological analysis can be used to focus these future investigations. This series of
histological stains covers a wider range of time points than are typical for studies, and this
canvassing of the acute (3dpi), subacute (1 and 2 wpi), and chronic (12wpi) time points
identifies the subacute window as a key time for additional, more granular study. In my
data, Acomys show robust improvements in myelin sparing and reverse unfavorable trends
in neuron death between 1 and 2wpi. Concurrently, the glial scar matures into a robust
delineation between the lesion core and penumbral tissues, while the Acomys lesion appears
to shrink and develop into a cavity. Results presented in chapters 2-5 further bolster the
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argument that there are interesting and meaningful secondary processes taking place in the
subacute window that warrant more granular subsequent studies.
The formation of a cavity is an unexpected and interesting outcome of these
histological investigations. Formation of cyst-like cavities typically occurs in the grey
matter of the injury epicenter, where it is assumed that tissue is completely destroyed,
leaving only a rim of subpial preserved tissue that can include myelinated axons84. Cavity
formation is actually rather common amongst mammals, including rats85, hamsters86, and
humans87. It would seem that the filled Mus injury core is somewhat unique amongst
mammals86,88. Here, we see that Acomys form a cavity in the subacute time points after
injury, which persists and even expands chronically. The cavity in the central cord with
EC/NF-H-positive tracts around the edges, seems analogous to the grey matter cavity with
a rim of white matter sparing described by Guest and colleagues in humans84. In terms of
translation, this suggests that frank anatomical pathology of Acomys SCI more closely
mimics humans than that of Mus.
Collectively, these histological investigations into Acomys anatomical response to
SCI reveal that they do not have enhanced neuron or axon sparing after injury, but may
have better preservation of spinal tissue than Mus. These results provide important insights
for SCI researchers, especially when considered in the context of enhanced functional
recovery in Acomys.

2.6

Insights into Functional Recovery and Anatomical Pathology from Acomys Spinal
Cord Injury
Spinal crush results in some functional recovery in Mus over the first 2 weeks after

SCI, after which functional recovery ceases and leaves animals with chronic functional
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deficits. The moderate functional recovery in Mus is expected and in accordance with other
studies of thoracic SCI using similar injury biomechanics (discussed in Chapter 5), namely
contusion and compression70,89. While Acomys do not fully recover from spinal crush, they
recover significantly better hindlimb function compared to Mus beginning at 2wpi and
sustaining to chronic time points. Interestingly, these robust and sustained functional
improvements in motor function do not coincide with robust improvements in soma or
axon pathology, but do coincide with decreased frank tissue pathology.
While we expect anatomical repair to underly functional recovery, a disconnect
between anatomy and function is not unprecedented63. In rats, injuries induced by graded
increases in tissue displacement lead to graded spinal damage and motor deficits, but
sensory deficits only manifested after reaching a threshold of white matter damage24.
Indeed, even in highly-controlled preclinical models, lesions of similar size can differ
subtly in shape or location and thereby elicit significant differences in function63.
Furthermore, improvements in motor function can occur without any axon recovery90. In
humans, women have more natural neurologic recovery than men, but men tend to show
better functional recovery from rehabilitation91. Individuals can manifest worsening
functional status according to the ASIA impairment scale despite actual neurologic
improvement52.
Perhaps the most relatable experiment showing a disconnect of anatomical and
functional recovery from SCI is the comparative biology investigation of SCI in the
MRL/MpJ mouse by Kostyk and colleagues. MRL/MpJ is a strain of Mus musculus noted
for its enhanced wound repair. After SCI, the MRL/MpJ mouse had many more neurites
growing through the lesion core, but did not exhibit greater tissue sparing (indicated by
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Luxol Fast Blue staining of myelin) and exhibited significantly worse functional recovery
(according to BMS) through 6wpi92. A subsequent study of MRL/MpJ mice contradicts
Kostyk and colleagues by showing MRL/MpJ mice return to baseline function on a rotating
rod and a grid walk, but these improvements can be attributed to worse functional
performance of MRL/MpJ mice at baseline rather than superior post-injury hindlimb
function compared to C57BL/6 controls93.
Acomys show the inverse of MRL/MpJ mice, with significantly more tissue sparing
and functional recovery, but no apparent improvements in axon growth out to 12wpi.
Accordingly, while Kostyk et al. conclude that the permissive MRL/MpJ environment
allows extensive axon growth but an inability to restore tissue integrity92, my data indicate
that Acomys are able to maintain tissue integrity and thereby facilitate enhanced spinal
signaling without similarly-robust increases in axon sparing or growth. This finding
situates Acomys as a more valuable translational model for uncovering therapeutic targets
for mammalian SCI considering that the primary goal of therapies is functional
improvements for injured individuals.
There are several ways by which Acomys could be inducing functional recovery
without robust neuronal or axonal sparing. Myelination of axons enhances signal
propagation and axon stability, and this myelination is known to occur in both the subacute
and chronic windows after SCI84,94. This process depends on oligodendrocytes and
oligodendrocyte precursor cells (OPCs) that are sensitive to secondary injury through
processes such as hemorrhage95 and inflammation96,97, and can be influenced or stimulated
by microenvironmental ECM molecules98,99 and growth factors100,101. Later chapters will
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further investigate these secondary processes that may be influencing oligodendrocyte and
OPC survival and remyelination.
Alternatively, improvements in Acomys motor function could be facilitated by
intra-spinal rather than supra-spinal pathways. Central pattern generators (CPGs) exist in
the lumbar spinal cord and assist in the maintenance of rhythmic movement78. While CPGs
are typically under the control of supra-spinal pathways including serotonergic input74,
evidence suggests that CPGs can also operate independent of supra-spinal input102. Some
studies have identified that enhanced functional recovery from interventions after SCI can
rely solely on these intra-spinal pathways90. In this investigation we do not observe
enhanced 5HT growth across the lesion site. However, the robust—yet notably
uncoordinated—hindlimb function in Acomys could potentially be facilitated by these
intra-spinal pathways and CPGs rather than recovery of supra-spinal pathway recovery.
Further investigations could identify if the increased spinal function is occurring at
the injury site by several methods. One straightforward way to assess the involvement of
supra- vs. intra-spinal circuits is to allow animals to recover from a first SCI then
performing a second SCI—preferably a transection90. While this experiment would reveal
if the functional recovery is attributable to caudal intraspinal circuits, it compromises the
ability to analyze long-term sequalae by adding an additional injury. Alternatively,
measuring electrical signaling through strategically-placed stimulating and recording
electrodes, a process known as electrophysiology, could provide evidence for intra- or
supra-spinal signal propagation103,104. While this method provides important insight into
the nature of supra- and/or intra-spinal signaling, stimulation changes the native spinal
environment and electrode placement can destroy tissues, compromising the ability to
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perform informative histological assessments. Future investigations could employ these
spinal function assessments to better understand Acomys functional recovery on a tissuespecific level.
Mus are somewhat unique among mammals in that they do not form cavities after
SCI. Some hypothesized that the Mus response to SCI, where the lesion site is moderately
contracted and filled in with macrophages, fibroblasts, and fibrotic scar, is advantageous
compared to cavity formation86,88. Here, we observe that Acomys form cavities at subacute
time points (2wpi), and that these cavities persist—perhaps even expand—chronically
(12wpi). Considering this phenomena in the context of robust improvements in Acomys
hindlimb function suggests that cavities are not inherently detrimental to functional
recovery after injury. This assertion is supported by neonatal opossum models of SCI,
where cavities form at the lesion site but animals still recover weight-bearing
locomotion105. Full regeneration of intact spinal tissues is surely an ideal goal for SCI
wound repair. However, the insights gained from these models of enhanced mammalian
repair suggest that filling in spinal cavities should not be a top priority when attempting to
recover weight-bearing locomotion.
Collectively, this first investigation into Acomys functional and anatomical
recovery after SCI develops our foundational understanding of enhanced repair of the
mammalian spinal cord. It appears that salvaging tracts of tissue integrity, regardless of
cavity formation and despite similar neuron and axon sparing, is sufficient to enable robust
hindlimb functional recovery after thoracic spinal crush. Investigations in subsequent
chapters will endeavor to understand the injury responses that underly Acomys functional
recovery.
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CHAPTER 3. DAMPENED INFLAMMATORY RESPONSE IN ACOMYS SPINAL CORD INJURY
Spinal cord injury evokes a robust inflammatory response at the injury site and
distant spinal regions, which persists chronically18,106. Recent research has revealed that
the inflammatory response is highly nuanced, and that subtle shifts in the inflammatory
profile can cause meaningful changes in outcomes of SCI2,107,108. These studies primarily
use rat and mouse models—which roughly recapitulate human SCI inflammation and
outcomes—to evaluate how manipulating inflammation affects the progression of SCI.
However, the field is still clarifying the exact role of inflammation. In this chapter, I will
discuss my work studying inflammation in Acomys SCI, a novel model of enhanced
recovery. These studies provide critical insight into mammalian inflammatory responses
that allow or enable enhanced recovery from SCI, and can inform future efforts for
therapeutic development.

3.1

Overview of Inflammation Following Spinal Cord Injury
Inflammation is critically important for clearing debris and is a normal phase of

wound healing, preceding the proliferative phase and subsequent remodeling phase109,110.
Innate immune cells, including circulating macrophages and CNS-resident microglia, are
key cellular mediators of the inflammatory response. Spinal cord injury creates cellular
debris and releases intracellular proteins that act as potent inflammatory stimuli. These
injury-exposed signals, also called damage-associated molecular patterns (DAMPs), are
normally concealed from immune surveillance within the intact CNS111. After injury,
though, DAMPs engage pattern recognition receptors (PRRs) on inflammatory cells and
mediate activation of resident inflammatory cells including astrocytes and microglia112.
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Reactive astrocytes and microglia release a wide variety of oxidative stress
regulators, cytokines, chemokines, growth factors, and other inflammatory mediators113.
Microglia also alter cellular morphology and protein expression profiles after SCI. Under
normal conditions, microglia have long, thin processes that extend out from the central cell
body to sample the extracellular environment. Following injury, microglia retract their
processes and assume a more amoeboid morphology, better suited for phagocytosis and
debris clearance. Visualizing these cells through F4/80-, Iba1-, and/or CD11b-targeted
immunohistology shows that these activated microglia closely resemble circulating
macrophage morphology114.
Along with the morphological changes comes the release of chemokines and
cytokines which serve to recruit peripheral neutrophils and macrophages into the injured
spinal cord115-118. Chemokines drive increased expression of selectins and cell adhesion
proteins on nearby endothelial cells, and integrin-mediated adhesion of circulating immune
cells facilitates extravasation of monocytes and neutrophils into the spinal cord119.
The first wave of infiltrating immune cells are neutrophils, which peak in rodent
and human spinal cords around 1dpi16,18,106,120-123. Neutrophils perform bactericidal
functions as the first line of defense against invaders. However, neutrophil bactericidal
mechanisms can contribute to SCI pathology. For instance, the oxidative burst of reactive
oxygen species (ROS) can prove cytotoxic to otherwise-spared penumbral tissues80,117,124.
Conflicting studies report varying degrees of neutrophil-mediated oxidative damage
following rodent SCI 125,126. Neutrophil levels drastically decrease in the rodent and human
spinal cord within the first week post-injury, but low levels can persist
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chronically16,121,127,128. The resolution of neutrophils is coincident with increased
monocyte-derived macrophage infiltration into the spinal cord129.
Infiltrating macrophages contribute proteolytic enzymes, ROS, and inflammatory
cytokines to the injury microenvironment, but also perform necessary functions of debris
clearance, cellular remodeling, and production of pro-regenerative factors114,129,130. The
dual beneficial and reparative functions of macrophages make understanding their role in
the injury response difficult. Endogenous microglia-derived and recruited monocytederived macrophages are also difficult to distinguish in the injured spinal cord. As
discussed above, macrophages are very similar to microglia in morphology, protein
expression, and function. Indeed, disentangling the two cell types required flow cytometry
or genetic methods until very recent identification of protein markers distinct to the
microglia131,132.
Our understanding of the role of neuroinflammation is rapidly evolving to
encompass detrimental and beneficial effects of each cell type during various phases post
injury. Some studies show that monocyte depletion improves functional recovery from
SCI119,133, while others show that implanting macrophages or microglia improves
function134-137. Understanding the role of neuroinflammation is critical for treating
neurotrauma because human studies have shown us that neuroinflammation starkly
increases within the first few days of SCI and persists for weeks to months after injury16.

3.2

Dual Role of Macrophages and Microglia in Secondary Damage and Wound Repair
Macrophages play diverse roles throughout the inflammatory, proliferation, and

remodeling phases of wound healing. In the inflammatory phase, macrophage-mediated
inflammation releases a slew of toxic products to clear debris and protect the injury from
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potential infection. During this inflammatory phase, common cytotoxic products from
macrophages include proinflammatory cytokines such as tumor necrosis factor-α (TNFα)
and interleukin-1β (IL-1β), free radicals such as nitric oxide (NO) and ROS, and
metabolites such as eicosanoids and quinolinic acid130,138,139. However, macrophages and
microglia are also critical for proliferative and remodeling phases of wound repair.
Macrophages release pro-regenerative cytokines such as interleukin-4 (IL-4) and
interleukin-10 (IL-10), and growth factors such as platelet derived growth factor (PDGF)
and transforming growth factor-β (TGFβ)140-142. In an organized system, these macrophage
functions complement one another over space and time to facilitate a cohesive and
beneficial wound repair response107,143,144.
Unfortunately, coordination of the complex macrophage-mediated wound healing
response can be derailed and result in dysregulated damage. Macrophages are highly
influenced by contextual cues143, and evidence suggests that macrophages sustain a
prolonged inflammatory response to SCI, which contrasts the peripheral wound healing
response that features a more timely transition into proliferative and remodeling
phases39,107,127. Prolonged inflammation coincides with long-term ROS deposition145,146,
blood-spinal cord-barrier (BSCB) disruption147,148, and proinflammatory cytokine
deposition16,116.

Decreasing

macrophage-mediated

inflammation

by

depleting

macrophages, inhibiting macrophage entry into the spinal cord, or pharmacologically
limiting inflammation can improve anatomical and functional recovery from
SCI80,117,119,133,149.
While most studies point toward the detrimental effects of over-abundant and overactivated macrophages in the spinal cord, there are many that suggest a beneficial effect of
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macrophages and microglia. Microglia-laden grafts allow enhanced axon growth135 and
injections of peripheral nerve-stimulated macrophages enhances functional recovery136 in
the injured rat spinal cord. Other studies show that depleting macrophages decreases tissue
integrity and decreases functional recovery from SCI134,137. The sum of these experiments
suggests that limiting inflammation may be beneficial, but specifically harnessing
inflammation—by maintaining strictly controlled cell numbers and activation states—is a
more nuanced and powerful tool for maximizing endogenous repair mechanisms2. To
develop such therapies, we must gain a nuanced understanding of the role of inflammation
in spinal repair.

3.3

Comparative Models Inform Our View of Macrophages in Wound Repair
Adult mammals are limited in their wound repair capabilities, which allows

recapitulation of human healing responses but limits insight into naturally-occurring
responses that facilitate enhanced repair. Comparative analysis of tissues and animals with
enhanced repair, on the other hand, can illuminate a pathway for researchers to follow in
pursuit of reparative therapeutic targets. These comparative studies across various organ
systems, developmental stages, and animal species have highlighted a critical role of
macrophages in injury responses and wound repair.
Macrophages are necessary for regeneration of various tissues across different
animal models38,150-152. While there are no studies definitively showing that macrophages
are required for spinal cord regeneration, many lines of evidence point towards their
importance in spinal repair. Resident inflammatory cells activate, migrate, and proliferate
in response to SCI in lamprey153,154, zebrafish155, and salamanders156. Studying these nonmammalian models of SCI repair has illuminated the importance of macrophage/microglia58

mediated inflammation in axon guidance153,154,157 and in supporting proliferation158.
However, inflammation is not ubiquitously beneficial for spinal regeneration in these
animals. Regeneration can be increased by removing particular proinflammatory factors in
the zebrafish159 or by inhibiting microglial inflammation in salamanders160. These results
indicate that the non-mammalian inflammatory response is nuanced, and that the specific
differences are critical in facilitating spinal repair.
While macrophages are present early in development and exist almost ubiquitously
across vertebrates, these macrophages have distinct differences from adult mammalian
analogues32,161. Targets identified in neonatal or non-mammalian models may be vastly
different or entirely absent in the adult mammal. Therefore, researchers have attempted to
find comparative models within the adult mammal. Comparing the non-regenerating rat
spinal cord to the rat sciatic nerve, which regenerates after injury, Leskovar and colleagues
see fewer macrophages and cytokines within the first 3 weeks of sciatic nerve injury 162.
Other attempts to glean insight into adult mammalian repair have used the
MRL/MpJ strain of Mus, which has been shown to respond with enhanced wound repair in
the ear. Brain stab and dorsal hemisection show increased microglia response in the acute
phases of injury (<2wpi)93,163, while another study of spinal contusion injury shows
decreased macrophage/microglia response at later time points (14-42dpi)92. Collectively,
the MRL/MpJ CNS injury studies do not reach a consensus, but may indicate that a
dampened inflammatory response at later time points may allow or enables greater axon
growth in the damaged spinal cord.
This project investigates inflammatory response to SCI in Acomys, a rodent that
responds to injury in multiple organs with robust wound repair. Importantly, Acomys
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wound repair across each organ system coincides with a uniquely regulated inflammatory
response, especially pertaining to macrophages. Acomys were first noted for regeneration
of autotomized skin, which was hypothesized to be a defense mechanism akin to gekkos
and lizards43. Further investigations of Acomys skin regeneration show almost no F4/80+
macrophages enter the injury site, while there are many F4/80+ macrophages in the Mus
injury and in the spleen of both species33. A recent proteomic analysis also suggests that
Acomys skin regeneration has lower levels of multiple components of the complement
cascade, but many components were below a detectable threshold164. Some data also
suggest that Acomys have lower levels of inflammation-stimulating and chemotactic
cytokines at the skin injury site, but these results are inconsistent and require further
study165,166. As the focus on Acomys as a mammalian model of regeneration has grown,
evidence suggests that the dampened inflammatory responses to injury also applies to
internal organ systems. Kidney and muscle injuries result in less F4/80+ staining for
macrophages at the injury site compared Mus 36,37.
Perhaps the most thorough study of the Acomys inflammatory response was
performed by Simkin and colleagues in the context of the ear hole punch injury. They note
that while circulating levels of inflammatory cells are similar between Acomys and Mus,
the Acomys ear injury site shows fewer Iba1+ macrophages than Mus38. Furthermore,
Acomys appear to achieve sophisticated spatial control of macrophage subsets. Acomys
restrict pro-inflammatory (CD86+) macrophages from the leading edge of regeneration,
while allowing pro-reparative (CD206+) macrophages access; Mus, on the other hand,
have greater levels of both macrophage phenotypes without any apparent spatial
restriction38. Perhaps the most important takeaway from this study is the requirement of
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macrophages for Acomys ear regeneration. Macrophage depletion with clodronate-loaded
liposomes prevents ear hole closure in Acomys, but regeneration resumes after a washout
period and return of macrophages38. This study elegantly shows Acomys achieve
sophisticated control of a blunted inflammatory response, which is required for repair of
ear punch injuries.

3.4

Acomys Have Dampened Macrophage/Microglia Response to Spinal Cord Injury
As outlined earlier, injury causes macrophages and microglia to activate, migrate

to the injury site, and proliferate. These inflammatory cells have both beneficial and
detrimental effects on repair in the injured cord107, but general trends indicate that robust,
widespread inflammation exacerbates cellular damage and inhibits functional
recovery119,133,167. Acomys have shown a dampened inflammatory response with
sophisticated control of macrophage localization33,37,38 in peripheral organ systems after
injury. Considering this, along with the fact that that Acomys show less frank tissue damage
and better functional recovery from SCI compared to Mus, I sought to investigate
macrophage/microglia-mediated inflammation in the injured Acomys spinal cord.
In lab mouse SCI, microglia respond within hours, macrophages begin infiltrating
within 3 days, and inflammation reaches peak levels around 1wpi, but inflammation
persists for months after injury129. To analyze the spatiotemporal patterning of the
inflammatory response, we created a time course of histological spinal samples from
animals with mid-thoracic (T9) spinal crush injuries including acute (3dpi), subacute (1
and 2wpi), and chronic (12wpi) time points. These sagittal spinal sections were
immunostained targeting allograft inflammatory factor 1 (Iba1), glial fibrillary acidic
protein (GFAP), and DAPI to visualize macrophages/microglia, astrocytes, and nuclei,
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respectively. Stained sections were then imaged using a “scan scope” to capture a fulltissue montage of 20x images, and these images were analyzed for staining density above
threshold in a series of five 500µm2 square ROIs positioned at the injury epicenter and
abutting one-another rostral and caudal to the injury epicenter. Whole cord staining was
determined as the density of staining across all 5 ROIs. Collectively, this analysis method
enables analysis of macrophage/microglia density across various times post-injury and
over various rostral-caudal distances across the cord.
As expected, macrophage/microglia density increases from 3dpi to 1wpi in the
injury epicenter (Figure 3.4.1B) and across the wider rostral-caudal extent of the cord
(Figure 3.4.1A). Historical studies suggest this increase in inflammatory density is due to
the infiltration of peripheral macrophages into the lesion core2,118. Acomys show
significantly lower density of macrophages/microglia across the whole cord (species effect
p < 0.001) and specifically at the injury epicenter (species effect p < 0.05). Furthermore,
there is a significant difference in the progression of whole-cord macrophage/microglia
response between Acomys and Mus (interaction effect p < 0.05). This effect seems to be
driven by a consistently sustained inflammatory response in Mus while Acomys have less
inflammation at 2wpi (p < 0.05) that remains dampened at 12wpi (p < 0.01). Interestingly,
these effects are less profound in the injury epicenter. While Acomys have less
macrophage/microglia inflammation in the injury epicenter over time (species effect p <
0.05), there is no difference between species at subacute time points and a statistically
significant difference only emerges at 12wpi (p < 0.05), although there is not a statistically
significant difference over all time points (interaction [species x time]).
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Figure 3.4.1: Acomys have a dampened immune response over time.
Spinal cords were harvested from injured animals 3dpi, 1wpi, 2wpi, and
12wpi, then sagittal sections were fluorescently immunostained for
macrophages/microglia by labelling Iba1. Density of positive staining was
analyzed in a single 500µm2 square ROI at the injury epicenter (B) or in a
series of five 500µm2 square ROIs expanding rostral and caudal to the injury
epicenter (A). Acomys have significantly less macrophage/micoglia staining
at the injury epicenter (B) and more broadly across the cord (A). Mus 3dpi
(n=7), 1wpi (n=6), 2wpi (n=5), 12wpi (n=7); Acomys 3dpi (n=6), 1wpi (n=5),
2wpi (n=4), 12wpi (n=9). Data analyzed by two-way ANOVA with Sidak’s
multiple comparison correction, species effect and interaction (species x time)
effect displayed below graphs, ns=no significant difference, *p<0.05,
**p<0.01, ***p<0.001, ****p<0.0001.
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Representative images the quantification of a less robust inflammatory response in
Acomys compared to Mus. Amoeboid, activated macrophages/microglia are readily
apparent in both Acomys and Mus lesion cores at all time points after injury, but the spread
of these activated macrophages/microglia is more robust in Mus than Acomys (Figure
3.4.2). This trend of more widespread macrophage/microglia activity is particularly
apparent in the subacute window 2wpi (Figure 3.4.2G-L). However, this spatial restriction
is not apparent at chronic time points (Figure 3.4.2M-Q). Macrophages/microglia also
appear to have a distinct morphologies between species. While we expect to see the more
amoeboid shape in the lesion core with ramified, quiescent microglia further from the
injury core, there are ramified microglia much closer to the injury site in Acomys and some
macrophages/microglia appear to adopt an almost spheroid morphology in Acomys cords
at chronic time points (Figure 3.4.2L,Q). These qualitative observations are valuable, but
further analysis is necessary to confirm unique morphological or other phenotypic profiles
in macrophages and microglia after Acomys SCI.
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Figure 3.4.2: Acomys have a unique, dampened inflammatory response
to SCI.
Representative images from histological samples of spinal cords 1, 2, and
12wpi immunostained for macrophages/microglia (Iba1, red), astrocytes
(GFAP, green), and nuclei (DAPI, blue). Activated, amoeboid
macrophages/microglia are readily apparent in the lesion core and in
penumbral areas of the spinal cord.
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Figure 3.4.3: Acomys have a dampened inflammatory response with
spatial restriction of macrophages/microglia.
Quantification of Iba1+ staining density at various times after injury show
that Acomys have less macrophage/microglia density in the spinal cord 2wpi
and 12wpi. Additionally, macrophage/microglia are more specifically
localized to the Acomys injury epicenter at 2wpi while inflammation is
widespread in Mus. Mus 3dpi (n=7), 1wpi (n=6), 2wpi (n=5), 12wpi (n=7);
Acomys 3dpi (n=6), 1wpi (n=5), 2wpi (n=4), 12wpi (n=9). Data analyzed by
two-way ANOVA with Sidak’s multiple comparison correction, species
effect and interaction (species x distance) effect displayed below graphs,
ns=no significant difference, *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001.
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Analyzing macrophage/microglia density across various regions of the SCI site
provides insight into the spatiotemporal patterning of the inflammatory response in
Acomys. By analyzing Iba1+ density across the rostral-caudal extent of the spinal cord, we
see that inflammation is generally increased at the injury epicenter in both Acomys and Mus
with a dampened inflammatory response in Acomys at 2wpi (species effect p<0.05) and
12wpi (species effect p<0.0001; Figure 3.4.3). Interestingly, at 2wpi we see a significant
difference in macrophage/microglia distribution between species (interaction effect p <
0.001). While both species have similar macrophage/microglia density at the injury
epicenter, Mus have a similarly-robust macrophage/microglia response at areas more
distant rostral and caudal to the injury site, while the Acomys rostral-caudal cord has less
inflammation (Figure 3.4.3C). Widespread inflammation is considered to be a chief
mediator of secondary damage and responsible for the spread of spinal pathology in the
subacute windows of SCI, and these results may indicate a means by which Acomys limit
subacute damage in the injured spinal cord.
As discussed earlier, it is important to consider that these histological samples are
isolated from different animals at each time point when interpreting effects over time.
While we would expect the group averages to normalize animal-to-animal differences and
provide a snapshot of true group phenomenon at each time point, data should not be
interpreted as changes over time within the same animal. Longitudinal imaging within the
same animal would be favorable to see the dynamic shifts of macrophages/microglia over
time, but these advanced techniques were not possible at this time for the Acomys study.
Furthermore, spinal cords isolated at 12wpi were cut into 25µm-thick sections whereas all
other time points were cut into 10µm-thick sections. This approach was taken to help
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visualize full axon tracts in the histological analysis of axon sparing, but complicates
interpretation of staining density. These caveats should be considered when interpreting
data over time, especially chronic time points.
These results agree with previous studies in Mus showing excessive macrophage
activation at the SCI epicenter and spread of inflammation distant to the epicenter. One
other study has investigated macrophage/microglia activation in Acomys after SCI. Streeter
and colleagues visualized macrophages and microglia in the Acomys and Mus spinal cords
4wpi using Iba1, and noted unique macrophage/microglia morphologies between species.
Contrary to our results, they do not find a statistical difference in the density of Iba1+
staining between Acomys and Mus61. There are several potential contributors to these
contrary findings. First, Streeter and colleagues use a unilateral dorsal crush injury in the
cervical spinal cord. Previous data suggest that SCI responses in the cervical cord are
distinct from those in the thoracic cord103. Additionally, their data reflect a whole-cord
analysis at a single time point after injury. While our data do reflect a species difference in
our “whole cord” outcomes at 2wpi and 12wpi, Streeter et al. see only statistical trends for
a difference in the “entire ipsilateral cord” at 4wpi. There is potential that the 4wpi time
point may represent a unique inflammatory response compared to our 2 and 12wpi time
points. Previous analysis of the time course of inflammation and immune responses
suggests that macrophages and microglia respond to SCI with a multiphasic response,
reaching multiple peaks over the course of a 180 days16. More likely, though, the sampling
areas account for statistical inconsistencies. It is unclear exactly how large of an area is
sampled by Streeter et al., but a large enough area may wash out the statistical effects that
we see in our analysis. Judging from representative images in the Streeter et al. study, it
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appears that there is a spatial restriction and a dampened inflammatory response similar to
the response seen in our study. While this qualitative similarity is important and supportive
of a uniform effect across studies in different labs, the statistical inconsistencies raise some
concerns and merit further study of the macrophage/microglia inflammatory response in
Acomys SCI. Third, their analysis method does not differentiate Iba1+ staining in various
regions of the cord, but rather in a general ROI that is proportional to total cord size. This
analysis method may wash out region-specific effects such as the ones we see at 2 wpi.
Indeed, qualitative assessment of their representative images appear to have more
widespread Iba1+ macrophages/microglia in the Mus cord than the Acomys cord, and the
quantifications do have trends toward less Iba1+ staining in Acomys61.
Acomys appear to have sophisticated spatial regulation of inflammation. This study
suggests that inflammation in the spinal cord is strictly localized to the SCI lesion epicenter.
Simkin and colleagues show spatial restriction is also evident in ear injuries. While Mus
have higher levels of all macrophage subtypes in the ear injury site, Acomys only allow
pro-reparative macrophages to enter the leading edge of regeneration. Macrophage
phenotypes are also critically important in determining axon growth and neurotoxicity in
the injured spinal cord. Histological investigation of macrophage phenotypes in SCI could
show if Acomys achieve a similar spatial restriction of macrophage subsets in CNS injury.

3.5

Acomys Macrophages are Less Toxic to Neurons
Researchers now discuss the beneficial versus pathological roles of macrophages

in SCI through subcategorization of macrophages into a variety of activation states114.
Categorization of these activation states in SCI has been revisited several times in recent
years beginning with the identification of classically activated and alternatively activated
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macrophages in the injured spinal cord, which have been shown to be pathological and
reparative, respectively107. While past classifications have listed macrophage phenotypes
as M1 and M2, with further subdivisions into M2a, M2b, and M2c, more recent trends
abandon strict classification because we now recognize that individual cells can exhibit a
diversity of phenotypic markers over time, dynamically shifting through a spectrum of
activation states107,114.
Regardless of terminology, researchers recognize that macrophages can increase
axon regeneration and neuronal function, but can also exacerbate tissue destruction168.
Unfortunately, pro-inflammatory macrophages predominate after injury in rodents108 and
there is evidence of a sustained pro-inflammatory monocyte activation after human SCI18.
Clinicians and scientists are developing immunomodulatory therapies to target the dual
roles of macrophages and potentiate reparative microglia and macrophage activation within
the injured spinal cord. Past experimental and clinical attempts involved transplantation of
pre-stimulated exogenous microglia or macrophages135,169. With the identification of
endogenously activated reparative macrophages and microglia after SCI108, more recent
immunomodulatory therapeutic approaches are instead focused on altering endogenous
cells.
This study aims to understand the Acomys injury responses and overall outcomes
of SCI. While we identify that Acomys respond to SCI with fewer macrophages, we must
also understand how these macrophages affect neuron health. To investigate the effects of
Acomys and Mus macrophages on neurons, we moved to an in vitro system. Wellestablished methods show that primary bone marrow stem cells can be isolated and induced
to become bone marrow derived macrophages (BMDMs). Our lab and others use these
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BMDMs as a system to investigate specifics of macrophage physiology without the
extraneous variables that are inevitable in a whole-animal in vivo system.
We collected, grew, and stimulated macrophages from Acomys and Mus as
previously described38. Briefly, pluripotent bone marrow stem cells were isolated from
Acomys and Mus femurs and tibias, promoted to differentiate into macrophages, and either
activated or left unactivated before supernatants were collected. I chose to activate
macrophages using lipopolysaccharide (LPS), a bacterial cell wall constituent normally
used to achieve pro-inflammatory phenotype in vitro, and interleukin 4 (IL-4), a cytokine
normally used to achieve an anti-inflammatory phenotype in vitro. These activated
macrophages are intended to adopt an intermediate phenotype that may more closely
resemble macrophages the activated macrophages we expect to see in vivo. After allowing
the activated macrophages 24h to emit their normal milieu of cytokines, growth factors,
oxidative species, etc., I collected the supernatant media. I applied the macrophageconditioned media to N2A neurons to evaluate the effects of the macrophage-produced
milieu on neuron health.
Neurons were exposed to macrophage-conditioned media for 32 hr then assessed
for viability using the MTT assay, which provides a colorimetric measure of cell metabolic
activity that is indicative of cell viability170. As expected, media from activated Mus
macrophages led to less neuron viability than media from unactivated Mus macrophages
(p < 0.0001; Figure 3.5.1). However, media from activated Acomys macrophages did not
result in decreased neuron viability compared to media from unactivated Acomys
macrophages (p = 0.968). Furthermore, media from unactivated and activated Acomys
macrophages led to more neuron viability than media from activated Mus macrophages
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(both p < 0.0001). Interestingly, media from unactivated and activated Acomys
macrophages resulted in slightly less neuron viability than supernatant from unactivated
Mus macrophages. However, this trend was not statistically significant, and was marginal
(6% and 5% reduction, respectively) especially when compared to supernatant from
activated Mus macrophages (20% reduction). These results show that activation of
macrophages in Mus increases neurotoxicity, but Acomys macrophages do not become
more neurotoxic upon activation.
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Figure 3.5.1: Activated Acomys macrophages are less neurotoxic than
activated Mus macrophages.
Stimulating N2A neurons with supernatant from activated Mus macrophages
causes significantly more neurotoxicity than supernatant from activated
Acomys macrophages or from unactivated macrophages from either species.
n=10 per stimulation type, data analyzed by two-way ANOVA with Sidak’s
multiple comparison correction, ****p<0.0001.

74

While this is the first investigation of Acomys macrophage neurotoxicity to our
knowledge, the Mus neurotoxicity trend is consistent with past experiments in our lab and
others. Activating Mus macrophages causes a shift in in the genetic profile, protein
production, and production of toxic species107,114. These activated macrophage products
are likely to cause neurotoxicity, but the MTT assay is an indirect measure of neurotoxicity.
The MTT assay measures the colorimetric reaction of mitochondrial succinate
dehydrogenase

catabolizing

3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium

bromide (MTT) to MTT-formazan. While this assay is commonly used to evaluate cell
viability, the results may indicate a change in mitochondrial respiration that is not
necessarily linked to either cell viability or cellular energy capacity. Future studies using a
more direct and/or more sensitive measure of cell viability are warranted to provide more
concrete evidence of species-specific macrophage neurotoxicity.
Our study uses a macrophage activation/stimulation paradigm that aims to elicit an
“intermediate” phenotype. Past studies in our lab and others have used LPS + interferon
gamma (IFNγ) to produce classically activated “M1” macrophages and IL-4 or IL-13 to
produce alternatively activated “M2” macrophages71,171,172. Simkin and colleagues have
shown that Acomys BMDMs upregulate hallmark M1 and M2 protein markers similarly to
Mus BMDMs in response to typical M1 and M2 stimulation38. However, macrophages
rarely, if ever, exhibit phenotypes that strictly adhere to M1 and M2 paradigms created in
vitro171. As more stimulation paradigms are employed, more nuance and subdivision are
added to the categories and the spectrum of macrophage activation114. We sought to more
closely reflect in vivo conditions by activating macrophages with an intermediate
phenotype, but our results may be specifically applicable to our particular stimulation
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paradigm. Future studies could use spinal homogenates or specific spinal cord constituents
to stimulate BMDMs to a phenotype more indicative of true in vivo activated spinal
inflammatory phenotypes. For instance, a study in our lab performed by Tim Kopper shows
that myelin exacerbates M1 toxicity in Mus BMDMs. Further study of spinal macrophage
phenotypes in Acomys are warranted to better understand their contribution to neurotoxicity
and/or repair in the spinal cord.

3.6

Understanding the Role of Inflammation in Mammalian Spinal Repair through
Acomys
Macrophage- and microglia-mediated inflammation is an important part of

secondary responses to mammalian SCI. These cells are thought to facilitate the clearance
of debris and protect from foreign invaders in the injured cord, but are also capable of
damaging previously spared tissues, thereby contributing to the spread of spinal pathology.
Investigations outlined in chapter 2 show that Acomys exhibit enhanced functional recovery
from SCI at the subacute and chronic time points after injury, which coincides with
decreased frank tissue pathology. These findings suggest that secondary process in the
Acomys spinal cord are able to enhance recovery. Histological analysis shows that Acomys
have significantly less macrophage/microglia density in the injured spinal cord than Mus
at subacute and chronic time points. Furthermore, these histological experiments show that
there is a subacute spatial restriction of Acomys macrophages/microglia to the injury
epicenter. Finally, in vitro experiments show that activated Acomys macrophages are less
toxic to neurons. Collectively, these results suggest that spinal inflammation may be at
least partially responsible for the enhanced Acomys recovery after SCI.
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The association of a blunted inflammatory response and improved recovery from
SCI has been thoroughly investigated in the past. Indeed, the only previously approved
pharmacologic treatment for SCI was the immunosuppressant methylprednisolone173. The
addition of exogenous substances to inhibit macrophage entry into the spinal cord119 or to
directly deplete circulating macrophages133 have been shown to moderately improve
functional recovery. This paradigm has been criticized, however, because some evidence
suggests that macrophages aid in functional recovery134. Indeed, insights from comparative
studies show that macrophages are necessary for proper wound repair, including neonatal
mouse heart regeneration150 and Acomys ear regeneration38. In perhaps the most relatable
experiments,

the

MRL/MpJ

mouse

responds

to

SCI

with

a

diminished

macrophage/microglia response at subacute and chronic time points92. While the dampened
inflammatory response in MRL/MpJ mice does correspond with increased axon growth in
the lesion site, it results in worse functional outcomes92. These results stand in stark
contrast to those in Acomys, where dampened inflammation results in no improvements to
axon growth but robust improvements in functional recovery. Collectively, these results
suggest that simple magnitude of inflammation is not the sole determinant of recovery, or
that there is some deeper, more important aspect to inflammation that determines the
subsequent effects on tissue sparing and functional recovery.
Temporal pattens of inflammation are a key detail determining the pathologic or
reparative role after injury. One approach is to delay the onset of robust inflammation.
Transient blockade of neutrophils has been shown to delay macrophage infiltration in rats
and lead to improved sensory, autonomic, and motor function149. Similarly, benefits of
methylprednisolone were only evident when the drug was administered early and for a
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short period of time174. The results of experiments in Acomys, however, suggest that a
shorter duration of macrophage/microglia inflammation is associated with favorable SCI
outcomes. The Acomys inflammatory response is in line with a more traditional wound
healing response in peripheral tissues—proceeding through 1) inflammation, 2)
proliferation, and 3) remodeling phases—as opposed to the typical rodent SCI response
which apparently fails to properly execute the remodeling phase85,107,127. Inflammatory
resolution in the later phases of wound repair is still an active area of investigation. Some
posit that inflammatory resolution occurs when cells “fizzle out” in the absence of proinflammatory stimuli, while others suggest that the resolution is a much more active
process of encouraging cell apoptosis or exit via vasculature and lymph175,176. Recent
investigations suggest that endogenous resolution mediators, such as Maresin 1, are not
appropriately produced after SCI, and early application of these mediators can facilitate
inflammatory resolution and improved recovery from SCI177. Acomys provide an exciting
new opportunity to uncover and understand these endogenous mechanisms that drive
mammalian inflammatory resolution in the injured spinal cord.
The collective results of less inflammatory density, a spatial restriction of
macrophages to the injury core, and less macrophage-mediated neurotoxicity intuitively
suggests that Acomys should be less toxic to bystander tissues, particularly penumbral
neurons108,170,171. However, histological analysis of neural soma and axons in chapter 2
shows no benefit in Acomys neuron sparing. One potential explanation is that the in vivo
SCI microenvironment is activating macrophages and microglia to an activation state that
is distinct from the activation seen in vitro. Previous studies of Acomys ear injury show that
Acomys macrophages also bear hallmarks of pathologic and reparative phenotypes, but
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restrict pathological macrophages from the leading edge of the injury site38. However, the
spinal cord is a unique microenvironment that has equally unique effects on cellular
activity. In the SCI microenvironment, Acomys macrophages could be more toxic, Mus
macrophages could be less toxic, or both. Further investigation could not only uncover the
true phenotype of the Acomys macrophages, but also provide insight into how these
macrophages might interact with other components of the injury core.
The identification of spatial restriction of inflammation in Acomys has important
implications for the maintenance of tissue integrity and the recovery of spinal function.
Penumbral tissue is particularly important in SCI because small intact tracts of tissue are
capable of creating novel downstream connections that can compensate for lost spinal
pathways178. Less inflammation in those penumbral tissues is potentially beneficial for
many cell types, but is particularly important for oligodendrocytes and remyelination.
Oligodendrocytes are lost over the first few weeks post injury, and surviving
oligodendrocytes are limited in their remyelination because they are posmitotic179,180.
Therefore, OPCs are critical for the recovery of myelination and spinal function in the
lesion border181. Unfortunately, these cells are particularly at risk of macrophage- and
microglia-mediated inflammatory damage96. As discussed in chapter 2, myelination of
axons is critical for proper signal propagation and spinal function. Therefore, the restriction
of macrophages from these oligodendrocytes and OPCs in penumbral tissues could help to
facilitate spinal function in the absence of robust neuron or axon repair after injury.
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CHAPTER 4. DAMPENED FIBROTIC SCARRING IN ACOMYS SPINAL CORD INJURY
In typical injury responses, extracellular matrix (ECM) molecules are deposited in
a provisional scar to allow cellular infiltration and repair after injury, and in some cases a
persistent ECM scar serves as a structural surrogate for properly regenerated tissue. In the
mammalian CNS, tissue fails to regenerate and there is almost always chronic scar
deposition at the injury epicenter. The fibrotic scar in the spinal lesion core is considered
inhibitory to axon regrowth, and biomedical researchers have attempted degrading ECM
as a therapeutic approach for SCI. However, the scarring response is a diverse and dynamic
process that is facilitated by cells that are still being characterized in the injured spinal cord.
In this chapter, I will discuss my investigations into scarring responses to SCI in Acomys,
which identify dampened ECM deposition likely due to decreased density of ECMproducing cells in the injured cord. These findings provide unique insight into the
development and consequences of fibrotic scarring, which can inform future therapeutic
strategies for SCI.

4.1

Glial and Fibrotic Scarring After Spinal Cord Injury
SCI activates resident astrocytes and pericytes, and recruits infiltrating fibroblasts

and Schwann cells from the periphery, leading to the development of lasting glial (cellular)
and fibrotic (acellular) scars in the injured spinal cord. Astrocytes are perhaps the most
abundant cell type composing the glial scar that surround the lesion site in an area referred
to as the penumbra11,182. Perivascular cells, particularly pericytes, expressing traditional
fibroblast markers infiltrate into the lesion core where they are closely associated with
ECM components, including laminin, fibronectin, and collagens19,20. Schwann cells from
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peripheral nerve roots infiltrate into the lesion epicenter where they also express fibroblast
markers and closely associate with laminin, fibronectin, and collagen deposits183-185. In this
chapter, I will discuss the Acomys fibrotic (ECM) scar and the fibroblast response
following spinal cord injury.
The astrocytic and fibrotic components of the spinal scar are strictly separated to
the penumbra and lesion core, respectively. In fact, many studies use astrocytic boundaries
to demarcate regions of frank tissue pathology from more intact penumbral tissues71. The
interface of the surrounding glial scar and the core fibrotic scar is sometimes referred to as
the “glia limitans.” The strict sequestration is in stark contrast to regenerating species
where both ECM components and glial cells cross the lesion site and precede neural
regeneration32,156,186. Formation of the glia limitans may be species-specific or driven by
cellular interactions, as the phenomenon has been replicated in vitro by cocultures of
mammalian astrocytes and fibroblasts, which naturally maintain spatial separation and
inhibit neurite growth185,187,188.
After injury, proliferating astrocytes thicken cellular processes and surround the
lesion with a meshwork of overlapping outgrowths. Astrocyte activation and subsequent
glial scar boundaries are enhanced by the addition of transforming growth factor-beta
(TGF-β)187,189,190. Signal transducer and activator of transcription 3 (STAT3) is also
important for establishing the glial scar border that corrals infiltrating cells to the lesion
epicenter11,182. Previous schools of thought simply classified the glial scar as a
maladaptation opposing neurite regrowth. More recently, evidence indicates that the glial
scar is important for neurotrophin production, debris clearance, blood brain barrier repair,
and sequestration of toxic species to the injury core72,191.
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The fibrotic scar, the acellular components of the scar consisting of deposited ECM
materials, influences the cellular distribution of the glial scar. ECM molecules can increase
the rigidity of the environment, create a physical barrier, and provide nonspecific
topographical cues, all of which may affect cellular migration192-194. Additionally, ECM
components signal through cell surface receptors to influence cellular activity. For
example, tenascin and fibronectin increase matrix metalloproteases (MMPs) in various cell
types195-197 and MMPs influence outcomes of SCI including the infiltration of cells into the
injury core198-201. Despite the presence of tenascin, fibronectin, and MMPs at the glia
limitans, the demarcation remains intact chronically. Overall, investigations into the glia
limitans provide interesting pathophysiological descriptions, but have not led to therapeutic
strategies that interfere with the establishment of the scar demarcations.
The fibrotic scar is also a critical regulator of axonal regeneration and growth after
SCI. Cells within the lesion core mediate ECM dynamics through production of ECM
components and proteolytic enzymes202-204. MMPs degrade ECM molecules, allowing
receptor mediated assembly into dense matrices202. Several of the ECM components, such
as chondroitin sulfate proteoglycans (CSPGs) and fibronectin, inhibit neurite regrowth in
vitro; others, such as laminin, promote greater neurite outgrowth8,205-208. Removal of
inhibitory ECM components, such as CSPGs, improves neurite growth in vivo5,209-212.
Alternatively, altering the physical properties of ECM components, such as orientation and
stiffness, can promote directional axon growth8,193,194,205,213. Collectively, these results
indicate that ECM of the fibrotic scar is dynamic, nuanced, and can be harnessed to
promote functional regrowth in the injured cord.
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The above components of the glial and fibrotic scar are primarily derived from
observations made in rodent SCI models. By comparison, data is limited regarding SCI
scar formation in humans. As in rodents, there is clear cellular demarcation of the glial scar
with astrocytes around the lesion border and fibroblasts, Schwann cells, and meningeal
cells sequestered within the lesion core106,183,214,215. However, some studies suggest that the
prominence of the astrocytic glial scar varies between species with less astrocytosis in
humans106,184.

4.2

Comparative Models Reveal Importance of Glia and ECM in Wound Repair
Using transgenic models, researchers have gained insight into therapeutic targets

that reduce the inhibitory effects of scarring on SCI repair. Targeted suppression of
astrocyte signaling pathways reduces scar formation and facilitates axon growth and
functional recovery from SCI216. Specifically, transgenic approaches have identified
astrocyte inhibition of TGF-β/Smad, TLR, JAK/STAT3, and JNK/c-Jun signaling
cascades, among others, as potential SCI therapies182. However, depending on the timing
post-injury, astrocyte inhibition also interferes with deposition of ECM, growth supportive
substrates, and neurotrophins (e.g., laminin, fibronectin, growth factors) thereby reducing
endogenous repair processes217. Indeed, transgenic models demonstrate that astrocytes play
an important role in limiting the spread of secondary injury events early after injury11,72.
Although these transgenic models are a powerful tool for investigating particular aspects
of the glial and fibrotic scars, they often incur off-target effects and induce changes that
disrupt homeostasis that is carefully engineered over millions of years of evolution.
Naturally-occurring models of enhanced repair offer the opportunity to understand
a roadmap to physiologically feasible endogenous repair. For instance, a common trend
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amongst non-mammalian models of spinal regeneration is the formation of a glial bridge
preceding axon regeneration32. Indeed, migration and alignment of glial cells that closely
resemble astrocytes or oligodendrocyte precursor cells (OPCs) is necessary for axon
regeneration in the goldfish, zebrafish, and turtle186,218,219. These findings stand in stark
contrast to the adult mammalian glial scar response to SCI, where glia form an opposing
wall against spread of injury and axonal regrowth. Indeed, evidence suggests that axonal
regrowth in the rat spinal cord coincides with incidences where astrocytes achieve proper
alignment along the rostral-caudal axis of the cord4.
Non-mammalian models of regeneration also provide insight into the importance
of ECM in wound repair, but the fibrotic scar in SCI is less thoroughly studied.
Nevertheless, studies in non-mammalian models of skin, limb, heart, and tail regeneration
consistently show a dependence on ECM molecule expression and ECM remodeling. In
peripheral nerve regeneration, ECM molecules such as collagen, laminin, and fibronectin
are key to providing a permissive environment at the distal stump8. Zebrafish normally
upregulate the ECM molecule tenascin-C when regenerating axons, but inhibiting
expression of this ECM molecule decreases axon growth, synapse formation, and
locomotor recovery220. Furthermore, axolotl spinal cords show dramatic increases in MMP
production during regeneration, implying that ECM remodeling is an important aspect of
spinal regeneration221. Collectively, these comparative models show that regeneration of
many tissues, including the spinal cord, require the right kind of ECM substrates rather
than a lack of ECM response.
Researchers investigated the MRL/MpJ strain of lab mouse in a comparative study
aimed to better understand the interplay of fibrosis and recovery from spinal cord injury.

84

The MRL/MpJ mouse deposits less ECM scar molecules in response to peripheral injuries,
and the same trend held for CSPGs stained in the spinal cord after contusion injury92.
However, fibronectin scarring in the contused spinal cord was more widespread but less
dense than C57BL/6J control mice92. These changes in MRL/MpJ fibrosis are associated
with widespread axon growth in the lesion epicenter, but do not result in enhanced recovery
of hindlimb function92. This improvement in axon growth is supported by studies of brain
injury that suggest fibronectin promotes axon growth222. Indeed, Acomys repair of ear
punch injuries also includes more fibronectin and less collagen than Mus, and the repaired
ear tissue is full of regrown axons34.

4.3

Extracellular Matrix Molecules Affect Mammalian Neurite Growth
To test the effects of key ECM molecules in axonal regrowth, I performed in vitro

experiments with dorsal root ganglion (DRG) neurons, testing their neurite regrowth on
coverslips coated with poly-D-lysine and specific ECM substrates. These DRG neurons
isolated from ganglia nestled just beside the spinal cord are often used as surrogates for
CNS neurons during in vitro experiments222,223. After isolating DRGs from the animal, the
neurons can be cultured in a highly controlled environment to test the effects of various
stimuli and/or treatments on neurite growth222,224. In our experiment, we used poly-Dlysine and laminin-coated coverslips to allow DRG neuron adhesion and axon growth, and
added fibronectin, collagen IV, or aggrecan to evaluate the effects of each ECM substrate
on neurons from each species.
Laminins are protein constituents of the lamina lucida, which is part of the basal
lamina that lines body surfaces including blood vessels. Laminin self-assembles into
trimers that are readily bound by cells and contribute to cell attachment, differentiation,
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movement, and survival225. Laminin seems to play a critical role in the myelination of
axons in the peripheral nervous system98,99,226. In vitro experiments often use laminin as an
adhesive molecule for neurons, and coating a 2D or 3D environment with laminin increases
neurite growth from DRG neurons10,207. After CNS injury, laminin is readily deposited into
the injury core either in association with neovasculature or independent of vasculature as a
general connective tissue matrix227,228. Axon growth appears to be directed by laminin both
in vitro205 and in the injured spinal cord229.
Fibronectin is an ECM protein that acts as a “biological glue”, and in both its
soluble fibrils and insoluble matrices it provides binding sites for additional fibronectin,
other ECM molecules, and cells230,231. Consistent with its characterization as a sticky
scaffolding, fibronectin is important for the attachment and migration of cells in the early
wound healing process7,232. Fibronectin is readily deposited in the lesion core after CNS
injury19,202,233, but its role is complex and incompletely understood. While fibronectin
appears to aid axon regrowth after brain injury222, it is also implicated as a barrier to
regeneration in the spinal cord234. Similarly, there is not consensus on the effects of
fibronectin on neurite growth in vitro. Petri dishes covered with fibronectin allow DRG
neuron adhesion and allow robust DRG neurite growth, but do not allow retinal or spinal
neuron adhesion208. Similarly, DRG neurons adhere and readily grow neurites on
fibronectin-coated coverslips and blocking fibronectin with antibodies prevents neurite
growth222. However, fibronectin in hydrogels slightly decreases DRG neurite growth and
neurite length10.
Collagens are extremely common structural ECM proteins composing up to 2535% of mammals’ whole-body protein content227. There are 27 currently recognized types
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of collagens that exhibit unique peptide sequences, physical characteristics, and
distribution throughout the body. Type IV collagen (collagen IV) is primarily found in the
basal lamina, an ECM-rich layer of the basement membrane, that acts as lining for surfaces
such as the endothelium of blood vessels235. After CNS injury, collagen IV is found in the
injury core both associated with neovasculature and in matrix independent of endothelial
cells228. In some experiments inhibiting collagen IV decreases levels of accompanying
inhibitory ECM molecules and improves axon growth over glial cells236-238, implying that
collagen IV serves as a scaffold for inhibitory cues in the lesion epicenter. However, other
experiments fail to elicit axon regrowth by inhibiting basal lamina constituents, including
collagen IV227.
Chondroitin sulfate proteoglycans (CSPGs) are perhaps the most thoroughlystudied ECM constituents in SCI due to their potent inhibition of neurite growth. Aggrecan
is a core glycoprotein to which glycosaminoglycans (GAGs), such as CSPGs, can attach239.
Aggrecan and CSPGs normally form a perineuronal net around neuron soma240, and the
aggrecan core is present with or without its additional GAG chains after SCI241. The
cellular source of spinal CSPGs after injury is currently believed to be astrocytes of the
glial scar borders79,242, and the production of CSPGs begins within the first week and
continues to chronic time points after injury242,243. Actively degrading CSPGs with
chondoitinase ABC has shown profound improvements in axon growth and invasion into
the lesion core5,211. Aggrecan, specifically, inhibits axonal growth in the injured CNS241,
decreases neuronal plasticity240, and potently inhibits DRG neurite growth in vitro239,244,245.
In this experiment, we use aggrecan as a control to validate that our ECM coatings are able
to inhibit DRG neurite growth in vitro.
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Acomys have been shown to deposit less collagen and more fibronectin during
tissue regeneration than the non-regenerating Mus34,164. Furthermore, this “proregenerative” ECM microenvironment coincides with extensive neurite regrowth in the
regenerated ear34. Therefore, I sought to test how these ECM molecules affected neurite
growth and if Acomys and Mus neurons differ in their intrinsic growth potential over these
specific ECM substrates. In order to test the effects of the substrates themselves, we
collected DRG neurons from each species and allowed them to grow neurites on coverslips
coated with our substrates of interest. Then we analyzed their neurite growth using sholl
analysis, as previously described246,247. Briefly, we fixed the cells after 36hr of growth,
stained neurons using antibodies targeted to the cytoskeleton (ꞵ-tubulin), and counted the
number of neurites from each neuron crossing concentric circles. These data were plotted
as number of crossings (y coordinate) at each circle diameter (x coordinate), and analyzed
as the area under the curve.
In this experiment, laminin was intended as a positive control because it is the
standard ECM molecule used to promote axon growth, while aggrecan was intended as a
negative control because it is known as a potent axon growth inhibitor239,244,245. As
expected, the addition of aggrecan inhibited neurite growth in both Acomys and Mus. While
Mus neurites grew best on laminin, Acomys neurites unexpectedly tended to grow better on
fibronectin than on laminin—though this trend was not statistically significant (Figure
4.3.1). In fact, Acomys neurites grew best on fibronectin-coated coverslips, while
fibronectin only mildly inhibited neurite growth in Mus (Figure 4.3.1). Collagen IV, on the
other hand, significantly decreases neurite growth in both Mus and Acomys when compared
to the most growth-permissive ECM substrate for each species—laminin and fibronectin,
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respectively (Figure 4.3.1). Comparing between both species, it appears that Acomys DRGs
exhibit significantly less neurite growth on laminin (p<0.05) and aggrecan (p < 0.0001)
than Mus DRGs, with slightly less growth on collagen IV (p = 0.07). Neurite growth from
Acomys and Mus DRGs on fibronectin was very similar (p = 0.51). Collectively, these data
indicate that collagen IV and aggrecan inhibit neurite growth in both species, and suggest
that laminin and aggrecan are more growth-restrictive in Acomys than in Mus.
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Figure 4.3.1: Extracellular matrix molecules affect neurite growth.
Data collected by sholl analysis of DRG neurons grown on coverslips coated
with various ECM substrates. Collagen IV and aggrecan decrease neurite
growth in both species. Interestingly, both aggrecan and laminin appear to be
less growth-permissive to Acomys DRG neurites than those of Mus. *p<0.05.
Mus laminin (n=38), Mus fibronectin (n=64), Mus collagen IV (n=51), Mus
aggrecan (n=63), Acomys laminin (n=13), Acomys fibronectin (n=47),
Acomys collagen IV (n=24), Acomys aggrecan (n=39). Data analyzed by oneway ANOVA with Tukey’s multiple comparison correction, *p<0.05.
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This experiment provides important information about the growth potential of
Acomys and Mus neurons on various ECM substrates. My original hypothesis was that
Acomys would deposit an ECM profile that favors more axon growth in the injured cord
than Mus. If Acomys were to deposit more fibronectin and less collagen in the injured cord,
as they do in the ear34, these in vitro data suggest that ECM profile would support more
neurite growth. I did expect collagen IV to be more inhibitory to axon growth than
fibronectin, based on the historical context outlined above. However, less neurite growth
on laminin than fibronectin in Acomys is unexpected and merits further investigation.
There are some important considerations when translating the in vitro findings to
in vivo implications. First, DRGs contain sensory neurons that participate in afferent
signaling and therefore only represent a subset of axons that exist within the spinal cord.
Some studies suggest that these sensory afferent neurites show more robust growth over
ECM substrates after SCI than efferent motor pathways248. Furthermore, dissociated DRG
neurons consist of a wide variety of neuron subtypes that vary in receptor profiles, injury
response, and neurite growth249-251. There is potential for species differences in the
proportion of DRG neuron subtypes; which may account for the differences in neurite
growth between Acomys and Mus. Finally, the DRG neurons are located just outside the
spinal cord and project axons into the spinal cord, but they are still peripheral neurons and
are likely to behave differently than true CNS neurons. Previous experiments specifically
note that DRG neurons attach and extend neurites more readily on fibronectin than spinal
neurons208. Further investigations identifying the relative distribution of DRG neuron
subtypes in Acomys, the growth potential of these subtypes, and the growth potential of
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CNS neurons vs. DRG neurons would give further insight into the intrinsic ability of
Acomys neurons to regrow axons on ECM substrates.
Additionally, it is important to consider that these experiments were performed on
glass coverslips with poly-D-lysine and laminin coating in each experimental group. While
I considered poly-D-lysine and laminin necessary to encourage neuron attachment, these
substrates provide additional variables that may dilute or alter the effects of fibronectin,
collagen IV, and/or aggrecan alone. Indeed, Tong and colleagues find that double-coating
collagen I grafts with laminin and fibronectin improves sciatic nerve growth in vivo,
suggesting that these ECM molecules can synergize to change neurite growth potential252.
Additionally, these substrates are likely to affect axon growth differently in alternative
culture environments. For example, growing cells in planar vs. 3-dimensional matrices
changes cellular morphology, protein profile, and migration characteristics253-255.
Furthermore, microenvironmental factors such as stiffness and topographical cues can
affect neurite growth in a 3-dimensional culture256-258. While this study was designed to
specifically test the outgrowth potential of Mus and Acomys neurons in a controlled
microenvironment, future studies could identify if our results can be replicated in additional
contexts. Particularly, mirroring in vivo spinal ECM proportions could provide interesting
insight into neurite growth potential in the SCI-specific context.
Finally, it is important to consider these findings in the greater context of the whole
project. In chapter 2 I outline that Acomys do not have enhanced axon sparing or growth
following SCI. These data suggest that the presence of ECM molecules such as laminin,
collagen IV, or aggrecan may not permit as much Acomys neurite growth as in Mus. In the

92

next section, I will investigate the actual Acomys ECM deposition in the injured spinal cord
to understand what the true scarring responses are after Acomys SCI.

4.4

Acomys Have Dampened Fibrotic Scarring Response to SCI
The intact spinal cord typically has low levels of ECM molecule expression, largely

limited to the neurovasculature243. However, resident cells activate and fibroblasts invade
the injury core to deposit a dense meshwork of ECM known as the fibrotic scar2. The
formation of this dense fibrotic scar occurs within the subacute window after injury and
persists to chronic time points in both rodent and human SCI106,202,235. Researchers
currently consider this chronic scar tissue an impediment to axon growth106, which is
substantiated by approaches that have induced axon regrowth and functional recovery by
inhibiting deposition of ECM in the injured cord211,236,259. Acomys have now been
documented to deposit significantly less fibrotic scar, especially collagen, during the
regeneration of peripheral tissues, including the ear34, kidney37, and muscle36. Here, I use
histological analysis to determine the fibrotic scarring profile in Acomys over time after
thoracic spinal crush.
Collagen IV is a major component of the fibrotic scar in rodents and humans235,
and I show that collagen IV inhibits neurite growth in Acomys and Mus DRG neurons in
vitro. I histologically assessed collagen IV scarring in sagittal spinal sections collected 3
days, 1 week, 2 weeks, and 12 weeks after thoracic spinal crush, and immunostained for
collagen IV, astrocytes (GFAP), and nuclei (DAPI). As expected, initial observations of
the histology images show a robust deposition of collagen IV in the injury epicenter of Mus
spinal cords at 1, 2, and 12wpi (Figure 4.4.1). Acomys also have collagen IV deposition at
the injury epicenter, but there appears to be far less collagen IV density in Acomys
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compared to Mus, and Acomys collagen appears in vascular-like structures (Figure 4.4.1).
As a constituent of the basal membrane, collagen IV is expected to be present surrounding
vasculature. Indeed, collagen IV appears to follow this morphology in sections 3dpi
(Supplementary Figure A.1.6) and in regions distant from the injury epicenter in both
species. However, the maintenance of vascular-like morphology in Acomys at subacute and
chronic time points after SCI is surprising.
Quantification of histological samples shows that density of collagen IV increases
over time in the whole cord (Figure 4.4.2A), including the injury epicenter (Figure 4.4.2B),
in both species. However, Acomys have significantly less collagen IV density in both the
whole cord (species effect p<0.0001) and the injury epicenter (species effect p<0.0001).
Analyzing the collagen IV deposition at various distances across the rostral-caudal extent
of the injured cord shows that collagen deposition is most dense at the injury epicenter,
beginning at 1wpi in Mus (Figure 4.4.2D) and at 2wpi in Acomys (Figure 4.4.2E), and
continuing out to 12wpi in both species (Figure 4.4.2F). Interestingly, while there is no
significant difference in the progression of whole-cord collagen IV deposition between
species (interaction effect p=0.094), there is a significant difference in the injury epicenter
(interaction effect p<0.01). This difference in epicenter-specific collagen may be driven by
early subacute deposition. Acomys appear to maintain low collagen IV density across the
spinal cord without a noticeable increase at the injury epicenter at 3dpi or 1wpi, while Mus
show a significant increase in spinal collagen IV at the injury epicenter 1wpi (Figure
4.4.2D, interaction effect p < 0.001).
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Figure 4.4.1: Collagen IV histology after SCI in Mus and Acomys.
Immunostaining was used to visualize the fibrotic scar (collagen IV, red),
astrocytes (GFAP, green), and nuclei (DAPI, blue) at various times after SCI
in Acomys and Mus. This histological analysis reveals the blunted collagen
IV deposition in Acomys. While Mus form a dense, disordered fibrotic scar in
the injury core from subacute to chronic timepoints, Acomys remain in a
vessel-like orientation with only little mesh-like fibrotic scar formation at the
lesion epicenter. Each row contains images from a representative animal from
each species and time point. Species and time point are listed on the left.
Panes include an inset to indicate the location of magnified image to the right,
and a scale bar in the bottom of each pane.

96

Figure 4.4.2: Acomys deposit significantly less collagen IV in the injured
spinal cord than Mus.
Histology was quantified as density of collagen IV+ staining in 500µm2
square ROIs oriented at the epicenter and radiating out rostral and caudal to
the epicenter. Data from all 5 ROIs (A) and the injury epicenter ROI (B) show
progressive deposition of collagen IV in the injury site, with particularly
dense collagen IV deposition at the injury epicenter (D-F). Mus 3dpi (n=5),
1wpi (n=8), 2wpi (n=5), 12wpi (n=8); Acomys 3dpi (n=8), 1wpi (n=8), 2wpi
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(n=4), 12wpi (n=9). Data analyzed by two-way ANOVA with Sidak’s
multiple comparison correction, species effect and interaction (species x time
A-B, species x distance C-F) effect displayed below graphs, ns=no significant
difference, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.

98

Figure 4.4.3: Acomys show dampened fibrotic scarring across various
other ECM molecules.
Histological analysis shows that the dampened fibrotic scar extends to other
ECM moelecules, including collagen fibrils (A-C), laminin (D-F), and
fibronectin (G-I). Data are quantified as density of staining above threshold
in 500µm2 square ROIs at various distances from the lesion epicenter in cords
isolated 2wpi. n=4 for each species with each ECM target. Data analyzed by
two-way ANOVA with Sidak’s multiple comparison correction, species
effect and interaction (species x distance) effect displayed below graphs,
ns=no significant difference, *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001.
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Many different ECM molecules are deposited in the injured spinal cord, including
other types of collagens235, laminin228, and fibronectin202. While collagen IV forms dense
networks in the basal lamina, other types of collagens—namely types I, II, III, V, and XI—
form fibril structures that can be visualized by shining polarized light on sections stained
with the birefringent dye, picrosirius red260,261. I used picrosirius red and fluorescent
immunostaining targeted to laminin and fibronectin proteins to evaluate the density of other
ECM constituents within the injured cord 2wpi. Histological analysis reveals lower density
of collagen fibrils (species effect p < 0.05), laminin (species effect p < 0.0001), and
fibronectin (species effect p < 0.05) in the injured cord of Acomys compared to Mus (Figure
4.4.3).
Collectively, these histological assessments identify a significantly lower density
of collagen IV, collagen fibrils, laminin, and fibronectin in the injured Acomys spinal cord
compared to Mus. The results do not support my original hypothesis that Acomys would
respond to SCI with a growth-permissive fibrotic scar that mimicked trends seen in the ear,
with less collagen and more fibronectin. Rather, these results suggest that Acomys have a
dampened fibrotic scarring response across all tested ECM molecules. While the global
effects on ECM molecules is somewhat simpler than selective up- and down-regulation of
specific ECM constituents, this result is complicated by the diverse and divergent effects
of each of theses ECM molecules on recovery from SCI. As discussed before, studies
suggest that collagens are detrimental to recovery from SCI235, but laminin is viewed as
beneficial for axon growth and remyelination99,229, and fibronectin has been identified as
beneficial and detrimental in different contexts222,234.
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In addition to considering the dichotomous theoretical effects of various ECM
molecules and subtypes, it is important to consider the limitations imposed by these
specific histological methods. While collagen IV and laminin staining do appear to follow
vascular-like morphologies and are known constituents of the perivascular basal lamina, it
is possible that this is an overinterpretation of the observation. A subsequent study that
pairs a vascular stain in the form of an epithelial marker or a circulatory dye—paired with
these ECM-targeted stains—could identify if these ECM molecules are indeed more tightly
restricted to vasculature in Acomys. Furthermore, as with the inflammatory histology in
chapter 3, it is important to remember that a time course of histological samples is collected
from different animals at each time point rather than a single animal longitudinally.
Overinterpretation of histological trends over time is possible, especially for the 12wpi
tissue that is cut to a different thickness from the earlier timepoints. Regardless, the effect
of a dampened fibrotic scarring response is robust at each time point individually and
independent of vascular associations. Furthermore, the dampened fibrotic scar response is
supported by an independent study by Streeter et al. that shows less collagen IV deposition
in the injured cord of Acomys compared to Mus61.

4.5

Acomys Have Fewer PDGFRβ+ Cells in the Injured Spinal Cord
Considering the robust effects of dampened ECM deposition within the injured

Acomys spinal cord, I sought to determine if this was attributable to a decrease in cells that
deposit ECM. The general term used for the fibrotic tissue-depositing cells is fibroblasts,
but fibroblasts are difficult to define and label262. The particular origin of ECM-depositing
fibroblasts within the injured spinal cord is still an area of active debate. Astrocytes have
long been studied for their deposition of ECM molecules, especially CSPGs79,210,217. Some
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point toward infiltrating schwann cells that express high levels of growth-modulating ECM
molecules, especially in the human cord106,183. Perhaps the most thoroughly-studied
cellular source of ECM, though, is the pericyte. Multiple genetic studies have shown that
perivascular cells, likely subsets of pericytes, enter the lesion core after injury and deposit
ECM19,20,263. Genetically depleting these cells decreases ECM deposition within the injured
cord264, and allowing the return can resume ECM deposition at subacute time points263.
Collectively, it seems multiple cell types contribute to the fibrotic scar after SCI but
pericytes are likely the primary cellular source of spinal fibroblasts.
Göritz and colleagues genetically labelled a specific GLAST+ subset of pericytes
that abandon blood vessels to invade the lesion core, and deposit ECM within the injured
cord20. Furthermore, genetic deletion of this pericyte subset decreases cellular infiltration
and ECM deposition in the lesion core after SCI20. Soderblom and colleagues also find that
perivascular cells—potentially the same subset identified by Göritz and colleagues—are a
key source of ECM in the injured cord. Using light-sheet microscopy to evaluate
colocalization of genetically-labelled collagen-producing cells (Col1α1+) and a suite of
histological markers, Soderblom and colleagues conclude that fibroblasts migrate into the
injury site as early as 5dpi, peak around 7dpi, and persist in the injury core until at least
56dpi19. While Soderblom and colleagues show that their Col1α1+ fibroblasts are distinct
from NG2+ pericytes, Hesp and colleagues show that inhibiting NG2+ proliferation
decreases fibroblast levels and ECM in the injured cord263. They suggest that non-fibroblast
pericytes may provide a necessary substrate for fibroblasts to enter the lesion core263.
Together, these studies identify an important role for fibroblasts of a pericyte origin in
establishing a robust fibrotic scar in the injured rodent spinal cord. Unfortunately, the
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genetic labelling strategies employed in these investigations are currently unavailable in
the burgeoning model system of Acomys, and histological assessments of fibroblasts in SCI
is not straightforward.
Platelet-derived growth factor receptor (PDGFR) is a common receptor among
fibroblasts and is key in regulating fibroblast behavior following injury. The receptor itself
is a dimer composed of any combination of ɑ and ꞵ subunits (PDGFRɑ and PDGFRꞵ,
respectively). While both are responsible for propagating signals for cell differentiation,
cell growth, and development, we focus on PDGFRꞵ because it has been specifically
identified in genetically labelled fibroblasts after SCI. Soderblom et al. identify that 96%
of their genetically labelled (Col1α1+) fibroblasts express PDGFRꞵ19,20. Göritz et al. show
that fibroblasts express both PDGFRɑ and PDGFRꞵ while in contact with blood vessels,
but express only PDGFRꞵ when they have abandoned vessels and infiltrated into the spinal
lesion core20. PDGFRꞵ+ pericytes are similarly seen “lifting away” from the vasculature
while migrating and proliferating after penetrating injuries to the human brain265. PDGFRꞵ
is also a functionally relevant marker for fibroblasts. Studies show that inhibiting PDGFRꞵ
in vivo and in vitro decreases fibroblast and pericyte proliferation and migration into injury
sites266. In this study I use PDGFRβ as a histological marker of ECM-producing cells.
While this marker is not perfect, and will not solely identify fibroblasts262, PDGFRβ
histology is an informative surrogate for genetic studies of fibroblasts.
I performed histological assessment of PDGFRβ and other fibroblast markers in
spinal cords isolated 3 days, 1 week, 2 weeks, and 12 weeks post spinal crush in Mus and
Acomys to gain a better understanding of the cells that may be contributing to the fibrotic
scar after SCI. Before injury there are very few PDGFRβ+ cells in the injured cord and
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these cells are largely isolated to the vasculature19,20. Levels of PDGFRβ are similarly low
at 3dpi, but upregulate in the whole cord (Figure 4.5.1A) and injury epicenter (Figure
4.5.1B) by 1wpi. However, Mus maintain a significantly higher density of PDGFRβ+
staining at 2wpi and 12wpi, while Acomys return to a lower level of PDGFRβ+ staining
density (Figure 4.5.1). Indeed, Acomys have significantly lower PDGFRβ+ staining density
in the whole cord (species effect p < 0.01) and injury epicenter (species effect p < 0.0001).
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Figure 4.5.1: Histological analysis of spinal PDGFRβ over time in the
injured spinal cord.
Histological analysis of spinal sections 3dpi, 1wpi, 2wpi, and 12wpi shows
that whole-cord (A) and epicenter (B) PDGFRβ expression increases after
SCI. While Mus maintain high PDGFRβ through chronic time points, Acomys
have significantly less PDGFRβ, which seems to be driven by a decrease at
2wpi and 12wpi. Mus 3dpi (n=6), 1wpi (n=8), 2wpi (n=5), 12wpi (n=8);
Acomys 3dpi (n=8), 1wpi (n=7), 2wpi (n=4), 12wpi (n=9). Data analyzed by
two-way ANOVA with Sidak’s multiple comparison correction, species
effect and interaction (species x time) effect displayed below graphs, ns=no
significant difference, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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Figure 4.5.2: Acomys have less spinal PDGFRβ at 2wpi.
Representative images from each species suggest that while both species may
have a dense accumulation of PDGFRβ in the lesion core 1wpi (A-F),
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expression spreads across the cord in Mus at 2wpi (G-I) while it decreases in
Acomys (J-L). Histological analysis of injured spinal cords harvested 1 and
2wpi shows similar PDGFRβ density between species at 1wpi (M), but a
significant decrease in PDGFRβ density in Acomys 2wpi (N). Mus 1wpi
(n=8), 2wpi (n=5); Acomys 1wpi (n=7), 2wpi (n=4). Data analyzed by twoway ANOVA with Sidak’s multiple comparison correction, species effect and
interaction (species x distance) effect displayed below graphs, ns=no
significant difference, **p<0.01, ****p<0.0001.
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Mus
Acomys
Figure 4.5.3: Acomys have less PDGFRβ chronically after SCI.
Representative images from each species suggest that while Mus have a
dense, sheet-like patterning of PDGFRβ in the lesion core (A-C), while
Acomys PDGFRβ seems to follow vessel-like morphology (D-F).Histological
analysis of injured spinal cords harvested 12wpi shows decreased PDGFRβ
density in Acomys compared to Mus (G). Mus n=8, Acomys n=9, data
analyzed by two-way ANOVA with Sidak’s multiple comparison correction,
species effect and interaction (species x distance) effect displayed below
graphs, **p<0.01, ****p<0.0001.
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When analyzing individual ROIs at various distances rostral and caudal to the
injury epicenter, both species show an upregulation of PDGFRβ+ staining at the injury
epicenter (Figure 4.5.2 and Figure 4.5.3). However, Mus have significantly higher
PDGFRβ density at the injury epicenter 2wpi (Figure 4.5.2N, p < 0.01) and 12wpi (Figure
4.5.3G p < 0.01). At 2 and 12wpi Acomys have significantly less PDGFRβ density in the
injured cord (species effect p<0.01) and a significant difference in the patterning of
PDGFRβ+ density (interaction effect p < 0.0001; Figure 4.5.2N, Figure 4.5.3G).
Representative images from each species reflect these differences, with generalized
staining in the lesion epicenter in both species 1wpi, followed by more discrete areas of
staining at 2 and 12wpi. Mus appear to fill in the lesion core with generalized mesh-like
patterning (Figure 4.5.2G-I and Figure 4.5.3A-C), as expected from previous
investigations19,20,263, while Acomys PDGFRβ staining appears to adopt a more vessel-like
morphology at 2wpi (Figure 4.5.2J-L) and 12wpi (Figure 4.5.3D-F).
As discussed above, PDGFRβ staining is an imperfect indicator of fibroblasts in
SCI. While the vast majority of Col1α1+ fibroblasts express PDGFRβ, it is not necessarily
restricted to fibroblasts alone19. To better understand the identity of these PDGFRβ+ cells,
I sought converging evidence with an alternative fibroblast marker, periostin. Periostin is
an ECM protein that plays a role in bone, tooth, and heart morphogenesis in embryonic
development, but is downregulated in adulthood outside the context of an insult or
injury267,268. Specifically, periostin has been used as a cardiac269 and CNS270 fibroblast
marker, including specific association with ECM-producing pericytes271. Co-staining for
PDGFRβ and periostin shows similar species trends at 1wpi (Figure 4.5.4A,B) and 2wpi
(Figure 4.5.4C,D). Representative images also show similar staining patterns for PDGFRβ
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and periostin in both species 2wpi (Figure 4.5.4E, left column). This converging evidence
suggests that Acomys have a lower fibroblast density in the injured cord. Further
immunostaining with periostin and α-smooth muscle actin (aSMA), a marker of
myofibroblasts, shows that only a small proportion of these cells are likely myofibroblasts
(Figure 4.5.4E, right column).
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Figure 4.5.4: PDGFRβ+ staining has high overlap with alternative
fibroblast marker, periostin.
Periostin, a fibroblast marker, shows similar expression patterns at subacute
time points to PDGFRβ (A-D). Representative images from spinal cords 2wpi
show that PDGFRβ and periostin are closely associated and may be coexpressed within the same cells (E). On the other hand, there is far less aSMA
expression with only some co-expression with periostin, suggesting there are
few myofibroblasts in the injured spinal cord of Mus and Acomys 2wpi. Mus
PDGFRβ 1wpi n=8, Mus PDGFRβ 2wpi n=5, Mus periostin 1wpi n=8, Mus
periostin 2wpi n=4; Acomys PDGFRβ 1wpi n=7, Acomys PDGFRβ 2wpi n=4,
Acomys periostin 1wpi n=7, Acomys periostin 2wpi n=4. Data analyzed by
two-way ANOVA with Sidak’s multiple comparison correction, species
effect and interaction (species x distance) effect displayed below graphs,
ns=no significant difference, *p<0.05, **p<0.01, ****p<0.0001.
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Converging evidence from PDGFRβ and periostin histology suggests that Acomys
may have fewer fibroblast in the lesion epicenter after SCI. The presence of a dense, meshlike accumulation of PDGFRβ+ cells in the Mus injury site is supported by previous
studies, where similar spinal histology is seen 2 weeks19 and 3 weeks263 after contusion
injury. Furthermore, the upregulation of PDGFRβ between 3dpi and 1wpi is supported by
studies showing a robust increase in genetically labeled spinal fibroblasts between 49dpi19,20. Finally, the spatial profile of Mus PDGFRβ+ cells—where widespread expression
is condensed into persistent expression in the lesion core—is consistent with studies of
genetically labeled fibroblasts19 and general PDGFRβ265,272 expression in the injured CNS.
However, the resolution of lesion core PDGFRβ expression in Acomys is unique amongst
mammalian models of CNS injury.
When interpreting these data, it is important to remember that both PDGFRβ and
periostin are imperfect histological markers of fibroblasts. PDGFRβ expression is robust
in fibroblasts19,20 but is also present in vascular pericytes273, vascular smooth muscle274,
and neurons275,276. While periostin was seen in astrocytes, macrophage/microglia,
periendothelium, and fibroblasts in the first week after ischemic stroke, periostin was only
found in fibroblasts in the peri-infarct and lesion core 2wpi and 4wpi270. However, it is
unlikely that the robust lesion core PDGFRβ and periostin staining is reflective of neurons,
as we see neuron soma are not present in the lesion core (Figure 2.5.4). The spatiotemporal
patterning also suggests that PDGFRβ and periostin staining are unlikely to be solely
attributable to vasculature or neovasculature in the injured cord. Neovascularization in the
injured rodent cord occurs mostly within the first week post injury 228,277 and this
neovascularization is primarily in areas distant to the injury epicenter (1000µm rostral and
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caudal)277, where we see the least PDGFRβ and periostin staining. There are mature vessels
that appear in the epicenter of injured Mus spinal cords at subacute and chronic time points
after injury, but these vessels are distinct in both their spacing and morphology147,278.
Indeed, high-powered fluorescence and electron microscopy has been used to show
PDGFRβ+ cells abandon vessels and adopt the sheet-like meshwork in the later stages of
CNS injury20,272. Therefore, while some PDGFRβ and periostin staining may be
attributable to vasculature and vessel-associated cells in the injured spinal cord, historical
evidence suggests that the majority of PDGFRβ and periostin staining in the subacute
injury core is reflective of extravascular, non-neuronal cells.
Decreased PDGFRβ+ and periostin+ staining density in the injured Acomys cord
can be attributed to less cell proliferation, less cell infiltration, or less cell-to-cell protein
expression. The diverse assemblage of cells and microenvironmental stimuli provides
many factors to drive fibroblast proliferation, infiltration, and/or protein expression.
Fibroblasts are highly responsive to growth factors279, cytokines140,280, ECM
components196,281, and topographical cues282 both in vivo and in vitro110. Many believe that
the primary chemotactic signal for invading fibroblasts is PDGF released by platelets and
macrophages283. Macrophage-induced fibroblast infiltration and proliferation is part of the
normal course of wound healing for peripheral injuries
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. Accordingly, inhibiting

PDGFRβ activation prevents fibroblast proliferation and infiltration in a mouse model of
cutaneous wound repair266. Similarly, periostin has been suggested as a regulator of
fibroblast function in SCI. Using a genetic deletion model, Yokota and colleagues show
that inhibiting periostin decreases total PDGFRβ staining and ECM deposition in mouse
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SCI271. The functional role of these fibroblast markers is discussed in further detail in
chapter 6.

4.6

Understanding the Role of Fibrotic Scarring in Mammalian Spinal Cord Repair
through Acomys
Extracellular matrix is a key part of normal physiological function, but some

injuries evoke an overactive fibrotic scarring response that does not facilitate repair. Many
have suggested that the fibrotic scar, deposited by fibroblasts in the lesion core, prevents
spinal repair after injury2,235,238,284. In this chapter, I describe a dampened fibrotic scarring
response in the injured spinal cord of Acomys, a mammalian model of enhanced functional
recovery from SCI. Histological analysis suggests that less ECM deposition—specifically,
less collagen IV, collagen fibrils, laminin, and fibronectin—is likely underpinned by fewer
ECM-depositing cells, as indicated by less PDGFRβ and periostin staining in Acomys SCI
than than in Mus.
One unifying factor for several of these stains is the traditional association with
vasculature. Basal lamina constituents, collagen IV and laminin, and PDGFRβ+ pericytes
typically surround vascular endothelium in the CNS. While evidence from past studies
shows a profound upregulation of extravascular collagen IV, laminin, and PDGFRβ
staining in rodent models of SCI20,228,235,265, this study does not include endothelial or other
vascular markers. Histological markers of endothelial cells, particularly PECAM/CD31,
would enable visualization of the vascular endothelium. Pairing these stains with
proliferative markers would give further indication of neovascularization in the injured
cord228,277. Alternatively, circulatory dyes and dextrans can be used to mark intact
vasculature. Qualitatively, basal lamina constituents, PDGFRβ, and periostin appear to be
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restricted to a vessel-like morphology in Acomys. Pairing vascular labeling methods with
basal lamina and fibroblast markers would provide valuable insight into the extravasation
(or lack thereof) that underlies the robust effects seen in this investigation.
While the vascular dynamics in the injured Mus vs. Acomys spinal cord may
underlie some effects, I hypothesize that ECM trends are driven by non-vascular ECM
production of these PDGFRβ+/periostin+ cells in their functions as fibroblasts. Results in
Acomys seem similar to genetic studies in the mouse that limit PDGFRβ and ECM in the
injury core20,263. Limiting the proliferation of PDGFRβ+ fibroblasts leads to a profound
decrease in fibronectin deposition at SCI site20. Indirectly preventing PDGFRβ+ cell
expansion in the injured cord—likely by preventing entry into the injury core—leads to
dramatic decreases in laminin deposition263. Inhibiting periostin causes a decrease in
PDGFRβ and collagen fibrils in the injured cord271. As in Acomys, these models of
decreased PDGFRβ and ECM in the injured cord show increased functional recovery from
SCI263,271. While genetic and antibody-based inhibition studies support our results to show
the importance of fibroblasts in functional recovery of the injured spinal cord, the common
therapeutic approach in SCI is to target ECM directly rather than targeting ECM-depositing
cells. By altering the activity of spinal fibroblasts, biomedical researchers may be able to
facilitate endogenous repair rather than fighting against a maladaptive system. Acomys
provide an exciting opportunity to better understand naturally occuring endogenous
mechanisms of fibrosis that can facilitate enhanced recovery.
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CHAPTER 5. INJURY BIOMECHANICS AFFECT SPINAL CORD INJURY PROGRESSION
Identifying key cellular and molecular pathways that facilitate pathology and repair
is a key first step in developing biomedical therapies. An equally important aspect, though,
is identifying the contexts in which these therapies will be beneficial. Context is doubly
important in the extremely heterogeneous condition of SCI. In this chapter I will discuss
additional studies in a novel SCI paradigm developed to study mammalian SCI
progression. By specifically controlling the parameters of the SCI insult, I was able to
identify how these initial injury biomechanics affect downstream secondary injury
responses and the overall outcomes of SCI. This project, which has previously been
published in the Journal of Neurotrauma70, provides important contextual information to
identify when immunomodulatory therapies would be most efficacious for treating SCI.

5.1

Spinal Cord Injury is Meaningfully Heterogeneous
Spinal cord injury is not bound by any demographic or specific injury

biomechanics. Clinically, traumatic SCI involves a wide array biomechanical variables,
each of which can vary broadly. For instance, the force applied to the cord can vary in
velocity, acceleration, duration, direction, distribution, and magnitude. Each of these
biomechanical details are clinically meaningful to the clinical presentation of SCI and are
readily apparent in typical SCI cases. SCI can occur abruptly due to motor vehicle
accidents, falls, and sport injuries, or it can occur gradually as a result of spinal stenosis,
osteoarthritis, abscess, and tumors1. The speed of force application can affect the
deformation of the soft spinal tissues as they absorb and diffuse the force27. Unfortunately,
the overt heterogeneity of SCI is at odds with efforts of researchers who strive to minimize
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extraneous variables and create consistent injuries to derive reproducible results. In this
chapter, I will discuss how different SCI biomechanics can affect injury progression and
the implications of these differences both in the laboratory and in the clinic.
Severity of injury is one of the more foundational and straight-forward aspects of
SCI. In the clinic, physicians will commonly classify SCI based on the American Spinal
Injury Association (ASIA) Impairment Scale as A, B, C, D, or E which represent functional
deficits from most to least severe, respectively51. While the ASIA scale is fairly obtuse and
has been criticized for failing to account for many granular aspects of injury285, it provides
evidence of the non-binary nature of clinical deficits after SCI. Many research groups have
investigated the effects of varying severities of their particular animal SCI paradigms.
Greater force applied to the cord in contusion injuries can cause greater anatomical and
functional deficits22,286,287. Similarly, greater contusion-induced tissue displacement results
in decreased tissue sparing and functional recovery25. Severity-dependent deficits are not
unique to contusion injury. Stepwise compression injury also causes stepwise decreases in
tissue sparing and function, as shown in a model of spinal crush with forceps restricted to
various maximum closure distances

23

. Thus, the severity of contusion and compression

injuries plays a key role in determining overall anatomical and functional outcomes in SCI.
Subtle differences in injury biomechanics also affect SCI progression. The
direction of force application affects neuron permeability. Shear force (applied parallel to
the hydrogel surface) causes more cellular permeability than the same cultures loaded with
compressive force (applied perpendicular)27. Furthermore, in vivo experiments identify
that these various directions of force loading are evident even within different regions of
the same injury27. Oxland and collaegues created sophisticated, clinically relevant injury
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paradigms to further investigate SCI biomechanics, which include dislocation (shifting
vertebra outside of spinal axis), distraction (pulling vertebra apart along the spinal axis),
and contusion (exposing and impacting the spinal cord) injures. Dislocation, distraction,
and contusion SCI each produced unique histological and functional deficits and at a
cellular level, affecting apoptosis, permeability, and axon degeneration288. Collectively,
these experiments show that highly specific aspects of injury biomechanics, such as
direction of force application, can affect the progression of SCI pathology on a organ-wide
and cellular level.
Beyond the direct effects on pathology, it is also important to understand how SCI
biomechanics affect secondary injury responses and shape the SCI microenvironment over
time. As discussed earlier, the overall outcomes of SCI are heavily influenced by the
complex secondary injury cascades that can serve protective and reparative roles but can
also exacerbate damage and contribute to progressive injury. Macrophages and microglia,
in particular, are major mediators of spinal inflammation and exhibit high levels of contextdependent plasticity. Specific stimuli shift macrophage and microglia along a spectrum of
phenotypes ranging from pro-reparative to pathological143,289. Injury biomechanics
establish the SCI microenvironment and can dictate the contextual cues for macrophages
and microglia. For instance, residual compression increases hemorrhage290, and
hemorrhage-induced hypoxia alters cellular bioenergetics291. The implications of these
relationships should be considered both in the lab and in the clinic.
In this chapter, I will discuss our study investigating the effects of residual
compression on spinal inflammation and progression of SCI. Importantly, this study
investigates residual compression across various injury severities in an effort to disentangle
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effects specific to compression from effects of injury severity. We used the Infinite
Horizons (IH) impactor286 to deliver spinal contusion to mice with specifically controlled
impact force and duration, effectively created injuries of various severity with and without
residual compression. Then, we analyzed locomotor function, anatomical deficits, and
inflammatory profiles of mice at various times after injury. These experiments show that
residual compression causes exacerbated spinal pathology, a premature cessation of
functional recovery, and a downstream shift in macrophage/microglia phenotypes.

5.2

Experimental Design to Study the Effects of Compression in Spinal Cord Injury
We set out to understand the effects of compression on SCI progression and injury

responses by designing our experiment with moderate (50 kdyn) and severe (75 kdyn)
contusion injuries with or without 20 sec of sustained compression after contusion. This
gives us 4 injury groups, which will hereafter be labelled as (1) 75 kdyn, (2) 75 kdyn 20
sec, (3) 50 kdyn, and (4) 50 kdyn 20 sec. Using these four injury groups, we were able to
investigate the effects of compression in moderate and severe injuries specifically, but
could also investigate effects of compression regardless of injury severity.
We performed our experiments using 90 3–4 month old female C57BL/6 mice
(Jackson Laboratory, Bar Harbor, Maine), a common species and strain for SCI research.
Animals were housed in individually ventilated cages with ad libitum access to food and
water. All procedures were performed in accordance with the guidelines of the Office of
Responsible Research Practices and with the approval of the Institutional Animal Care and
Use Committee at the University of Kentucky.
Mice were anesthetized via intraperitoneal (ip) injections of ketamine (100 mg/kg)
and xylazine (10 mg/kg). After a T9 laminectomy, a mid-thoracic SCI was produced using
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the IH injury device286. A previous study suggests that the duration of compression has
negligible effects on outcomes29. Based on these findings, we performed pilot studies
examining different compression times and found no obvious differences in injury severity
between groups. This finding is consistent with a previous study reporting an injury
threshold at 15 sec of sustained compression after IH contusion SCI292. Thus, we
determined a 20 sec sustained compression was sufficient and reproducible within our
stereotaxic mode of injury application.
Mice were divided randomly to receive SCI with varying impact force (50 or 75
kdyn) and duration of maintained compression (i.e., dwell time: 0sec or 20sec), yielding
four groups: 50 kdyn, 50 kdyn 20 sec, 75 kdyn, and 75 kdyn 20 sec. After injury, muscle
and skin incisions were closed using monofilament suture. Post-surgically, animals
received one subcutaneous injection of buprenorphine-SR (1 mg/kg) for pain and 2 mL of
saline + antibiotic (5 mg/kg, enroloxacin 2.27%: Norbook Inc, Lenexa, KS); buprenorphine
has been shown to produce analgesic effects without affecting molecular, anatomical,
behavioral, or physiological parameters after SCI293. Animals were housed in warming
cages overnight. Animals continued to received 1mL saline + prophylactic antibiotics
subcutaneously for five days. Food and water intake and the incision site were monitored
throughout the course of the study. Bladder expression was performed on injured mice
twice daily until mice reached voluntary evacuation. Two mice received SCI with
abnormalities in the force versus time curve generated by the IH device, indicating bone
contact or spinal cord movement during impact. Based on these pre-determined exclusion
criteria, these two mice were excluded from further analyses. Groupwise spinal cord injury
parameters are summarized in (Table 5.2.1).
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Table 5.2.1: Spinal Cord Injury Parameters
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Animals (n=9-11/group) were tested for functional recovery of hindlimb
locomotion using the Basso Mouse Scale (BMS) before euthanizing the animal to collect
spinal tissue at 28 days post injury (dpi). Behavioral testing with BMS is described in more
detail later in Appendix 2. Separate cohorts were injured and euthanized for spinal tissue
collection 3, 7, or 14 dpi (n=4-6 per time point).
We analyze the anatomical responses to injury 3, 7, 14, or 28 dpi by collecting
spinal tissues from injured mice. To collect these tissues, mice were anesthetized with a
lethal dose of ketamine (150 mg/kg) and xylazine (15 mg/kg), then transcardially perfused
with cold phosphate buffered saline (PBS) (0.1 M, pH 7.4), followed by perfusion with
cold 4% paraformaldehyde (PFA). Dissected spinal cords (1 cm) were post-fixed for 2hr
in 4% PFA, then rinsed and stored in cold phosphate buffer (0.2 M, pH 7.4) overnight at
4°C. Tissue was cryoprotected in 30% sucrose at 4°C for one week, then rapidly frozen
using optimal cutting temperature compound (Sakura Finetek USA, Inc., Torrance, CA)
on dry ice. Tissue was systematically randomized into blocks with equal group distribution
in each block to ensure uniformity of staining across groups. Tissue was stored at -80°C
before sectioning. Tissue blocks were cut in 10µm thick serial cross sections and mounted
onto Colorfrost plus slides (Fisher #12-550-17).
Spinal tissue was stained for visualization through chemical or antibody-based
stains specifically described in Appendices 2 and 3. Briefly, brightfield chemical staining
with eriochrome cyanine (EC) and neurofilament (NF-H; Aves Labs, #NFH) was used to
visualize spared tissue as described previously69,71, while antibody-mediated fluorescent
staining of various macrophage/microglia phenotypic markers were employed to visualize
the macrophage/microglia responses to injury. Stained spinal tissue was then imaged and

123

analyzed using semi-automated analysis processes on the MetaMorph analysis program
(Molecular Devices, Sunnyvale, CA).
Because of unknown, at the time, temperature inconsistencies during tissue
processing and sectioning, some cross sections were lost or folded during staining, making
analysis impossible. Mice without an obvious and fully intact epicenter were not included
for histological analysis, decreasing the total number of mice analyzed for histological
analyses from 88 to 71.
Investigators blinded to experimental groups performed all data acquisition and
analysis. Statistical analyses were completed using GraphPad Prism 6.0 (GraphPad
Software). Data were analyzed using one- or two-way analysis of variance (ANOVA)
followed by the Holm-Sidak test for multiple comparisons. Specifically, repeated measures
two-way ANOVA was used to analyze BMS (time [repeated] x injury), 28d tissue sparing
(distance [repeated] x injury), and macrophage phenotype (ROI [repeated] x injury).
Ordinary two-way ANOVA was used to analyze tissue sparing over time (time x injury).
All other outcomes were analyzed using one- way ANOVA or independent sample t tests
when appropriate. Comparisons include groups differing only in contusion force (50 kdyn
vs. 75 kdyn, 50 kdyn 20 sec vs. 75 kdyn 20 sec) or compression (50 kdyn vs. 50 kdyn 20
sec, 75 kdyn vs. 75 kdyn 20 sec); other groups were not analyzed statistically to avoid
comparing across multiple independent variables. The robust regression and outlier
removal method with a false positive rate for detecting outliers (Q-value) of 1% was used
to automatically identify outliers, and imputed mean values were used when necessary for
repeated measures294. Results were considered statistically significant at p<0.05. All data
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are presented as mean ± standard error of the mean unless otherwise noted. Figures were
prepared using Adobe Photoshop CS6 (Adobe Systems) and Prism 6.0.

5.3

Sustained Compression Decreases Functional Recovery from Contusion Spinal
Cord Injury
Initial injury biomechanics are highly influential on the progression of pathology

and recovery from SCI. Clinically, function is used to categorize the severity of injury on
the ASIA scale51. In the lab, behavioral outcomes have been similarly evaluated on their
ability to detect differences between animals injured with graded contusion severities22.
Several studies have shown that graded increases in compression cause progressive
functional deficits23,295, but this is the first study to investigate if compression, as a unique
injury biomechanic independent of injury severity, causes unique progression of injury
and/or recovery.
We assessed locomotor hindlimb function in injured mice using the BMS as
described previously54. Two observers blinded to group inclusion observed and scored
mice in an open field for 4 min at 1, 3, 7, 14, 21, and 28dpi. Each hindlimb was scored
separately based on hindlimb movement (e.g., ankle placement and stepping),
coordination, and trunk stability, then averaged to generate a single score for each animal.
A score of 0 indicates complete paralysis while a score of 9 indicates normal locomotion.
The BMS subscore is sensitive to atypical patterns of locomotor recovery54 and was used
to analyze specific aspects of locomotion (e.g., paw placement and coordination).
Our injury model was consistent with previous reports that locomotor function
varied significantly depending on the contusion force25,54. Specifically, recovery was
significantly worse for animals receiving 75 kdyn versus 50 kdyn contusions regardless of
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compression (main effect of 50 kdyn vs. 75 kdyn or 50 kdyn 20 sec vs. 75 kdyn 20 sec p <
0.01; Table 5.3.1 and Figure 5.3.1). Compression also significantly decreased recovery
independent of contusion severity (main effect of 50 kdyn vs. 50 kdyn 20 sec or 75 kdyn
vs. 75 kdyn 20 sec p < 0.0001). These data help support previous data indicating that both
increased severity and the addition of compression contribute to functional deficits from
SCI.
To account for atypical patterns of recovery that may occur with sustained
compression, we further investigated recovery using the BMS subscore at 28dpi. This
composite score is based on the functional levels achieved for stepping, coordination, paw
position, trunk stability, and tail placement independent of the pattern of recovery54. Figure
5.3.1B shows that the total BMS subscore is decreased by increased contusion force (50
kdyn vs. 75 kdyn, p < 0.05), and with the addition of compression at each contusion force
(50 kdyn vs. 50 kdyn 20 sec, p < 0.0001; 75 kdyn vs. 75 kdyn 20 sec, p < 0.01). Particular
aspects of the BMS subscore highlight specific functional tasks, all of which follow a
similar pattern to the overall BMS subscore and functional outcomes at 28dpi.
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Figure 5.3.1: Compression impairs functional recovery from contusion
SCI.
A) Over a 28-day period, groups with higher impact force have worse
hindlimb function than groups with lower impact force and groups with
compression had worse hindlimb function than groups without compression
(statistics detailed in Table 5.3.1). Specifics of hindlimb function are detailed
in 28dpi BMS subscores. Groups with compression performed significantly
worse than force-matched counterparts for every subscore. (B) Composite
BMS subscore is significantly decreased by increased severity and
compression. (C) Coordination is graded as 2 = mostly coordinated (>50%),
1 = some coordination (<50%), or 0 = no coordination. (D) Plantar stepping
is graded as 1 = consistent or 0 = less than consistent. (E) Paw position is
graded as 2 = parallel throughout, 1 = parallel and rotated, or 0 = rotated
throughout. *p<0.05, **p<0.01, ****p < 0.0001.
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Table 5.3.1: Basso Mouse Scale Statistical Summary (p values)
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Coordination of stepping is significantly compromised in animals whose injuries
include compression. Figure 5.3.1C shows the coordination subscore that quantifies
forelimb-hindlimb stepping as mostly coordinated (at least 50% coordinated, score = 2),
some coordination (at least 1 coordinated pass, score = 1), or no coordination (score = 0).
Compression significantly decreased forelimb-hindlimb stepping coordination (50 kdyn
vs. 50 kdyn 20 sec, p < 0.0001; 75 kdyn vs. 75 kdyn 20 sec, p < 0.0001). Figure 5.3.1D
shows the plantar stepping subscore that distinguishes between frequent hindlimb plantar
stepping (at least 50% stepping, score = 1) and occasional/no hindlimb plantar stepping
(<50% stepping, score = 0). Compression significantly decreased hindlimb plantar stepping
performance (50 kdyn vs. 50 kdyn 20 sec, p < 0.01; 75 kdyn vs. 75 kdyn 20 sec, p <
0.05).
Positioning of the paw during hindlimb stepping is significantly impaired in
animals with injuries including compression. The paw position subscore included in Figure
5.3.1E quantifies paw rotation during stepping from the initial contact through liftoff as
parallel throughout (score = 2), parallel and rotated (score = 1), or rotated throughout (score
= 0). Animals that have injuries without compression sometimes achieve parallel paw
positioning while stepping, but animals with compression injuries cannot achieve parallel
paw placement while stepping (50 kdyn vs. 50 kdyn 20 sec, p < 0.001; 75 kdyn vs. 75 kdyn
20 sec, p < 0.05). Collectively, BMS score and subscore indicate that functional recovery
is impaired by additional compression at the time of contusion regardless of impact force.
Only a few studies have reported long-term recovery after contusion injury with or
without subsequent compression. For example, Streijger and colleagues examined foreand hindlimb recovery after cervical IH contusion in mice with or with subsequent
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compression (0, 15, or 30 sec)292. Depending on the outcome measure, recovery was noted
in the contusion alone group after two weeks (e.g., forelimb grip strength); however, little
recovery was observed within the first month across a range of functional measures in
combined contusion-compression groups292. Chronically (12 wks), some behaviors did
improve across all groups; however, functional decline was noted only in the combined
contusion/compression groups over this period.
The behavioral results are less consistent in rat models of contusion with
subsequent compression injury. When a spacer was placed on the dura after contusion SCI
to maintain compression for various periods (hours to weeks), the rate and overall extent
of recovery varied with spacer size and compression duration296,297. These data, along with
a rat study with various compression times after IH contusion
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, indicate that the

compression itself, and not the duration of the compression, worsens functional outcome.
Collectively, these published results, along with the results of the current study, indicate
that the mode of injury is an important determinant of functional recovery. Indeed, a recent
comparison across contusion, dislocation, and distraction SCI reported different rates of
recovery depending on the mode of SCI 28.
Our study was specifically designed to disentangle the injury biomechanics of
severity and compression. Adding compression to a contusion injury could lead to effects
due to increasing injury severity or due compression itself. However, by collapsing groups
of moderate (50 kdyn) and severe (75 kdyn) injuries to create two groups (with 20 sec
compression and without 20 sec compression), we can gain insight into the effects
generalized effects of compression in contusion injury regardless of severity. Through this
analysis, we uncover that compression significantly impairs hindlimb function, as
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quantified on the BMS, at all time points (Figure 5.3.2A; p < 0.0001, main effect of
compression). Furthermore, this analysis highlights the fact that compression causes early
cessation in functional recovery, resulting in a premature recovery plateau 14 dpi.
Specifically, mice injured without compression improved an average of 1.5 points on the
BMS scale between 14 dpi and 28 dpi (Figure 5.3.2B). On the other hand, mice injured
with sustained compression after contusion SCI improve significantly less ( p < 0.005),
only increasing their BMS score an average of 0.3 points between 14 and 28 dpi (Figure
5.3.2B).
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Figure 5.3.2: Compression deceases functional recovery regardless of
severity.
Both 50 and 75 kdyn spinal cord injury contusion groups were collapsed and
the effect of 20 sec of sustained compression was compared between
aggregate groups. (A) Animals with compression injuries do not recover as
much hindlimb function, according to the Basso Mouse Scale, as counterparts
whose injuries did not include compression (n=19-20; main effect p <
0.0001). In additional, (B) animals injured without compression demonstrate
improved function from 14 to 28 dpi, while animals whose injuries included
subsequent compression prematurely cease recovery after 14 dpi. **p<0.01,
***p<0.001, ****p<0.0001.
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Interestingly, a similar two-week plateau in functional recovery has been reported
after varying degrees of compression injury alone and after severe IH contusion injury25,298.
While it is not surprising that little recovery would be detectable after severe injuries, it is
interesting to note that clip-compression SCI, a form of contusion with sustained
compression, results in little recovery after the first few weeks of injury in both rats and
mice89,295. Collectively these data indicate that compression significantly impairs
functional recovery from SCI, potentially by creating a premature cessation in the
progression of functional recovery.

5.4

Sustained Compression Decreases Tissue Sparing in Contusion Spinal Cord Injury
Previous studies have shown that injury biomechanics affect lesion size and tissue

sparing 22,28. Additionally, studies show adding compression 292 and increasing the extent
of compression

290

can causes increased tissue pathology in contusion spinal cord injury.

However, our study is the first to investigate effects of compression across various
contusion severities. Understanding the effects of compression on tissue pathology
independent of injury severity is critical to building a better understanding of the interplay
of these clinically relevant injury biomechanics.
To determine whether long-term anatomical recovery was affected by the addition
of compression to a contusion SCI, we investigated tissue changes through histological
analysis of serial spinal cord cross sections. As validated and described previously, spared
tissue was identified using a combination of eriochrome cyanine (EC) and NF-H to label
myelin and axons, respectively

69,71

. Tissue sparing images were collected using an

Olympus AX-80 and Aperio Scanscope, and images were analyzed using the MetaMorph
analysis to create custom regions of interest (ROIs) outlining areas of frank pathology that
133

quantified spared and lesioned area. We performed tissue sparing analysis at 28 dpi on
sections identified as the lesion epicenter as well as sections 0.2 mm, 0.5 mm, and 1.0 mm
rostral and caudal to the lesion epicenter.
Our histological results were consistent with previous reports22,286 in showing
decrease epicenter tissue sparing with increased contusion severity (50 kdyn vs. 75 kdyn p
= 0.03; Figure 5.4.1 and Table 5.4.1). Further, our data reveal that compression
significantly decreases tissue sparing at the lesion epicenter of animals at both injury
severities (50 kdyn vs. 50 kdyn 20 sec and 75 kdyn vs. 75 kdyn 20 sec p < 0.0001). These
lesions consumed a larger portion of the cord at the injury epicenter, but analysis of sections
rostral and caudal to the immediate injury site also reveal that tissue pathology spread
throughout the cord (Figure 5.4.1A and Table 5.4.2).
To gain insight into the progression of tissue damage, additional epicenter tissue
sparing data were gathered at 3, 7, and 14 dpi. The proportional area data reflect a highly
dynamic spinal lesion, which changes over time due to transient edema and active
clearance of debris. Still, our longitudinal histology reveals compression causes long-term
(28 dpi) tissue loss that is similar to acute (7 dpi) pathology, while tissue pathology in
spinal cords injured without compression recover to a greater proportional area of spared
tissue (Figure 5.4.1). This trend for compression-induced sustained tissue pathology is
more evident and is statistically significant when analyzing groups collapsed across
contusion severities (Figure 5.4.2; effect of compression p<0.001).
Penumbral areas are often spared from the initial mechanical damage but are still
susceptible to secondary injury. Considering the body of evidence suggesting that primary
biomechanics affect secondary injury progression31,288, it is likely that compression
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influences these secondary injury cascades and thereby the overall progression of SCI.
Indeed, previous studies show that compression after contusion induces increased
hemorrhage, decreases spinal cord perfusion, and increases indicators of hypoxia in
penumbral and distal areas of the spinal cord relative to the lesion epicenter290,291,297. These
changes can have widespread effects, including effects on the macrophages and microglia,
which are especially responsive to hemorrhage and its accompanying blood
components299,300.
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Figure 5.4.1: Compression significantly decreases anatomical recovery
from contusion spinal cord injury.
A) Tissue sparing at 28 dpi is decreased by both increased force and
compression at the epicenter and at regions rostral and caudal to the
epicenter. (B) Tissue sparing at 3, 7, 14, and 28dpi, reflected by myelin (EC,
blue) and axon (NF-H, brown) at the lesion epicenter is decreased by both
increased impact force and compression. (C) Representative images reflect
decreased tissue sparing in groups that receive compression. Scale bar, 400
µm. Statistical details are included Tables 5.4.1 and 5.4.2.
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Table 5.4.1: Statistical summary (p values) for time course of epicenter
tissue sparing
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Table 5.4.2: Statistical summary (p values) for 28dpi rostral-caudal
tissue sparing
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Figure 5.4.2: Compression decreases anatomical recovery regardless of
severity.
Both 50 and 75 kdyn SCI contusion groups were collapsed and the effect of
20sec of sustained compression was compared between aggregate groups.
Frank tissue pathology at the lesion epicenter, determined by myelin (EC) and
axon (NF-H) stains, is significantly worse with compression at 14 and 28dpi.
**p<0.01, ****p<0.0001.
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5.5

Sustained Compression Alters Inflammatory Response to Spinal Cord Injury
We began to observe significant compression-mediated differences in tissue

sparing and functional recovery at 7dpi with a clear plateau by 14dpi. These time points
coincide with the peak of SCI macrophage infiltration and subsequent predominance of
proinflammatory activation107,129. The inflammatory response at these time points is
dominated by infiltrating, hematogeneous macrophages and resident microglia. Once
activated, macrophage and microglia adopt amoeboid morphologies and upregulate
specific

protein

expression

profiles.

Macrophages

and

microglia

are

nearly

indistinguishable from one another, but both cell types adopt a spectrum of activation states
characterized by gene and protein expression profiles that indicate their propensity to
promote tissue recovery or exacerbate tissue pathology2,301. These phenotypes are
dynamically controlled by microenvironmental cues. Therefore, we investigated the effects
of compression and injury severity on macrophage/microglia polarization 7 and 14dpi.
We used previously described histological markers to evaluate macrophage
polarization within the lesioned spinal cord. Macrophages and microglia were assessed for
hallmarks of alternatively activated, reparative phenotypes and classically activated,
cytotoxic phenotypes. Each of these markers are analyzed on cells labeled with Tomato
Lectin (TomL) staining. Lectins are carbohydrate-binding proteins that can be conjugated
to biotin or fluorescent components to visualize carbohydrate-expressing cells. Tomato
lectin is a well-known product of Lycopersicon esculentum, which binds to carbohydrates
on macrophages and microglia302. Therefore, we captured a snapshot of the
macrophage/microglia inflammatory response at specific timepoints with TomL, and then
assessed these inflammatory cells for hallmarks of their activation state and phenotype.
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Alternatively activated, reparative macrophages and microglia express mannose
receptor (CD206) and Arginase 1 (Arg1)114. CD206 is a lectin that recognizes terminal
mannose and facilitates phagocytosis for antigen presentation and evaluation of potential
pathogens. CD206 performs anti-inflammatory functions indirectly by clearing
glycoprotein stimuli and directly by altering cytokine production303,304. Arginase 1 is an
enzyme responsible for converting L-arginine to ornithine and urea in the final step of the
urea cycle. Arginase has been proposed to facilitate anti-inflammatory effects via several
mechanisms. One potential mechanism is Arg1 inhibition of oxidative damage through
substrate competition with nitric oxide synthase. Arginase consumption of L-arginine is
associated with a decreased production of the potent oxidative molecule, nitric oxide, in
various contexts, including SCI305,306. Alternatively, Arg may achieve anti-inflammatory
effects through affecting autophagy. Immunosuppression elicited by Arg administration
mimics chemical inhibition of autophagy307. Both CD206 and Arg1 have been found to be
upregulated in alternatively activated macrophages and microglia in vitro and in vivo, and
these cells are associated with pro-growth and reparative functions in many contexts,
including SCI107,144.
Classically activated, cytotoxic macrophages and microglia express CD86 and
macrophage receptor with collagenous structure (MARCO)308. CD86 performs antigen
presentation to adaptive immune cells, and is a costimulatory protein (acting with CD80)
responsible for T-cell activation and survival. Upon stimulation, CD86 signals through NFκB to cause production of pro-inflammatory cytokines309,310. MARCO is a class A
scavenger receptor that assists in the phagocytosis of a wide variety of particles and
promotes

production

of

proinflammatory
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cytokines

mediated

through

TLR2

signaling311,312. The binding properties of MARCO enable this cell surface receptor to
recognize pathogen- and damage-associated molecular patterns with polyanionic
properties. Specifically, MARCO can recognize lipopolysaccharides, nucleic acids, and
modified lipids

313-315

, and the loss of macrophage-specific MARCO expression leads to

accumulation of oxidized lipids in lung models of oxidant inhalation316. Representative
images show spinal macrophages/microglia expressing these hallmarks of cytotoxic
(Figure 5.5.1A,B) and reparative (Figure 5.5.1C,D) phenotypes.
For immunohistochemical analyses of macrophage/microglia phenotypes, sections
were incubated with goat anti-CD206 (1:100 dilution, AF2535, R&D Systems,
Minneapolis, MN), goat anti-Arg1 (1:100, SC-18354, Santa Cruz Biotechnology, Dallas,
TX), rat anti-CD86 (1:100, 553689, BD Biosciences, San Jose, CA), or rat anti- MARCO
(1:1000, MCA1849, BioRad, Hercules, CA). Slides were incubated with these primary
antibodies overnight at 4°C in 0.1M PBS with 5% normal donkey serum, 0.1% fish gelatin
(Sigma- Aldrich, G7765), 1% BSA and 0.1% Triton X-100. Sections were subsequently
incubated with a biotinylated tomato lectin (1:1000, L0651; Sigma-Aldrich, St. Louis, MO)
to counterstain for total macrophage numbers. Detection of primary antibodies was
performed with donkey anti-rat Alexa Fluor (AF) 488, donkey anti-goat AF 568, and
streptavidin AF 647 (all secondaries at 1:1000 dilution, Life Technologies, Carlsbad, CA)
for 1 hr at room temperature. To validate antibody staining, negative controls were run
without primary antibody, and full dilution curves were analyzed.
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Figure 5.5.1: Representative imagesof macrophage/microglia phenotypic
markers for histological analysis 7dpi and 14dpi.
All images are collected from the epicenter of the spinal cord injury of
animals in the 50 kdyn 20 sec group. (A) Macrophage receptor with
collagenous structure (MARCO; panel 1 and panel 3, green) and tomato lectin
(TomL; panel 2 and panel 3, blue) positive cells at 7dpi (top panels) compared
with fractured, noncellular MARCO staining at 14dpi (bottom panels). (B)
CD86 (green) and TomL (blue) positive cells observed at 7 and 14 dpi. (C)
CD206 (red) and TomL (blue) positive cells observed at 7 and 14 dpi. (D)
Arginase 1 (Arg-1; red) and TomL (blue) positive cells observed at 7 and
14dpi. Scale bars = 20mm.
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Macrophage/microglia images were collected using an Axioplan 2 imaging
microscope (Carl Zeiss) at 20x magnification, and were analyzed via MetaMorph. We
collected three or four images per subject within the lesion epicenter, as visualized in
Figure 5.5.2A. Injury epicenter section selection was accomplished by evaluating serial
sections from EC/NF staining to identify the section with the least proportional spared
tissue. Macrophage phenotypic marker (Arg1, CD206, MARCO, and CD86) expression
was evaluated via threshold-based positive staining within each of these images from the
injury epicenter. The total area of positive signal for macrophage markers was then
normalized to total TomL-positive area for each image to determine proportion of positive
macrophages within the lesion. Although lesion size varied across groups, we observed a
similar macrophage density within the lesion epicenter in all injury groups at both time
points (Figure 5.5.2A and Figure 5.5.3A; p > 0.4 main effect injury, n = 3–5 per group).
At 7 dpi, there was no effect of force or compression on the percentage of
macrophages positive for protective markers, CD206 (p = 0.4 and 0.6, main effect of force
and compression, respectively) and Arg1 (p = 0.7 and 0.5, main effect of force and
compression, respectively) (Figure 5.5.2B,C). Similarly, macrophages positive for the
proinflammatory marker, CD86, are present at comparable levels with a force-dependent
trend toward increased expression after 50 kydn injuries ( p = 0.1 and 0.5, main effect of
force and compression, respectively, Figure5.5.2D,E). We observed a significant
difference, however, in the percent of macrophage positive for MARCO (Figure 5.5.2E,F)
with compression at the time of contusion increasing the proportion of MARCO+ cells
twofold to threefold compared with contusion alone (50 kdyn 20 sec = 10.3% and 75 kdyn
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20 sec = 14.0% vs. 50 kdyn = 2.4% and 75 kdyn = 3.6%; main effect of compression p =
0.02, main effect of force p = 0.5).
At 14 dpi, we observed that compression at the time of contusion decreased the
proportion of Arg1+ macrophages one and one half to twofold compared with contusion
alone (50 kdyn 20 sec = 13.0% and 75 kdyn 20 sec = 17.8% vs. 50 kdyn = 23.8% and 75
kdyn = 29.05%; main effect of compression p = 0.04, main effect of force, p = 0.4)
(Figure5.5.3B,C). We observed no effect of injury type on the percentage of macrophages
positive for CD206 ( p = 0.3 and p = 0.5, main effect force and compression, respectively;
Figure 5.5.3D) or CD86 ( p = 0.3 and p = 0.3; main effect force and compression,
respectively; Figure 5.5.3E). In addition, whereas MARCO staining was observed on the
cell surface of macrophages cells at 7 dpi (Figure 5.5.2E), by 14 dpi, MARCO displayed
fractured staining with no definitive localization in all treatment samples. Thus, we did not
observe any MARCO+/TomL+ cells at 14 dpi.
We collapsed groups across both contusion injury severities (50 kdyn and 75 kdyn)
to perform comparisons in groups injured with vs. without sustained compression. When
performing this analysis, we uncover that residual compression, regardless of contusion
severity, significantly alters markers of macrophage/microglia phenotype. Compression
significantly increased MARCO expression 7dpi (Figure 5.5.4A) and significantly
decreased Arg1 expression 14dpi (Figure 5.5.4B). Collectively, these data show that
compression alters the inflammatory profile of macrophages/microglia in the injured spinal
cord.
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Figure 5.5.2: Compression alters spinal cord injury macrophage
activation at 7 dpi.
A) Three regions of interest (dorsal, left, and right) within the lesion
epicenter of each animal were analyzed at 7 dpi for macrophage (TomL)
density. The TomL+ area was similar across the four injury paradigms:
50 kdyn, 75 kdyn without compression (open bars) and 50 kdyn, 75
kdyn with compression (black bars). (B) Percent of TomL+ cells
positive for Arg1 across treatments. (C) Percent of TomL+ cells positive
for CD206 across treatments. (D) Percent of TomL+ cells positive for
CD86, and (E) percent of TomL+ cells positive for MARCO (p=0.03
main effect of compression). (F) Representative images for analysis of
TomL+ (blue)/MARCO+ (green) cells across treatments. Scale bar = 50
µm; n=3-4 per group; error bars = SEM.
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Figure 5.5.3: Compression alters macrophage/microglia phenotypes 14
dpi.
A) Four regions of interest within the lesion epicenter of each animal (as
depicted in Figure 7.6A and ventral) were analyzed at 14 dpi for TomL+
density. The TomL+ area was comparable across all four injuries: 50 kdyn,
75 kdyn without compression (open bars) and 50 kdyn, 75kdyn with
compression (black bars). (B) Percent of TomL+ cells positive for Arg1
across treatments (p=0.036 main effect compression). (C) Representative
images for analysis of tomato lectin+(blue)/Arg1+(red) cells across
treatments. Scale bar=50µm.(D) Percent of TomL+ cells positive for CD206,
and (E) percent of TomL+ cells positive for CD86. n=5, error bars=standard
error of the mean.
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Figure 5.5.4: Macrophage/microglia phenotypes are specifically
regulated by compression independent of contusion severity.
Both 50 and 75 kdyn spinal cord injury contusion groups were collapsed, and
the effect of 20s of sustained compression was compared between aggregate
groups. (A) Tomato lectin (TomL)+ macrophages in spinal cords injured with
compression show increased MARCO expression 7 dpi (A) and decrease
Arg1 expression 14 dpi (B) compared to spinal cords injured without
sustained compression. *p<0.05
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Neuroinflammation plays a major role in orchestrating secondary injury
mechanisms109. Specifically, macrophage activation is dictated, in part, by the
microenvironment, and macrophages can adopt proinflammatory, neurotoxic phenotypes
or purportedly reparative phenotypes depending on the stimuli present in the injured spinal
cord108. A novel observation in the current study is that the proportion of macrophages
phenotypes shift to displaying more pathological and less reparative markers after
contusion-compression SCI than after contusion-alone injuries. It is important to note that
we normalized to the overall magnitude of the macrophage response, thereby concluding
that biomechanics, and not injury sizes are likely driving this unique macrophage profile.
In support of this idea, it was previously observed that the extent of
macrophage/microglia activation after SCI varied across contusion, dislocation, and
distraction injuries31. Differences have also been observed in the immune system response
to brain injury versus SCI317. Indeed, while both central nervous system organs are
extremely similar, subtle differences in blood barriers and resident glial cells can lead to
robust differences in immune cell activity and distribution148,301. In addition, Zhang and
colleagues299 show microenvironment-specific differences in toll-like receptor 4 (TLR4)
expression on activated macrophages after compression SCI. TLR4 is important for
lipopolysaccharide-mediated proinflammatory macrophage activation, and that article
demonstrated that even within the same organ with the same injury, microenvironmental
conditions significantly impact proinflammatory responses.
It is also important to consider that although microglia and monocyte-derived
macrophages express similar histological markers of myeloid cells, they are distinct
populations and may play distinct roles in SCI pathophysiology. We observed
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compression-specific changes in MARCO and Arg1. Interestingly, both phenotypic
markers are predominantly expressed in monocyte-derived macrophages. Specifically,
using a transgenic model to label infiltrating cells, Greenhalgh and colleagues132 detected
Arg1 exclusively on monocyte-derived macrophages after contusion SCI.
Targeting MARCO reduces monocyte trafficking in models of myocardial
infarction, experimental autoimmune encephalomyelitis, colitis, peritonitis, and
encephalitis318. Therefore, MARCO may be a hallmark for proinflammatory monocytes.
Indeed, in the current study we focused our analyses on the lesion core, an area
predominantly populated by monocyte-derived macrophages after contusion SCI131.
Collectively, our observations suggest that compression polarizes monocyte-derived
macrophages toward a proinflammatory phenotype. It is also possible the compression
alters the distribution of microglia after injury or upregulates markers in microglia not
normally expressed after contusion SCI. Further studies are warranted to parse out the
specific contribution of injury biomechanics to environmental and chemotactic cues for
macrophages and microglia independently.
In the current study, we detected a compression-specific increase in the proportion
of macrophages expressing MARCO. This finding is especially interesting when
considering the role of MARCO as a scavenger receptor that binds DAMPs, including
oxidized targets314,319. SCI biomechanics influence microenvironmental factors such as 3NT, cytochrome c, and membrane permeability

31,288

. Compression specifically adds a

component of reperfusion and hemorrhage that alters fluid dynamics290,320. Collectively,
these published data and the increased MARCO+ macrophages observed with compression
in the current study, suggest that macrophages may be specifically upregulating receptors
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to bind to the specific type of damage caused by reperfusion, excessive oxidants, and
oxidized lipids in contusion-compression SCI.
The shift in MARCO and Arg1 macrophages not only reflects differences in the
microenvironment after a compression-contusion injury, but also is a likely player in
secondary pathology. MARCO is specifically expressed by proinflammatory, neurotoxic
macrophages308 and is integral in the uptake of immune-modifying microparticles, which
subsequently inhibits trafficking of pathological macrophages318. Our lab previously
observed an age-dependent decrease in recovery and increase in tissue pathology
coincident with decreased Arg1 expression in macrophages/microglia321. Whether
MARCO and Arg1 alone or a large repertoire of proteins are affected by the compression
microenvironment, these secondary responses are likely critical to overall outcomes of SCI,
and thus are important targets for therapeutic intervention.
The heterogeneous nature of human SCI creates a challenge for recapitulation in
controlled experimental models. Resolving SCI into its composite parts has provided
valuable insight, but extrapolating findings from oversimplified injury paradigms risks
erroneous inductive generalizations. The model employed in this study provides valuable
information about the interaction of biomechanics common to clinical SCI. It shows that
compression affects overall outcomes of SCI and specifically alters at least one secondary
injury response. These results simply introduce additional questions as to how contusion,
compression, and other injury biomechanics affect other secondary responses to injury.
Developing a deeper understanding of how specific injury biomechanics affect specific
injury responses will help us develop and implement more effective therapies for SCI.
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CHAPTER 6. CONCLUSIONS ON TARGETING SECONDARY INJURY RESPONSES TO IMPROVE
RECOVERY FROM SPINAL CORD INJURY
Many factors that can influence the progression SCI pathology and repair. Chapters
2-5 describe novel mammalian models of SCI I employed to better understand the role of
secondary injury responders—particularly spinal inflammation and scarring—with the
intent of informing future therapeutic development. Considering these studies together
provides interesting perspectives on how to effectively facilitate endogenous repair in the
mammalian spinal cord. Here, I will discuss insights gained from my graduate studies, and
how these insights may contribute to SCI therapeutic development.

6.1

Crosstalk between macrophages and fibroblasts in injury responses
Proper wound healing involves concerted responses of many different cell types,

including inflammatory cells and fibroblasts. Inflammatory cells and fibroblasts enter into
the injury site and begin secreting a suite of growth factors and cytokines, which exert
autocrine and paracrine effects that are highly influential on the inflammatory and fibrotic
profile322. In typical peripheral wound healing, this cellular response orchestrates proper
progression through inflammatory, proliferative, and remodeling phases of tissue
repair144,323,324. However, these responses are dysregulated in SCI and result in a persistent
inflammation and a fibrotic scar107. Many lines of evidence point toward crosstalk between
macrophages and fibroblasts as a lynchpin for proper wound healing progression325.
The phenotypic profiles of macrophages and fibroblasts, particularly their secreted
factors, are highly influential on the progression and degree of wound healing.
Macrophage-derived interleukins are known to play a key role in fibroblast recruitment
and macrophage-derived tumor necrosis factor α (TNFα) triggers collagen synthesis322.
152

Similarly, fibroblasts can recruit macrophages through secretion of interleukins and other
chemokines, while simultaneously affecting fibroblast and macrophage phenotype through
factors such as transforming growth factor β (TGFβ)322,326,327. The cytokines are not solely
deleterious. Persistent high levels of pro-inflammatory cytokines leads to poor recovery
and chronic wounds328, but proper cytokine signaling is necessary to facilitate repair140.
Furthermore, these macrophages and fibroblasts also produce growth factors, including
PDGF, which are necessary for wound healing329. Macrophages and fibroblasts exist in a
delicate balance to facilitate repair, but can easily slip into a vicious cycle that selfsustaining inflammatory damage. Perhaps this vicious cycle is a main driver in the
increased pro-inflammatory and decreased pro-reparative macrophage profile we see in the
contusion-compression injuries vs. contusion-alone.
Studies in models of regeneration show that macrophages are necessary to facilitate
wound repair at least partially through their effects on fibroblasts. Godwin and colleagues
show that early depletion of macrophages in axolotl limb amputation inhibits the normal
limb regeneration. Furthermore, the macrophage-depleted injury site features a significant
increase in pro-inflammatory cytokines, myofibroblasts, and collagen deposition,
suggesting that the macrophages regulate both inflammation and fibrosis after injury152. In
a similar series of experiments, Godwin and colleagues show that macrophage depletion
also impairs axolotl regeneration from cryo-injury of the heart. The macrophage-depleted
axolotl heart also has a robust increase in myofibroblasts and collagens, as well as lower
levels of growth factors that aid heart regeneration151. These non-mammalian results have
been replicated in the neonatal Mus, where macrophage depletion inhibits heart
regeneration and results in the formation of a robust fibrotic scar150. Furthermore,
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macrophage depletion inhibits Acomys ear regeneration38. The exact nature of macrophage
and fibroblast crosstalk is an area of active investigation, and understanding the context of
this interplay is incredibly important. For instance, Zhu and colleagues show that
macrophage depletion in mouse SCI leads to fewer genetically labelled (Col1α1+)
fibroblasts in the spinal cord 1 and 2wpi167. This phenomena is more in line with trends
seen in Acomys, where there are fewer macrophages/microglia and fewer cells expressing
fibroblast markers at subacute time points. This suggests that macrophage-fibroblast
interactions are likely unique in the Acomys spinal cord, and merit further study to
understand how they contribute to enhanced recovery from SCI.
In addition to the general organ environment, macrophage and fibroblast crosstalk
may also be influenced by local ECM. Fibroblasts are key players in establishing the ECM
microenvironment, which has subsequent effects on cellular dynamics, particularly those
of the highly responsive macrophage. For instance, periostin induces macrophage
migration and expression of TNF-α in a mouse model of SCI271. These ECM-induced
changes in macrophage phenotype are thought to be primarily mediated by integrin
receptors, which can induce macrophage chemotaxis119, reactive oxygen species
production117, and cytokine production330 after SCI. Preclinical efforts have reduced early
inflammation and improved recovery from SCI by acute inhibiting integrin binding using
monoclonal antibodies117,119,149. Specific ECM components do have specific integrin
counterparts331. For instance, stimulating α9β1 integrin binding improves DRG axon
growth over Tenascin-C332. On the other hand, fibroblast-produced fibronectin binds α5β1
integrins on macrophages and fibroblasts in the injured cord, and may provide an
opportunity to limit cellular infiltration202.
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Macrophages and fibroblasts also collaborate in the remodeling of the ECM
microenvironment

through

release

of

proteolytic

enzymes,

such

as

matrix

metalloproteinases (MMPs)333, and tissue inhibitors of these proteases (TIMPs)322. While
macrophages/microglia are identified as the major source of MMPs and TIMPs in the
injured spinal cord, fibroblasts are also known to release a wide variety of MMPs that can
cleave and rearrange various ECM constitutents333. MMP release by either cell type can
affect cell migration through the dense meshwork of ECM, including axon growth and
revascularization199,334,335. Furthermore, the effects of proteolytic enzymes affect ECM
stiffness, which is a key determinant for fibroblast proliferation192,336 and ECM deposition
profile337. Interestingly, Acomys produce significantly more MMPs than Mus in skin164 and
ear34 injuries. Extracellular matrix remodeling may therefore be another mediator of
divergent inflammatory and fibrotic responses to SCI in Acomys.
The collective evidence suggests that macrophages and fibroblasts coexist in injury
responses, and that their crosstalk dynamically influences self- and cross-regulation. For
example, fibroblasts are instrumental in establishing the ECM microenvironment,
including the deposition of periostin338, which causes macrophages to produce more TNFα, which in turn promotes proliferation of ECM-producing pericytes271. Misbalance of
macrophage and fibroblast interactions may inhibit proper progression through wound
healing, leading to improper tissue repair and the establishment of chronic fibrotic scar and
inflammation2,107. The microenvironmental context during spinal cord injury leads to a
vicious cycle2,107. One of the few studies investigating macrophage-fibroblast interactions
in SCI suggests that disrupting the interaction between these two cell types can decrease
inflammation and scarring while increasing axon growth167. My investigations into Acomys
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SCI show that enhanced functional recovery is associated with a dampened inflammatory
and fibrotic response to injury. Future studies to more deeply understand the cross-talk
between these two injury responses could identify if one or both of the cell types are driving
the dampened response. Understanding this phenomenon in a naturally occurring system
of enhanced recovery provides an excellent opportunity to illuminate a path for inducing
endogenous spinal repair after injury.

6.2

Role of PDGFRβ in tissue damage and repair
An important regulator of wound healing responses is platelet-derived growth

factor (PDGF) and its receptor (PDGFR). This growth factor has long been recognized for
its importance to wound healing. Healing-impaired diabetic and glucocorticoid-treated
mice have lower expression of PDGFs and PDGFRs329,339, and a delayed appearance of
PDGF and PDGFRs in age is associated with impaired wound healing340. Furthermore, it
likely sits at the intersection of macrophage and fibroblast responses to injury. Studies of
pulmonary fibrosis have shown that alveolar macrophages produce PDGF, the majority of
which is PDGF-B, that acts on pulmonary fibroblasts and contributes to fibrotic
deposition276,341,342. These examples effectively reflect our understanding of PDGF and
PDGFR in wound repair: they are necessary to facilitate proper wound healing, but can
lead to improper repair (e.g. fibrosis) when overexpressed.
Some suggest replacing damaged tissues in the injured cord with newly proliferated
cells would be advantageous compared to the absence of cells in spinal cysts88,248.
However, evidence from our study and a study in neonatal opossums105 shows that the
formation of fluid-filled cysts does not necessarily preclude robust functional recovery.
PDGF and PDGFR are important for the migration and proliferation of cells in the injured
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cord, and several studies, including mine, show that PDGFRβ is robustly expressed in the
chronic SCI core where there is inflammation and fibrotic scarring20,263. Targeting PDGFR,
and PDGFRβ in particular, may provide a powerful tool for decreasing inflammatory and
fibrotic cell infiltration and proliferation in the injured cord.
Directly targeting PDGFRs has led to improved recovery from CNS trauma. In a
mouse model of seizure, the fibrotic scar is associated with PDGFRβ and can be activated
by the PDGFRβ agonist PDGF-BB and inhibited by the PDGFRβ antagonist, imatinib343.
Indeed, the tyrosine kinase inhibitor, imatinib, has also shown benefits in rodent models of
traumatic brain injury (TBI) and SCI. Administration of imatinib for the first 5 days after
TBI and SCI improves functional recovery, likely by reducing BBB and BSCB breakdown
and reducing inflammation344-346. These results have even led to a phase 2 clinical trial in
SCI (NCT02363361). However, it is important to note that an independent lab failed to
reproduce improvements in SCI with imatinib administration347.
An important consideration is the timing of imatinib administration. Dosing for the
first 5 days after injury is expected to inhibit early inflammation, as reported by tracking
inflammatory biomarkers344, and vascular dynamics. Indeed, while some reports indicate
decreased hemorrhage by tyrosine kinase inhibition with imatinib346, other studies identify
an important role for PDGFRβ, in particular, in limiting hemorrhage275. Shen and
colleagues show that PDGFRβ is protective in mouse middle cerebral artery occlusion
because PDGFRβ knockout mice have delayed recovery and more hemorrhage after
injury275. Histological investigations show that PDGFRβ knockout mice have significantly
fewer myofibroblasts and significantly less astrocytic scar density than wildtype mice after
ischemic brain injury275. These results are in line with the general theme that vascular
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stability and astrocytic scarring helps protect from the spread of CNS injury11,182, and
identify an important role for PDGFRβ in those beneficial injury responses. However, the
lack of a fibrotic scar formation in this injury model275 begs the question whether PDGFRβ
and PDGFRβ-expressing cells are protective in injuries that do evoke a robust fibrotic
response, like TBI and SCI.
Alternatively, it may be possible to indirectly target PDGFRβ+ cells in the injured
cord. Hesp and colleagues show that genetic inhibition of NG2+ pericytes leads to
decreased PDGFRβ+ staining, increased axon growth, and improved locomotor function
after mouse cervical hemicontusion SCI263. These results are somewhat distinct from
results in Acomys presented in chapters 2 and 4, where Acomys show a decrease in
PDGFRβ+ density and an improvement in locomotor function, but no notable increase in
axon growth. Hesp and colleagues suggest that the genetic inhibition of NG2+ cell
proliferation acts on axon growth and fibrotic scarring independently through effects on
NG2+ glia and NG2+ pericytes, respectively. They hypothesize that inhibiting NG2+ glia
proliferation disrupts the glial scar formation over the first 11dpi and allows enhanced axon
growth, while inhibiting NG2+ pericyte proliferation prevents angiogenesis that deprives
a physical substrate for PDGFRβ+ fibroblast infiltration into the lesion core263. According
to this hypothesis, inhibited pericyte proliferation could underlie dampened PDGFRβ and
ECM responses in the injured Acomys cord without any robust effects on axon growth.
Furthermore, this trend could be specifically driven by NG2+ pericytes that are distinct
from the PDGFRβ+ pool visualized in our studies. This line of reasoning offers an
interesting prospect for therapeutic development, but undoubtedly requires further
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investigation to better understand underlying NG2+ cell and vascular biology in Acomys
SCI.
I propose that targeting PDGFRβ signaling, either directly or indirectly, at subacute
time points would be preferable to early acute administration. Studies of PDGFRβ in CNS
injury consistently show increased expression in the subacute window as opposed to early
acute time points19,20,263,265. The disconnect between imatinib studies across different labs,
in particular, may be affected by a small effect size given the smaller potential pool of
tyrosine kinase receptors in the injured cord347,348. Furthermore, delaying to a subacute
administration would circumvent potential negative effects on vascular stability in the
acutely injured cord. Neovascularization has mostly occurred before 1wpi147,228, while the
peak of inflammation, fibroblast recruitment to the lesion core, and deposition of ECM in
fibrotic scarring occurs after 1wpi19,107,167. Overall, delaying treatment to the subacute
window would be preferable to disrupt the vicious cycle of inflammation and fibrosis in
the injured cord.
The results of my graduate studies are highly informative for the role of cell
expansion in SCI. In my studies, I see a divergence of Acomys from Mus and noncompression from compression-involving injuries in the subacute phase (1-2wpi) of injury
responses. Specifically, macrophages/microglia and PDGFRβ+ cells in the Mus cord are
maintained or expand after this 1wpi point, while Acomys have a dampened response and
improved recovery from SCI. Growth factors, and PDGFRβ in particular, are recognized
for being highly influentially in inflammatory and fibrotic cell migration and proliferation.
Future studies are warranted for the cell-to-cell crosstalk in the injured Acomys cord, and
specifically investigating the role of PDGFRβ in this cell-to-cell crosstalk is a reasonable
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place to start. Studying this system of enhanced spinal repair will give us a deeper
understanding of these injury responses and how they contribute to endogenous repair of
the injured cord.

6.3

Hemodynamics and SCI progression
Another potential link between inflammation, fibrosis, and overall outcomes of SCI

are hemodynamics in the injured cord. Because of the toxic nature of blood, coagulation is
a critical first step in the wound healing process. Release of tissue factors begins a
coagulation cascade that leads to the eventual activation of thrombin, which cleaves
fibrinogen into its active form of fibrin349. Fibrin quickly polymerizes and serves as a
scaffolding for the accumulation of platelets, which degranulate to provide a rich source of
cytokines and growth factors, including PDGF276. The dissolution of clots is similarly
important for wound healing processes. Plasmin, which is controlled by a wide variety of
activators and inhibitors, is the primary enzyme responsible for dissolving clots by cleaving
fibrin crosslinks349. Notably, plasmin can have direct influences on inflammatory cells at
the injury site350. The delicate balance of coagulation and fibrinolysis plays a major role in
wound healing processes.
Hemorrhage, coagulation, and fibrinolysis are particularly important to CNS
injuries. The immediate blood-spinal cord-barrier (BSCB) or blood-brain-barrier (BBB)
breakdown allows free hemorrhage into CNS, but this bleeding is prolonged during
subsequent neovascularization64,147. The toxic nature of dysfunctional hemodynamics is
well-recognized in the brain, especially during stroke351. Similarly, blood components are
toxic, even at low concentrations, to oligodendrocytes, OPCs, neurons, and other spinal
constitutents95,352,353. The toxicity of blood to oligodendrocytes and OPCs is particularly
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poignant given decreased frank myelin pathology in Acomys. Iron in the blood also induces
a pro-inflammatory state in macrophages354, leading to further exacerbation of CNS tissue
damage.
Hemodynamics in the CNS are further complicated by coagulopathy—improper
balance of the coagulation and fibrinolysis—which is readily apparent after CNS injury355358

. A leading theory for the cause of coagulopathy in CNS injury posits that the CNS is

rich in tissue factor, which can overactivate fibrinolysis early after injury359. The early
overactivation of fibrinolysis, known as consumptive coagulation, prevents proper clotting
initially and consumes enzymes necessary for proper fibrinolysis later in the wound healing
process358,360,361. The overall dysregulation of hemodynamics in the injured CNS sets the
stage for improper wound healing processes through its direct and indirect effects on
cellular facilitators of injury responses.
Hemodynamics are likely to play a role in divergent secondary injury responses
seen in Mus compression-contusion vs. contusion-only injuries. Previous studies show that
compression increases hemorrhage, thus, altering the fluid dynamics of the contused spinal
cord290296,353. Additionally, residual compression alters acute hypoxia and cellular
bioenergetics with significantly higher lactate:pyruvate ratios compared to contusion alone,
likely due to hemorrhage-induced ischemia291. In chapter 5, we observed that residual
compression drives a potentially destructive inflammatory response. As late as two weeks
after the initial insult, acute residual compression (for 20 seconds) at the time of contusion
SCI increased the relative ratio of pathological/pro-inflammatory to purportedly-reparative
macrophages/microglia compared to contusion-alone SCI. These subacute phase
differences between injury groups imply that some sustainable microenvironmental shift is
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induced by compression at the time of injury, and previous studies support the hypothesis
that this change may be, at least in part, driven by hemodynamics. Further studies of the
effect of hemorrhage after residual compression are warranted to better understand this
potential mechanistic driver of macrophage dynamics in the subacute spinal cord.
Notably, we utilized a thoracic spinal crush with a short (1sec) sustained
compression in our Acomys studies. While the SCI itself mostly shows blood/edema as a
bruise in the injured cord, there is some minor bleeding during the procedure while
exposing the spinal cord. Interestingly, during our surgeries in Acomys our two surgeons
independently noted a less bleeding in the Acomys compared to Mus. Considering the
importance of hemodynamics in compression-involving SCI, and the potential link
between hemodynamics, inflammation, and fibrosis, I decided to perform a histological
analysis of fibrin/fibrinogen, a key component of coagulation and fibrinolysis. After
creating a ROI around the entire SCI site and setting threshold values to distinguish positive
versus background fluorescent staining, I evaluated the density of fibrin/fibrinogen staining
in injured Mus and Acomys spinal cords. These preliminary results show a trend for more
fibrin/fibrinogen in the Acomys spinal cord at 3dpi and 7dpi, with a species effect across
both timepoints (two-way ANOVA p<0.05). In the typical clotting response, circulating
fibrinogen is cleaved by thrombin to create fibrin, which then polymerizes to form a fibrin
clot. This fibrin clot is then degraded by plasmin in a process known as fibrinolysis. The
increased fibrin/fibrinogen staining in the injured Acomys spinal cord may reflect more
circulating fibrinogen, more initial fibrin clot formation, or less degradation of established
fibrin clots. Follow-up studies are necessary to evaluate which step of the clotting process
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this trend reflects, and to evaluate if/how this phenomenon contributes to the
hemodynamics of the injured Acomys spinal cord.
Gene expression post-SCI in Acomys vs. Mus also indicates unique clotting control.
Streeter et al. show that both Mus and Acomys increase expression of Plau, Timp1, and
Serpine1 after injury, but Mus increase expression of these genes around 3-fold more than
Acomys61. Plau encodes a urokinase activator, Timp encodes a metallopeptidase inhibitor,
and Serpine1 encodes a plasminogen activator. These three components of the fibrinolysis
cascade are analogous to the gas and brakes, providing balancing control of plasmin
activation and subsequent breakdown of fibrin clots362. The overproduction of these
fibrinolysis-regulating factors potentially represents an out-of-control coagulation cascade
that leads to dysfunctional control of hemodynamics and coagulopathy in the Mus spinal
cord after injury.
Previous studies suggest that there is a tight window for anti-fibrinolytic therapies
to elicit positive effects in CNS injury. While acute anti-fibrinolytic therapy with
tranexamic acid (TXA) decreases hemorrhage and improves outcomes from CNS injury,
delayed treatment results in a loss of efficacy and poor outcomes363,364. Evidence suggests
that this loss of efficacy when not administered early is due to early consumption of
naturally occurring regulators of plasmin activity365. Cessation of anti-fibinolytic therapies
also needs to be properly timed. Using a genetic knockout or TXA to inhibit fibrinolysis,
Shiraishi and colleagues show that short-term inhibition of fibrinolysis limited short-term
vascular dysfunction and improved early functional recovery from mouse SCI, but
sustained inhibition prevented tissue remodeling and wound healing366. Collectively,
evidence suggests that inhibiting early consumption of coagulation-regulating enzymes by
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inhibiting early fibrinolysis can improve outcomes of CNS injury, but fibrinolysis must be
allowed to proceed at later time points to facilitate clot dissolution and proper wound repair.
Mus and human neurotrauma result in coagulopathy that worsens outcomes from
injury, but that Acomys respond to SCI with a unique coagulation/fibrinolysis profile.
Evidence suggest that Acomys may exhibit a more controlled coagulation cascade which
decreases bleeding at the time of injury, leads to greater fibrin/fibrinogen clotting at early
time points after injury, and requires less coagulation cascade regulators. However,
additional studies are necessary to investigate this possibility. These investigations are
important to inform future therapeutic development efforts. Indeed, early intervention to
stabilize hemodynamics in the injured spinal cord is likely to not only improve acute spinal
damage, but also improve subsequent injury responses, particularly inflammation. This
avenue of biomedical research is important for therapeutic development, particularly in
compression SCI.

6.4

Summary of conclusions
These studies describe novel mammalian models of spinal cord injury that were

developed to shed light on the secondary injury responses that shape the progression of
spinal damage and repair. Acomys were identified as a unique adult mammalian model of
enhanced recovery from SCI, and histological and in vitro analysis shows that this
enhanced recovery is likely facilitated by a dampened inflammatory and fibrotic response
that leads to decreased frank tissue pathology in the subacute and chronic windows after
injury. A novel compression-contusion injury model also identified that compression at the
time of injury dictates a more pro-inflammatory macrophage profile in the subacute
window, which leads to decreased functional recovery and increased tissue pathology after
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injury. Together, these studies identify the importance of the subacute inflammatory and
fibrotic responses in contributing to the overall functional and anatomical outcomes of SCI.
Moving forward, understanding the factors that dictate these injury responses could
enable therapeutics that enhance endogenous repair. Early antifibrinolytic therapy may
optimize hemodynamics to prevent out-of-control bleeding and inflammatory activation,
especially in SCIs that involve compression. Delayed PDGFRβ inhibition may decrease
cellular migration and proliferation, leading to a dampened inflammatory and fibrotic
profile that mimics the Acomys spinal cord. Potentially, intervening in both of these
processes would be necessary to establish the delicate balance necessary to facilitate proper
wound repair.
These studies provide a solid foundation for future investigations using these novel
models of SCI, and hopefully pave the way to therapeutic developments that will improve
the lives of people living with SCI.
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APPENDICES
1

Appendix 1: Supplementary Figures

Figure A1.1: Acomys and Mus had similar and stable body weight before
spinal crush surgery.
Animals were weighed before baseline functional measurements (1 week preinjury) and on the surgery day as a matter of routine animal care. After injury,
these animals were part of the cohort used for functional recovery data
(chapter 2, section 2.3) and for chronic 12wpi histology (chapters 2, 3, and
4). Two-way ANOVA with Sidak’s multiple comparisons test shows no
statistical difference in weight by species or by time within each species.

Figure A1.2: Mus and Acomys baseline sensory sensitivity.
Mechanical sensitivity was measured using an electronic von-frey filament,
which measures the amount of pressure applied to the paw before the animal
voluntarily withdraws from the stimulus. Thermal sensitivity was measured
using Hargreave’s test, which measures the amount of time before the animal
voluntarily withdraws its paw from an infrared thermal stimulus. A) Greater
force stimulus was required to evoke Acomys paw withdrawal (p<0.001). B)
However, Mus and Acomys withdrew paws around the same time during
graded increases in heat stimulus. These results are typically used to calibrate
post-injury returns to a baseline sensitivity, but animals did not reach a level
of functional recovery to enable reliable paw withdrawal.
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Figure A1.3: Gross neuroanatomy is similar in naïve Mus and Acomys
spinal cord.
The entire spinal column was removed from a Mus and Acomys. Both Acomys
and Mus had the same number of spinal vertebrae with similar vertebral
morphology. These vertebrae were used to categorize the spinal cord into
cervical, thoracic, and lumbar sections. Cords were stained for myelin
(eriochrome cyanine, blue) and nuclei (fast red, red) to visualize grey and
white matter in the Mus (A-D) and Acomys (E-H) cord. This histological
analysis shows qualitatively similar gross neuroanatomy between species,
with internal grey matter adopting a structure with apparent dorsal and ventral
horns. Quantificaiton shows that both species also have a similar proportion
of grey:white matter in the thoracic (T9) cord (J; Acomys ~34%, Mus ~36%).
While Acomys have consistently larger spinal cords than Mus (I) including at
T9 (J), both species have similar patterning of cervical and lumbar
enlargements with a smaller thoracic cord (I).

168

169

Figure A1.4: Naïve glia are similar in Mus and Acomys.
Spinal cords were collected from uninjured animals and histologically
evaluated for baseline glial density and morphology. Both Mus and Acomys
have similar macrophage/microglia density according to Iba1 staining (A, B)
and similar ramified macrophage/microglia morphology (C-F). Astrocyte
patterning and morphology also appears similar between species (G-J).
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Figure A1.5: Acomys and Mus have similar acute inflammatory
responses to spinal crush injury.
Histological analysis of macrophage/microglia marker (Iba1, red) in saggital
spinal sections isolated 3dpi show similar levels and patterning of Iba1+
staining density in Acomys and Mus spinal cords. At this acute time point,
Iba1+ staining shows the typical amoeboid shape of activated
macrophages/microglia.
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Figure A1.6: Acomys and Mus have similar collagen IV levels and
patterning in acute spinal crush injury.
Histological analysis of collagen IV (red) in saggital spinal sections isolated
3dpi show similar patterning and staining density in Acomys and Mus spinal
cords. At this acute time point, collagen IV staining is sparse and appears in
a vessel-like morphology.
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Figure A1.7: Acomys and Mus have similar PDGFRβ patterning in acute
spinal crush injury.
Histological analysis of PDGFRβ (red) and periostin (green) in saggital spinal
sections isolated 3dpi show similar patterning and staining density in Acomys
and Mus spinal cords. At this acute time point, both PDGFRβ and periostin
staining are sparse and appear in a vessel-like morphology.
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Figure A1.8: Acomys have more clot-promoting protein,
fibrin/fibrinogen, in the acutely-injured.
Immunohistological analysis of sagittal spinal sections isolated from animals
3 days and 1week after spinal crush shows that Acomys have significantly
more fibrin/fibrinogen than Mus. These results may suggest that Acomys have
more clotting and/or more propensity to clot early after SCI. *p<0.05.
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2

APPENDIX 2: Methods
*Recipes for solutions created in-house and specific product information for bought

materials are detailed in Appendix 2: Materials.
Animal Husbandry
Acomys cahirinus (Acomys) and Swiss Webster Mus Musculus (Mus) were housed
at the University of Kentucky, Lexington, KY in a vivarium managed by Dr. Ashley Seifert
and the Department of Laboratory Animal Research. Aco were bred in-house while Mus
were obtained from Charles River Laboratories. Animals were kept on an ambient light
cycle with the primary light source being exterior vivarium windows. Before SCI, Acomys
were housed at a density of 10–15 animals per cage in metal wire cages (24 inch x18 inch
x16 inch, height x width x depth) with dry pellet bedding and fed a 3:1 mixture by volume
of 14% protein mouse chow and black-oil sunflower seeds with ad libitum access to food
and water.
Before spinal cord injury, Mus were housed at a density of 5 individuals per cage
in Allentown Mouse Tub HTPC Cages (11 in x 7 in, width x depth) with sani-chip bedding
and fed 14% protein mouse chow with ad libitum access to food and water. Animals were
assessed for weight and health 3 days before SCI and were transferred to individual housing
in Allentown Mouse Tub HTPC Cages with sani-chip bedding and ad libitum access to
food and water. Animals were individually housed because preliminary studies showed a
proclivity for Acomys cannibalization and autophagy after SCI. Throughout the study,
cages were regularly rotated to compensate for any unlikely effects of disproportionate
access to light from windows.
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Table A2.1.1: Animals per experiment for comparative study (Ch 2-4)
Experiment ID
Intended Time Mus at time of spinal Acomys at time of spinal
Post Injury
crush Surgery
crush Surgery
01202020
3dpi
6
6
03182020

3dpi

4

4

01162020

1wpi

6

6

03142020

1wpi

4

4

09102019

2wpi

7

7

08262019

12wpi

10

10

Spinal Cord Injury and Spinal Isolation
The only method currently available to accurately recapitulated the SCI responses
and progression is to produce a SCI in an animal. Therefore, we administered spinal crush,
unilateral spinal hemisection, or spinal contusion injuries to rodents. Animals were
anesthetized with isoflurane, using 3% isoflurane in a chamber for induction and 1-2%
isoflurane in a nose cone throughout the procedure. Before injury, animals were weighed,
then the surgery site was shaved and sanitized with betadine and sterile alcohol wipes.
Skin, fat, and muscle were cut and opened to provide access to the 9th thoracic (T9)
vertebra. The dorsal aspect of the vertebra was removed to the most lateral-extent of the
vertebra. For spinal crush injuries, we crushed the entire T9 spinal cord for 1 sec using
Dumont #5 forceps that were modified with a spacer that physically restricts the maximum
closure distance to 0.5mm. For unilateral spinal hemisection injuries, we cut the spinal dura
on 1 lateral half of the spinal cord using microscissors then inserting a 29 gauge needle at
the spinal midline and dragging the needle laterally, repeating the 3 times; this process
effectively cuts the entire dorsal-ventral extent of 1 lateral side of the spinal cord. For
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spinal contusion injuries, we stabilized the spinal cord with a stereotactic device clamped
on T8 and T9 then impacted the spinal cord using the metal pneumatic impactor tip of
Infinite Horizons (IH) injury device, elicits injuries based on pre-defined impact force and
dwell times. Specific impact parameters are detailed in Chapter 7.
Each injury was verified immediately afterward by the surgeon, then the surgery
site was closed by discontinuous stitches in the overlying muscle, followed by continuous
stitches in the skin. Acomys skin tears at low tensile force and are able to regenerate
damaged skin quickly and reliably, so stitches were placed slightly further from the surgery
site and with slightly more slack than standard rodent stitching; injury sites for all animals
were monitored at least twice daily for the first 2 weeks post injury.
Spinal cords were collected from animals 3dpi, 1wpi, 2wpi, and 12wpi to perform
histological assessment of SCI progression and injury responses. At each specified
timepoint, animals were euthanized with a lethal dose of CO2, then transcardially perfused
with cold phosphate-buffered saline (PBS) (0.1 M, pH 7.4), followed by perfusion with
cold 4% paraformaldehyde (PFA). Dissected spinal cords (~1 cm) were post-fixed for 2 h
in 4% PFA, then rinsed and stored in cold phosphate buffer (0.2 M, pH 7.4) overnight at
4°C. Tissue was cryoprotected in 30% sucrose in dH2O at 4°C for 5 days (when the cords
sunk to the bottom of their container), then oriented for sagittal or coronal sectioning in
optimal cutting temperature compound and rapidly frozen using dry ice. Each OCT block
contained 2-3 spinal cords with at least 1 animal from each group in each block to ensure
uniformity of staining across groups. Tissue was stored at -80°C before sectioning. Tissue
blocks were cut in serial sections and mounted onto Colorfrost plus slides. Tissue was cut
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to 10 µm thickness for experiments except the chronic, 12 wpi time point, which was cut
to 25 µm in an effort to visualize full axons and to evaluate anatomical repair.
Table A2.2.1: Summary of Animal Characteristics
Endpoint
Injury
Species Sex
Animals
Age at
Type
Injured
Injury
3dpi
Crush
Mus
Male
4 or 6
3-6mo
3dpi

Crush

7dpi

Crush

7dpi
14dpi
14dpi
12wpi
12wpi

Acomys Male

4 or 6

3-6mo

Male

4 or 6

3-4 mo

Crush

Acomys Male

4 or 6

3-5 mo

Crush
Crush
Crush
Crush

Mus
Acomys
Mus
Acomys

7
7
10
10

4-5mo
4-6mo
3-4mo
3-5mo

Mus

Male
Male
Male
Male

Weight at
Injury
39.6 ± 1.1 or
36.3 ± 3.2g
43.4 ± 5.8 or
42.3 ± 4.1g
39.0 ± 1.9 or
36.5 ± 2.5g
43.6 ± 2.6 or
41.2 ± 3.4g
42.0 ± 1.9g
41.6 ± 2.8g
43.4 ± 3.8g
43.3 ± 5.3g

For our 14dpi analysis of Acomys and Mus SCI, 5 of 14 animals did not survive to
the endpoint and 1 was excluded from analysis: 1 Acomys died unexpectedly before the
endpoint; 2 Acomys exhibited autophagy 1dpi and were euthanized; 2 Mus were
euthanized 1dpi to match tissue for histological analysis; 1 Mus was excluded for an
incomplete injury (hindlimb function 1dpi and 3dpi was >1 standard deviation better than
all other animals, according to BMS).
For our chronic analysis of Acomys and Mus SCI, 3 of 20 animals did not survive
to the endpoint; 1 Acomys was euthanized after becoming lethargic 14dpi, 1 mouse died
for unknown reasons overnight between 1-2dpi, and 1 mouse died during bladder care
22dpi.
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All procedures were performed in accordance with the guidelines of the Office of
Responsible Research Practices and with the approval of the Institutional Animal Care and
Use Committee at the University of Kentucky.
Functional Analysis
Bladder voiding was analyzed as a Survival curve using the log-rank Mantel-Cox
test, where the species difference is p<0.0001 (displayed as ****).
Locomotor hindlimb function was assessed longitudinally using a battery of
functional tests. All animals were tested using an open field test based on the Basso Mouse
Scale, as described previously by Basso and colleagues62, to verify a consistent injury
within and between groups and to gain general insight into functional recovery. Briefly,
two trained observers observed and scored mice in an open field for 4 min at each specified
time point. Each hindlimb was scored separately based on movement (e.g., ankle placement
and stepping), coordination, and trunk stability, then averaged to generate a single score
for each animal. Each aspect of movement may serve as an outcome measure for functional
recovery, or a composite score designed by Basso et al., where a score of 0 indicates
complete paralysis while a score of 9 indicates normal locomotion, may summarize overall
hindlimb functional recovery. When using this scale, though, it is important to considering
that the BMS was specifically designed for Mus. Hindlimb functional recovery was
analyzed using BMS 3dpi, 1wpi, 2wpi, and 12wpi to determine initial functional deficits
from SCI and to follow functional recovery.
During the 4 minutes of free roaming for BMS, distinct hindlimb functions are
recorded on the BMS scoring sheet (Table A2.3.1). These distinct hindlimb functions can
be further analyzed as BMS subscores, as described by Basso and colleagues in the study
originally describing the BMS62. In this study I analyze specific hindlimb functions using
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subscores derived Basso and colleagues, specifically analyzing hindlimb plantar
placement, plantar stepping, and coordination. It is important to note that these subscores
are particularly informative because the BMS was designed to measure the functional
recovery progression in Mus, but Acomys may follow a distinct progression through
particular hindlimb function62. Furthermore, these BMS subscores are much easier to
interpret as they specifically measure and report a particular hindlimb function rather than
an ordinal scale that reflects a collection of hindlimb functions. Therefore, while the BMS
benefits from showing the progression of animals through a range of functional recovery
states, these BMS subscores are more informative for particular aspects of recovery.
To evaluate rearing, animals were placed in a translucent plexiglass activity box
with an array of infrared beams to track animal movement. Two rows of beams are arranged
such that “beam breaks” on the first row can identify both horizontal movement across the
ground, while beam breaks on the second row can discriminate rearing. The plexiglass box
is further subdivided into 2 small compartments so that 2 animals can be run concurrently.
We placed 1 animal of each species in the activity box, engaged the infrared beam activity
tracker, and allowed free movement for 10 minutes. We collected pre-injury baseline
rearing data, but only began collecting rearing data after animals began to recover stepping
ability (before the animals were able to step, none of them were able to rear on their
hindlimbs). The resultant data are analyzed as vertical/horizontal movement (top/bottom
row beam breaks), to normalize rearing movements to total animal movement.
Rearing and BMS data after injury were analyzed by two-way ANOVA using
species and time as independent variables, and multiple comparisons using Sidak’s test
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were used to compare hindlimb function between species at each time point. Baseline
rearing, BMS 3dpi, and BMS subscores were analyzed using a t-test.
Table A2.3.1: Basso Mouse Scale Grading Criteria (adapted from Basso
et al., 200662)
Score
Operational Definitions
0
No ankle movement
1
Slight ankle movement
2
Extensive ankle movement
3
Plantar placing of the paw with or without weight support *OR*
Occasional, frequent, or consistent dorsal stepping but no plantar stepping
4
Occasional plantar stepping
5
Frequent or consistent plantar stepping, no coordination *OR*
Frequent or consistent plantar stepping, some coordination, paws rotated at
initial contact and lift off
6
Frequent or consistent plantar stepping, some coordination, paws parallel at
initial contact (P/R) *OR*
Frequent or consistent plantar stepping, mostly coordinated, paw rotated at
initial contact and lift off
7
Frequent or consistent plantar stepping, mostly coordinated, paws parallel at
initial contact and rotated at lift off *OR*
Frequent or consistent plantar stepping, mostly coordinated, paws parallel at
initial contact and lift off, and severe trunk instability.
8
Frequent or consistent plantar stepping, mostly coordinated, paws parallel at
initial contact and lift off, and mild trunk instability *OR*
Frequent or consistent plantar stepping, mostly coordinated, paws parallel at
initial contact and lift off, normal trunk stability, and tail down or up & down
9
Frequent or consistent plantar stepping, mostly coordinated, paws parallel at
initial contact and lift off, normal trunk stability, and tail always up.
Spinal Cord Histology
Acomys SCI Studies (Ch. 2, 3, 4)
Before staining, slides were warmed for >1hr at 37C; for immunohistological
procedures antigen retrieval was performed in hot (approaching, but not reaching boiling)
Citrate Buffer pH 6. Massons Trichrome staining to visualize collagen fibers and gross
cellular/extracellular morphology followed routine protocol with Masson’s trichrome
(Richard-Allen Scientific, Kalamazoo, MI). PicoSirius Red staining to enhance
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birefringence and enable polarized light imaging of collagen fibrils followed standard
protocol using a PicoSirius Red Stain Kit (StatLab, McKinney, TX). As validated and
described previously, lesion size and spared tissue was identified using a combination of
eriochrome cyanine (EC) and neuro- filament (NF) (Aves Labs, #NFH) to label myelin and
axons, respectively69,70. For immunohistochemical measures, slides underwent antigen
retrieval in hot (close to, but not actually boiling) citrate buffer pH 6. To block non-specific
binding sites, slides were incubated in blocking buffer (0.1M PBS with 5% normal donkey
serum, 1% BSA and 0.1% Triton X-100) for 1hr, in blocking buffer with avidin for 15min,
and blocking buffer with biotin for 15min (Vector Labs, Burlingame, CA). Antibodies were
also diluted in blocking buffer. Slides were incubated in primary antibodies (listed in Table
A3.3.3) overnight at 4°C. Slides were incubated in secondary antibodies for 1hr at room
temperature. In the case of using biotinylated secondary antibodies, streptavidin was
diluted in 0.1M PB with 0.1% Triton X-100 and slides were incubated in this streptavidin
for 1hr at room temperature.
For lesion measurements, I used HALO image analysis software to delineate the
spinal lesion by tracing EC-negative regions. The pixel-to-µm+ conversion was performed
automatically using the software, and the “ruler” function was used to determine the length
between the most-rostral and most-caudal points of the lesion. These measurements gave
a lesion area and a lesion length for each spinal section. The final value for each animal
was determined by the average value of the 3 central-most sections from each animal.
For quantification of injury responses, I used HALO image analysis software to
create. The first step of the process was to hide the channel of interest (Iba1, collagen IV,
PDGFRβ, etc.) to prevent biased ROI placement based on that staining. Then 500µm2
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square ROIs were created and specifically placed on 3 spinal sections closest to the center
of the cord, as determined by the central canal and/or grey matter shape. An exclusion tool
was used to exclude any areas of autofluorescence or artificial tissue damage produced in
the tissue preparation process from analysis. The central ROI were placed at the injury
epicenter using other stains (usually GFAP and DAPI) as a guide, then ROIs were placed
rostral and caudal to the epicenter with edges abutting the injury epicenter ROI, and then
additional ROIs were placed rostral and caudal to those ROIs with edges abutting.
Collectively, this produced a series of five 500µm2 ROIs with their center at the injury
epicenter, 500µm rostral, 500µm caudal, 1000µm rostral, and 1000µm caudal to the injury
epicenter. Subsequent to ROI placement, the channel of interest was turned on and
threshold values were set to determine weak, moderate, and strong staining in the spinal
sections. The HALO software then ran an analysis of staining intensity across all regions
of interest, and produced a quantification of % staining at each intensity. Data reported are
%moderate + %strong staining in each ROI. Whole cord values were calculated as ((total
moderate area + total strong area)/total ROI are)*100.
Data were analyzed by a 2-way ANOVA to see overall species and interaction
(species x time) effects. Post-hoc analysis with Sidak’s multiple comparison test was used
to evaluate species effects at individual time points. Statistical significance is displayed as
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
Compression Studies (Ch. 5)
As validated and described previously, spared tissue was identified using a
combination of eriochrome cyanine (EC) and neurofilament (NF) to label myelin and
axons, respectively 31,176. For immunohistochemical analyses of macrophage
phenotypes, sections were incubated with goat anti-CD206 (1:100dilution, AF2535, R&D
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Systems, Minneapolis, MN), goat anti-Arg1(1:100, SC-18354, Santa Cruz Biotechnology,
Dallas, TX), rat anti-CD86 (1:100, 553689, BD Biosciences, San Jose, CA), or rat antiMARCO (1:1000, MCA1849, BioRad, Hercules, CA). Slides were incubated with these
primary antibodies overnight at 4°C in 0.1M PBS with 5% normal donkey serum, 1% FBS
and 0.1% Triton X-100. Sections were subsequently incubated with a biotinylated tomato
lectin (1:1000,L0651; Sigma-Aldrich, St. Louis, MO) to counterstain for tota lmacrophage
numbers.
Detection of primary antibodies was performed with donkey anti-rat Alexa Fluor
(AF) 488, donkey anti-rabbit AF 568, and streptavidin AF 647 (all secondaries at 1:1000
dilution, LifeTechnologies, Carlsbad, CA) for 1 h at room temperature. To validate
antibody staining, negative controls were run without primary antibody, and full dilution
curves were analyzed.
The EC/NF images were captured using an Olympus AX-80 and Aperio Scanscope.
To quantify spared tissue, the regions of dense EC staining were outlined and measured
using the MetaMorph analysis program (Molecular Devices, Sunnyvale, CA). To quantify
macrophage activation, three or four regions of interest (ROI) were captured per subject
using an Axioplan 2 imaging microscope(Carl Zeiss) at 20·magnification. The ROI were
taken from within the lesion epicenter using NF/EC stained serial sections as references
(Fig. 5.5.2A). Threshold based area measures of positive signal within the ROI were
performed using MetaMorph to determine total area of positive signal. The total area of
positive signal of macrophage markers (Arg1, CD206, MARCO, CD86) was then
normalized to total tomato lectin (TomL) positive area for each ROI to determine
proportion of positive macrophages within the lesion.
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Because of unknown, at the time, temperature inconsistencies during tissue
processing and sectioning, some cross sections were lost or folded during staining, making
analysis impossible. Mice without an obvious and fully intact epicenter were not included
for histological analysis, decreasing the total number of mice analyzed for histological
analyses from 88 to 71.
In vitro macrophage neurotoxicity
Data in Figure 5.3 represent 1 of 3 biological replicates, each of which show similar
trends. For each biological replicate experiment, 1 Acomys and 1 Mus were euthanized,
then skin and muscle were removed to access and collect intact femurs and tibias. Bones
were stored in ice-cold RPMI 1640 supplemented media before moving to an aseptic cell
culture hood for sterile isolation of bone marrow stem cells. To collect cells, we clip off
the ends of each of the bones and flush bone marrow into separate 50mL conical tubes
using syringes filled with RPMI 1640 supplemented media. After cells have been flushed
from all bones, cells were titurated and centrifuged (all centrifugation steps for switching
media were performed at 300 g for 5 min). To remove red blood cells, cells were
resuspended in red blood cell lysis buffer* for 3-5 min. After diluting and removing red
blood cell lysis buffer, the cell pellet was resuspended in BMDM culture media*. Cell
counts were acquired using a hemocytometer and a 10uL sample diluted 1:1 in trypan blue
and cells were plated at a density of 8-10x106cells/10mL in a T75 flask.
We stimulated bone marrow stem cells to become macrophages, then activated
these cells in vitro. The BMDM culture media contains supernatant from L929 cells, which
is rich in macrophage colony stimulating factor (MCSF) that promotes the differentiation
of pluripotent bone marrow stem cells into macrophages. T75 flasks were allowed to
differentiate into macrophages for 7 days in a cell culture incubator at 5% CO2 and 37°C,
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replacing fresh media 2, 4, and 6 days after plating. After the 7 days, we shocked
macrophages with cold phosphate buffered saline (PBS) before using a cell scraper to lift
the cells off of the flask. These floating macrophages were centrifuged and resuspended in
warm BMDM replating media*, counted, replated at a density of 3x106cells/3mL in 6-well
cell culture plates. BMDMs were seeded into 4 separate 6-well plate replicates. Plates were
incubated overnight to prevent cell death and allow macrophage adherence to the plate.
The next day, supernatant was removed and replaced with warm replating media with or
without activating stimuli. Macrophages were activated in warm BMDM activating media*
containing 50ng/mL lipopolysaccharide (LPS) + 20ng/mL interleukin 4 (IL-4) for 32 hr
before supernatant macrophage conditioned media (MCM) was collected and filtered.
Control unactivated macrophages were kept in warm BMDM activating media without
additional stimulants for 32 hr before collecting and filtering MCM.
Mouse neuroblastoma cells (Neuro-2a or N2A) cells were stored in liquid nitrogen
in a suspension of N2A growth media with 10% DMSO. We thawed cells from frozen
stock warm N2A growth media, centrifuged at 200 g for 5min to pellet cells and remove
toxic DMSO, and resuspended cells in 10-15mL N2A growth media in a T75 flask and
placed the flask in a cell culture incubator at 5% CO-2 and 37°C. When cells reached
confluence, we detatched cells with 3mL Trypsin for 2-5min, resuspending in N2A growth
media, and adding a small aliquot to a new T75 flask. N2A cells were grown and split for
1 week prior to counting cells using a an aliquot in a 1:1 suspension with Trypan Blue and
a hemocytometer, then replating 5x104 cells in 100uL of serum-free N2A growth media
(no FBS). N2A cells were seeded into 2 separate 96-well plates and a total of 70 wells.
Two plates were used in an effort to avoid evaporative loss from cells seeded on the edges
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of 96-well plates. After 24hr, supernatant was removed and 100µL MCM collected from
activated or unactivated BMDMs was applied to N2A Cells. N2A cells remained in MCM
for 32 hr before performing the MTT assay. Stimulation included 4-5 technical replicates
for each sample of collected MCM (4-5 N2A replicates x 4 MCM replicates = 18 total
wells per stimulation type). N2A cells were incubated in MCM in a cell culture incubator
5% CO2 and 37°C.
To test N2A cell health, we performed the MTT assay. After 32hr incubation in
MCM, 10µL thiazolyl blue tetrazolium bromide (MTT substrate) solution was added to
each well and the plate was incubated for 2hr in cell culture incubator at 5% CO2 and 37°C.
Mitochondrial dehydrogenases in viable cells cleave the tetrazolium ring of MTT substrate
to yield purple formazan crystals. These crystals were then dissolved in 100µL acidified
isopropanol (MTT solvent) using a multichannel pipette. After adding solvent to each well,
the solution was mixed well by pipetting up and down at least 10 times. The purple solution
created by the MTT assay was analyzed spectrophotometrically at 570nm in an Epoch
microplate reader using 690nm as a background absorbance.
Data were analyzed compared to the unactivated Mus MCM control. All data were
normalized to the mean value for unactivated Mus MCM absorbance to give relative
neurotoxicity. These data were analyzed by two-way ANOVA for overall species and
activation effects. For within-group analysis, we used Sidak’s multiple comparisons test.
In vitro neurite growth
Data presented are from 1 of 2 biological replicates, each of which show similar
trends. For each biological replicate, 1 animal from each species was euthanized, then the
skin, fat, fascia, and muscle were removed to visualize the spinal column. The dorsal half
of vertebrae were removed to allow access to the entire spinal cord and peri-spinal dorsal
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root ganglia. The spinal cord was periodically doused with cold 1X HBSS to prevent drying
and maintain cell health. Dorsal root ganglia were removed from the cervical, lumbar, and
thoracic cord by cutting nerve fiber projections with a pair of microscissors, then ganglia
were placed in a petri dish filled with cold 1X HBSS. This process was performed quickly
(<1hr) to preserve cellular integrity.
Isolated ganglia were further processed to remove any remaining nerve fiber
projections, then a small cut in the edge of the ganglia was made to facilitate later
dissociation and transferred to a 1.5mL conical tube. Allowed DRGs to sink to the bottom
of the conical tube before carefully removing excess liquid with a micropipette. DRG
dissociation was facilitated by collagenase/dispase enzymatic digestion of connective
tissues overnight at room temperature on a shaker plate. After enzymatic digestion, excess
liquid was carefully removed with a micropipette and 475µL of 1X HBSS was added. The
digested DRGs were lightly triturated with a fire-polished pipette for 1-3min until cells
were dissociated, as evident by cloudiness of solution. The resultant cell solution was
centrifuged at 200 g for 3min and supernatant was discarded before resuspending cells in
100µL DRG media*. DRG neurons were counted by diluting a sample from the cell
solution 1:1 in trypan blue and using a hemocytometer under a phase-contrast microscope,
and appropriate volumes of the cell solution and DRG media were combined to reach 250
cells/150µL/coverslip.
Coverslip preparation began 1 day before plating DRG neurons. Circular coverslips
sized to fit in 24-well cell culture plates were handled in sterile conditions for the
preparation process. Coverslips were sterilized with 3 treatments of 70% alcohol and 3
washes dH2O before placing on parafilm to serve as a hydrophobic barrier to maintain

188

liquid atop the coverslip. Coverslips were incubated in 157µL poly-D-lysine (PDL;
25µg/mL in dH2O) overnight in the cell culture hood to coat coverslips in PDL. The next
day, 3-4hr before time for plating DRG neurons, coverslips were washed 3x with sterile
dH2O then allowed to dry. Coverslips were incubated in 160µL of the ECM substrate for
2-3hr before time for plating DRG neurons in a cell culture incubator 5% CO2 and 37°C.
Laminin was added at a concentration of 10µg/mL, while fibronectin, collagen IV, and
aggrecan were added at a concentration of 5µg/mL.
After coverslips were coated with the appropriate substrates and DRG neurons were
dissociated and suspended at the appropriate concentration, the ECM solution was
aspirated from the coverslips and immediately replaced by 150µL of cell solution
containing 250 cells. Cells from each species were placed on 3 technical replicates of each
substrate type. Neurons were allowed to settle and adhere onto the coverslip with ECM
substrates for 15min in the cell culture hood before being transferred to a 24-well plate
with 500µL DRG media in each well. Neurons were maintained in these 24-well plates for
36hr before fixation with 500µL 4% paraformaldehyde. After 10min of fixation, each
coverslip was carefully removed, washed 3 times in 1X PBS, and placed on parafilm cellside up for staining.
For the staining procedure, parafilm was used as a hydrophobic barrier to maintain
liquid atop the coverslips. For each step, about 150 µL of liquid was added to each coverslip
by gentle droppers or removed by aspirating at a low suction force to prevent cell or neurite
damage during the staining process. Coverslips were blocked for 1hr at room temperature
in blocking buffer*. Blocking buffer was replaced with primary antibodies targeted to ꞵtubulin (1:2000 rabbit anti-ꞵ-tubulin) and neurofilament (1:2000 rat anti-NFH) and
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incubated for 1hr at room temperature. After 3 washes with 1X PBS, coverslips were
incubated for 1hr at room temperature in fluorescently-conjugated secondary antibodies
targeted to primary host species (1:2000 goat anti-rabbit alexa fluor 546 binding rabbit
anti-ꞵ-tubulin; goat anti-rat alexa fluor 488 binding rat anti-NF). After 3 washes with 1X
PBS, coverslips were incubated in 1:95 DAPI for 10min at room temperature, washed 3
more times in dH2O. Coverslips were carefully removed from parafilm with forceps and
mounted to colorfrost slides cell-side down using immumount mounting media. A blinded
colleague then assigned coding numbers to each slide, which was stored and not viewed
until analysis was completed.
Stained coverslips were imaged using an Axioscan ScanScope to collect 20x
magnification images of the entire coverslip. These large images were then analyzed using
HALO software, where the analyst transposed a premade grid over top of the coverslip to
select a reproducible and unbiased selection of neurons to analyze. Any neurons with soma
or neurites interacting with premade-boxes were imaged using the HALO software. If
multiple images were required for a single neuron, these images were stitched together
using Adobe Photoshop 6 software. Final images of each neuron were analyzed using
Metamorph software and a Sholl Analysis program to analyze neurite length. In sholl
analysis, an array of concentric rings with diameters of ((n-1)*25)+25µm diameters, where
n equals the number in sequence of the rings, are placed centered on the neuron soma.
Automated software then detects the number of times a neurite crosses each of the
concentric rings. Therefore the primary output has 2 vectors: 1) the number of crossings at
a ring of 2) a given distance from the neural soma. The area under the curve is then
extrapolated from the number of crossings at each given distance, to give a single neurite
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growth value for each neuron. Data in Figure 4.3.1 represent the mean and standard error
of the mean for each analyzed neuron from a given species and substrate type. Data were
analyzed by a two-way ANOVA with Sidak’s multiple comparison test to determine the
effect of each coverslip substrate on neurite growth of DRG neurons from a single species.
To compare growth between species, multiple Student’s T tests were conducted to compare
Mus vs. Acomys within a single coverslip substrate type (laminin, fibronectin, collagen IV,
or Aggrecan).
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APPENDIX 3: Materials
Animal Husbandry
Table A3.1.1: Animal Product Information
Names
Abbrev.
Source
Swiss Webster Mus
Mus
Charles Rivers
musculus
14% protein mouse chow
Teklad Global
Black-oil sunflower
Pennington Seed Inc.,
seeds
Madison, GA
Allentown Mouse Tub
Labex of MA,
HTPC Cages
Worchester, MA
Metal wire cages
Quality Cage
Company Portland,
OR
Teklad Sani-chip
Sani-chip bedding Envigo, Indianapolis,
bedding
IN
Dry pellet bedding
Southern States,
Richmon VA

Catalogue #
CFW

7090
10001915

Spinal Cord Injury and Spinal Isolation
Recipes:
•

•

4% Paraformaldehyde: dH2O with 20% 5X PBS, 4% weight by volume
paraformaldehyde powder. Dissolved powder by adding <1% NaOH and stirring
at 55°C. Adjusted to pH 7.4 at room temperature and filtered for final solution.
30% Sucrose: dH2O with 30% weight by volume sucrose powder, stirred until
dissolved.

Table A3.2.1: Spinal cord injury and spinal isolation product
information
Names
Abbrev.
Source
Catalogue #
Isoflurane
Iso
Betadine
Sterile Alcohol Wipes
Baytril
Infinite Horizons Injury
IH
Precision Systems and
Device
Instruments

Biosyn Monofilament
Absorbable Suture
6-0 Dermalon Blue 18”
P-10 Cutting
Optimum Cutting
Temperature Compound
Colorfrost plus slides

Absorbable suture

Covidien

GM875

Non-absorbable
suture
OCT

Esutures.com

1754-13

Sakura Finetek
Fisher

12-550-17

Spinal Macrophage Histology
Recipes
•
•
•
•

Antigen Retrieval/Citrate Buffer: dH O with 10mM Sodium Citrate, 0.05% Tween 20. Stirred til
dissolved and pH adjusted to 6.0.
Blocking Buffer: 1X PBS with 5% N_S (goat or donkey serum, to match secondary host species), 1%
FBS, 0.1% Triton X-100
Avidin Blocking Buffer: Blocking buffer with 4 drops/mL avidin (from avidin/biotin blocking kit)
Biotin Blocking Buffer: Blocking buffer with 4 drops/mL biotin (from avidin/biotin blocking kit)
2

Table A3.3.1: General staining supplies
Name
Abbrev
Source
Normal Donkey
NDS
Sigma-Aldrich
Serum
Normal Goat
NGS
Sigma-Aldrich
Serum
Fetal Bovine Serum FBS
Life Technologies
Triton X-100
Avidin/Biotin
Vector Laboratories
Blocking Kit
Eriochrome
EC
Cyanine
Picrosirius Red
Picrosirius
Statlab
Stain Kit
Massons Trichrome
Richard-Allen
Stain Kit
Scientific
DAB Peroxidase
DAB
Vector Laboratories
(HRP) Substrate
Kit
ImmPACT SG
SG
Vector Laboratories
Peroxidase (HRP)
Substrate

Catalogue #
D9663-10ML
G9023-10ML
10082147
SP-2001

SK-4100

SK-4705

Table A3.3.2: Antibodies and Lectins for Acomys Histology (Chs 2-4)
Abbrev.
Target
Host
Conjugate Dilution
Company
Cat #
193

GFAP

NF-H

NF-H

NeuN
5-HT
Iba1

ColIV

PDGFR
β

αSMA

Glial
Fibrillary
Acidic Protein
High
Molecular
Weight
Neurofilament
High
molecular
weight
neurofilament
NeuN

Chicken

1:500

Aves Labs

GFAP

Chicken

1:1000

Aves Labs

NFH

Rat

1:5000

Millipore
Sigma

MAB5
448

Rabbit

1:4000

Abcam

Serotonin
Allograft
inflammatory
factor 1
Collagen IV

Rabbit
Rabbit

1:5000
1:500

ImmunoStar
Wako
Chemicals

Ab177
487
20080
01919741

Rabbit

1:250

Abcam

Fibronectin

Rabbit

1:500

Laminin

Rabbit

1:500

EMD
Millipore
SigmaAldrich

Platelet
Derived
Growth
Factor
Receptor β
Periostin

Rabbit

1:500

Abcam

Goat

1:200

R&D
Systems
Abcam

AF295
5
Ab569
4

Life
Technologies
Life
Technologies

A1101
0
S3235
1

α smooth
muscle actin
Chicken Ab

Goat

Rat Ab

Goat

Rabbit Ab

Goat

Biotin

Streptavi
din

1:200
Alexa
Fluor 488
Biotinylate
d
Alexa
Fluor 546
Alexa
Fluor 405
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Ab658
6
AB20
33
L9393
-100
UL
Ab325
70

1:1000
1:1000
1:500
1:1000

Biotin

Alexa
Fluor 568
Alexa
Fluor 488

1:1000

Goat Ab

Streptavi
din
Donkey

Rabbit Ab

Donkey

Alexa
Fluor 568

1:500

1:500

Life
Technologies
Thermo
Fisher
Scientific
Life
Technologies

S11226
A11055
A1004
2

Table A3.3.3: Antibodies and Lectins for Compression Histology (Ch. 5)
Abbrev.
Target
Host
Conjugate Dilution
Company
Cat #
NF-H
High
Chicken Biotinylate 1:1000
Aves Labs
NFH
molecular
d
weight
neurofilament
CD206
Mannose
Goat
1:100
R&D
AF253
Receptor
Systems
5
Arg1
Arginase 1
Goat
1:100
Santa Cruz
SCBiotechnolog 18354
y
CD86
Cluster of
Rat
1:100
BD
55368
differentiation
Biosciences
9
86
MARC
Macrophage
Rat
1:1000
BioRad
MCA1
O
receptor with
849
collagenous
structure
TomL
Tomato
Biotinylate 1:1000
SigmaL0651
Lectin
d
Aldrich
AF488
Goat Ab
Donkey Alexa
1:1000
Thermo
AFluor 488
Fisher
11055
Scientific
AF568
Rat Ab
Donkey Alexa
1:1000
Life
Fluor 568
Technologies
AF647
Biotin
Streptavi Alexa
1:1000
Thermo
Sdin
Fluor 647
Fisher
21374
Scientific

In Vitro Macrophage Neurotoxicity
Recipes:
195

•
•

•
•
•

Red blood cell lysis buffer: 155 mM NH4Cl + 10 mM KHCO3 + 0.13 mM Na4EDTA in dH2O
BMDM culture media: RPMI 1640 supplemented media with 10% FBS, 1% HEPES, 1%
pen/strep, 0.001% β-mercaptoethanol, and 20% supernatant from L929 cells
▪ Supernatant from L929 Cells: L929 cells grown grown to confluency in T75
flasks in L929 media, supernatants removed from cells and stored at -20°C until
needed
▪ L929 media: RPMI 1640 supplemented media with 10% fetal bovine
serum, 1% FBS, 1% penicillin/streptomycin, 1% glutamax
BMDM replating media: DMEM with 10% FBS, 1% Glutamax, and 1% pen/strep
BMDM activating media: DMEM with 10% FBS, 1% Glutamax, 1% pen/strep, 50ng/mL LPS,
and 20ng/mL IL-4
N2A growth media: Half OPTI-MEM and half DMEM with 10% FBS, 1% pen/strep

Table A3.4.1: In Vitro Macrophage Neurotoxicity Product Information
Name
Abbrev
Source
Catalogue #
RPMI 1640
RMPI
Thermo Fisher
21870-092
supplemented media
Scientific
Fetal bovine serum
FBS
Thermo Fisher
10082147
Scientific
L929
Dr. Phil Popovich,
The Ohio State
University
4-(2-hydroxyethyl)-1HEPES
Sigma-Aldrich
83264-100ML-F
piperazineethanesulfonic
Corporation
acid
Penicillin and
Pen/strep
Thermo Fisher
15140122
streptomycin
Scientific
β-mercaptoethanol
Thermo Fisher
21985023
(55mM)
Scientific
Glutamax
Thermo Fisher
35050061
Scientific
Dulbecco’s Modified
DMEM
Fisher
10-313-039
Eagle’s Medium
Lipopolysaccharide
LPS
Invivogen
tlrl-b5lps
Interleukin 4
IL-4
R&D Systems
404-ML-010
Opti-MEM ReducedOpti-MEM
Life Technologies 31985-070
Serum Medium
Trypan Blue
Cell Culture Flask, T75 T75
Eppendorf
0030711122
Dimethyl Sulfoxide
DMSO
Trypsin-EDTA (0.05%), Trypsin
Thermo Fisher
25300-062
phenol red
Scientific
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Cell Growth
MTT Assay
Determination Kit, MTT
based
Epoch Microplate
Reader

Sigma-Aldrich

CGD1-1KT

In Vitro Neurite Growth
Recipes:
•

DRG Media: Neurobasal A + 2% B-27 Supplement + 1% Pen/Strep + 1% Glutamax

•

Blocking Buffer: 1X PBS + 5% NGS + 1% FBS + 0.1% Triton X-100

•

Laminin coverslip coating mixture: 10µg/mL laminin

•

Fibronectin coverslip coating mixture: 10µg/mL laminin + 5µg/mL fibronectin

•

Collagen IV coverslip coating mixture: 10µg/mL laminin + 5µg/mL collagen IV

•

Aggrecan coverslip coating mixture: 10µg/mL laminin + 5µg/mL aggrecan

Table A3.5.1: In Vitro Neurite Growth Product Information
Name
Abbrev
Source
Catalogue #
Hank’s Buffered Saline HBSS
Solution
Poly-d-lysine
PDL
EMD Millipore
A-003-E
Laminin
Invitrogen
23017-015
Fibronectin
EMD Millipore
FC010
Collagen IV
EMD Millipore
CC076
Aggrecan
Sigma-Aldrich
A1960-1MG
Collagenase/Dispase
Sigma-Aldrich
A1960-1MG
0.5oz Circular
Coverslips
24-well plates
Parafilm
Phosphate buffered
PBS
saline
Table A3.5.2: In Vitro Neurite Growth Antibody Product Information
Abbrev.
Target
Host
Conjugate Dilution
Company
Cat #
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ꞵtubulin
NF-H
AF546
AF488

4

ꞵ-tubulin

Rabbit

Neurofilament Chicken
heavy chain
Rabbit Ab
Goat
Chicken
antibody

Goat

1:2000
1:2000
Alexa
fluor 546
Alexa
Fluor 488

1:2000
1:2000

Thermo
Fisher
Aves Labs

PA516863
NFH

Life
Technologies
Life
Technologies

A1101
0
A1103
9

APPENDIX 4: Sample Sizes and Statistics

Table A4.1: Acomys Functional Recovery (Chapter 2, Appendix 1)
Figure
Outcome
Species Timepoint(s)
n
Analysis method
#s
Measure
2.3.1A

Bladder Voiding

Mus

Daily 1dpi –
84dpi

8

Log-rank (Mantel-Cox)
test

2.3.1A

Bladder Voiding

Acomys

Daily 1dpi –
84dpi

9

Log-rank (Mantel-Cox)
test

2.3.1B,
A1.1

Body Weight

Mus

Weekly -1wpi
– 12wpi

8

Two-way ANOVA,
Sidak’s multiple
comparison correction

2.3.1B,
A1.1

Body Weight

Acomys

Weekly -1wpi
– 12wpi

9

Two-way ANOVA,
Sidak’s multiple
comparison correction

2.3.2A

Rearing Baseline

Mus

1 week preinjury

8

Student’s T-Test

2.3.2A

Rearing Baseline

Acomys

1 week preinjury

9

Student’s T-Test

2.3.2B

Acute Basso
Mouse Scale

Mus

3dpi

8

Student’s T-Test

2.3.2B

Acute Basso
Mouse Scale

Acomys

3dpi

9

Student’s T-Test

2.3.3A

Basso Mouse
Scale

Mus

1dpi, 3dpi,
1wpi, 2wpi,
11wpi

8

Two-way ANOVA,
Sidak’s multiple
comparison correction
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2.3.3A

Basso Mouse
Scale

2.3.3B

Rearing

Acomys

1dpi, 3dpi,
1wpi, 2wpi,
11wpi

9

Two-way ANOVA,
Sidak’s multiple
comparison correction

Mus

4wpi, 5wpi,
6wpi, 7wpi,
9wpi, 10wpi

8

Two-way ANOVA,
Sidak’s multiple
comparison correction

9

Two-way ANOVA,
Sidak’s multiple
comparison correction

2.3.3B

Rearing

Acomys

4wpi, 5wpi,
6wpi, 7wpi,
9wpi, 10wpi

2.3.3C

Hindlimb Paw
Placement

Mus

11wpi

8

Student’s T-Test

2.3.3C

Hindlimb Paw
Placement

Acomys

11wpi

9

Student’s T-Test

2.3.3D

Hindlimb
Stepping

Mus

11wpi

8

Student’s T-Test

2.3.3D

Hindlimb
Stepping

Acomys

11wpi

9

Student’s T-Test

2.3.3E

Hindlimb
Coordination

Mus

11wpi

8

Student’s T-Test

2.3.3E

Hindlimb
Coordination

Acomys

11wpi

9

Student’s T-Test

A1.2A

Baseline Von
Frey

Mus

-1wpi

10

Student’s T-Test

A1.2A

Baseline Von
Frey

Acomys

-1wpi

10

Student’s T-Test

A1.2B

Baseline
Hargreaves

Mus

-1wpi

10

Student’s T-Test

A1.2B

Baseline
Hargreaves

Acomys

-1wpi

10

Student’s T-Test

Table A4.2: Compression Functional Recovery (Chapter 5)
Figure
Outcome
Injury
n
Timepoint(s)
Analysis method
#s
Measure
Group
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50kdyn

1dpi, 3dpi,
7dpi, 14dpi,
21dpi, 28dpi

11

Two-way ANOVA, Sidak’s
multiple comparison
correction

Basso Mouse
Scale and
Subscores

50kdyn
+ 20s

1dpi, 3dpi,
7dpi, 14dpi,
21dpi, 28dpi

9

Two-way ANOVA, Sidak’s
multiple comparison
correction

5.3.1
5.3.2

Basso Mouse
Scale and
Subscores

75kdyn

1dpi, 3dpi,
7dpi, 14dpi,
21dpi, 28dpi

9

Two-way ANOVA, Sidak’s
multiple comparison
correction

5.3.1
5.3.2

Basso Mouse
Scale and
Subscores

75kdyn
+ 20s

1dpi, 3dpi,
7dpi, 14dpi,
21dpi, 28dpi

10

Two-way ANOVA, Sidak’s
multiple comparison
correction

5.3.1
5.3.2

Basso Mouse
Scale and
Subscores

5.3.1
5.3.2

Table 4.3: Acomys histology (Chapters 2-4, Appendix 1)
Figure Outcome
3dpi 1wpi 2wpi 12wpi
Species
#s
Measure
n
n
n
n

Analysis method

2.5.5

Soma
Pathology
Length
(NeuN)

Mus

4

7

4

Two-way ANOVA,
Sidak’s multiple
comparison correction

2.5.5

Soma
Pathology
Length
(NeuN)

Acomys

8

8

4

Two-way ANOVA,
Sidak’s multiple
comparison correction

3.5.6A

Lesion Size
(EC/NF)

Mus

4

10

4

2.5.6A

Lesion Size
(EC/NF)

2.5.6B

Lesion
Length
(EC/NF)

Mus

3

10

2.5.6B

Lesion
Length
(EC/NF)

Acomys

8

8

Acomys

8

8
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8

Two-way ANOVA,
Sidak’s multiple
comparison correction

9

Two-way ANOVA,
Sidak’s multiple
comparison correction

5

8

Two-way ANOVA,
Sidak’s multiple
comparison correction

4

9

Two-way ANOVA,
Sidak’s multiple
comparison correction

4

3.4.1,
3.4.3

Macrophag
es/
microglia
(Iba1)

Mus

7

6

5

7

Two-way ANOVA,
Sidak’s multiple
comparison correction

3.4.1,
3.4.3

Macrophag
es/
microglia
(Iba1)

Acomys

6

5

4

9

Two-way ANOVA,
Sidak’s multiple
comparison correction

4.4.2

Collagen
IV

Mus

5

8

5

8

Two-way ANOVA,
Sidak’s multiple
comparison correction

4.4.2

Collagen
IV

9

Two-way ANOVA,
Sidak’s multiple
comparison correction

Acomys

8

8

4

4.5.2M,
N;
4.5.1;
4.5.3G

PDGFRβ

Mus

6

8

5

8

Two-way ANOVA,
Sidak’s multiple
comparison correction

4.5.2M,
N;
4.5.1;
4.5.3G

PDGFRβ

Acomys

8

7

4

9

Two-way ANOVA,
Sidak’s multiple
comparison correction

4.5.4B,
D

Periostin

Mus

8

4

Two-way ANOVA,
Sidak’s multiple
comparison correction

4

Two-way ANOVA,
Sidak’s multiple
comparison correction

4

Two-way ANOVA,
Sidak’s multiple
comparison correction

4

Two-way ANOVA,
Sidak’s multiple
comparison correction

4

Two-way ANOVA,
Sidak’s multiple
comparison correction

4.5.4B,
D

Periostin

4.4.3AC

Collagen
Fibrils
(Picrosirius
Red)

4.4.3AC

Collagen
Fibrils
(Picrosirius
Red)

4.4.3DF

Laminin

Acomys

7

Mus

Acomys

Mus

201

4.4.3DF

Laminin

Acomys

4

Two-way ANOVA,
Sidak’s multiple
comparison correction

4.4.3G-I

Fibronectin

Mus

4

Two-way ANOVA,
Sidak’s multiple
comparison correction

4.4.3G-I

Fibronectin

Acomys

4

Two-way ANOVA,
Sidak’s multiple
comparison correction

Table A4.4: Compression Histology (Chapter 5)
Figure
Outcome
Injury 3dpi
1wpi 2wpi
#
Measure
Group
n
n
n

5.4.1,
5.4.2

5.4.1,
5.4.2

5.4.1,
5.4.2

Anatomical
pathology
(EC/NF)

Anatomical
pathology
(EC/NF)

Anatomical
pathology
(EC/NF)

5.4.1,
5.4.2

Anatomical
pathology
(EC/NF)

5.5.2,
5.5.3,
5.5.4

MARCO mac.
phenotype

50kdyn

50kdyn
+ 20s

75kdyn

75kdyn
+ 20s

3

4

3

2

50kdyn

3

3

3

3

3
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5

5

5

5

5

12wpi
n

Analysis
method

8

Two-way
ANOVA,
Sidak’s
multiple
comparison
correction

8

Two-way
ANOVA,
Sidak’s
multiple
comparison
correction

9

Two-way
ANOVA,
Sidak’s
multiple
comparison
correction

9

Two-way
ANOVA,
Sidak’s
multiple
comparison
correction
Two-way
ANOVA,
Sidak’s
multiple

comparison
correction

5.5.2,
5.5.3,
5.5.4

5.5.2,
5.5.3,
5.5.4

5.5.2,
5.5.3,
5.5.4

5.5.2,
5.5.3,
5.5.4

5.5.2,
5.5.3,
5.5.4

MARCO mac.
phenotype

MARCO mac.
phenotype

MARCO mac.
phenotype

Arg1 mac.
phenotype

Arg1 mac.
phenotype

50kdyn
+ 20s

3

75kdyn

3

75kdyn
+ 20s

3

50kdyn

3

50kdyn
+ 20s

5.5.2,
5.5.3,
5.5.4

Arg1 mac.
phenotype

75kdyn

5.5.2,
5.5.3,
5.5.4

Arg1 mac.
phenotype

75kdyn
+ 20s

3

3

3
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5

Two-way
ANOVA,
Sidak’s
multiple
comparison
correction

4

Two-way
ANOVA,
Sidak’s
multiple
comparison
correction

5

Two-way
ANOVA,
Sidak’s
multiple
comparison
correction

5

Two-way
ANOVA,
Sidak’s
multiple
comparison
correction

5

Two-way
ANOVA,
Sidak’s
multiple
comparison
correction

4

Two-way
ANOVA,
Sidak’s
multiple
comparison
correction

5

Two-way
ANOVA,
Sidak’s
multiple

comparison
correction

5.5.2,
5.5.3,
5.5.4

5.5.2,
5.5.3,
5.5.4

5.5.2,
5.5.3,
5.5.4

5.5.2,
5.5.3,
5.5.4

5.5.2,
5.5.3,
5.5.4

CD86 mac.
phenotype

CD86 mac.
phenotype

CD86 mac.
phenotype

CD86 mac.
phenotype

CD206 mac.
phenotype

5.5.2,
5.5.3,
5.5.4

CD206 mac.
phenotype

5.5.2,
5.5.3,
5.5.4

CD206 mac.
phenotype

3

50kdyn

50kdyn
+ 20s

3

3

75kdyn

75kdyn
+ 20s

3

3

50kdyn

50kdyn
+ 20s

3

3

75kdyn
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5

Two-way
ANOVA,
Sidak’s
multiple
comparison
correction

5

Two-way
ANOVA,
Sidak’s
multiple
comparison
correction

5

Two-way
ANOVA,
Sidak’s
multiple
comparison
correction

5

Two-way
ANOVA,
Sidak’s
multiple
comparison
correction

5

Two-way
ANOVA,
Sidak’s
multiple
comparison
correction

5

Two-way
ANOVA,
Sidak’s
multiple
comparison
correction

5

Two-way
ANOVA,
Sidak’s
multiple

comparison
correction

5.5.2,
5.5.3,
5.5.4

CD206 mac.
phenotype

75kdyn
+ 20s

3

5

Two-way
ANOVA,
Sidak’s
multiple
comparison
correction

Table A4.5: Macrophage Neurotoxicity in vitro (Chapter 3)
Figure BMDM
BMDM
Neuron
Analysis Method
#
Species Stimulation
n
3.5.1

Mus

Activated

10

Two-way ANOVA with Sidak’s multiple
comparison correction

3.5.1

Mus

Unactivated

10

Two-way ANOVA with Sidak’s multiple
comparison correction

3.5.1

Acomys

Activated

10

Two-way ANOVA with Sidak’s multiple
comparison correction

3.5.1

Acomys

Unactivated

10

Two-way ANOVA with Sidak’s multiple
comparison correction

Table A4.5: DRG Neurite Growth in vitro (Chapter 4)
Figure
DRG
ECM
DRG
Analysis Method
#
Species Stimulant
n
4.3.1

Mus

Laminin

38

One-way ANOVA with Tukey’s multiple
comparison Correction

4.3.1

Mus

Laminin +
Fibronectin

64

One-way ANOVA with Tukey’s multiple
comparison Correction

4.3.1

Mus

Laminin +
Collagen IV

51

One-way ANOVA with Tukey’s multiple
comparison Correction

4.3.1

Mus

Laminin +
Aggrecan

63

One-way ANOVA with Tukey’s multiple
comparison Correction

4.3.1

Acomys

Laminin

13

One-way ANOVA with Tukey’s multiple
comparison Correction
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4.3.1

Acomys

Laminin +
Fibronectin

47

One-way ANOVA with Tukey’s multiple
comparison Correction

4.3.1

Acomys

Laminin +
Collagen IV

24

One-way ANOVA with Tukey’s multiple
comparison Correction

4.3.1

Acomys

Laminin +
Aggrecan

39

One-way ANOVA with Tukey’s multiple
comparison Correction

Table A4.6: Acomys Naïve Anatomy (Appendix 1)
Figure
Outcome Measure
Species n
Analysis method
#
A1.3

Naïve neuroanatomy
(EC/NF)

Mus

3

Two-way ANOVA, Sidak’s multiple
comparison correction

A1.3

Naïve neuroanatomy
(EC/NF)

Acomys

3

Two-way ANOVA, Sidak’s multiple
comparison correction

A1.4

Naïve glia (Iba1)

Mus

3

Two-way ANOVA, Sidak’s multiple
comparison correction

A1.4

Naïve glia (Iba1)

Acomys

3

Two-way ANOVA, Sidak’s multiple
comparison correction
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